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ABSTRACT 
Stroke is one of the leading causes of death and permanent disability worldwide. However, the clini-
cally approved therapies are strictly limited. One promising novel approach is the transplantation of 
stem cells to enhance recovery. Prior to a successful clinical translation, experimental models are 
necessary to reveal the underlying biological mechanisms. Noninvasive imaging, particularly magnet-
ic resonance imaging, evolved as a novel tool to study stem cell location and migration in the living 
animal over time. Contrast agents are used to label cells prior to transplantation and allow the dis-
crimination from the host tissue. One remaining drawback is the limitation on structural information. 
The question remains, how to elucidate additional cell properties - like viability and fate.  
This dissertation includes novel neuroimaging techniques: contrast agents responsive to a specific 
cellular function and optical reporters of cell viability and cell differentiation. The first project in-
cludes the development of a molecular probe, bioengineered to detect selectively the expression of 
glutamic acid decarboxylase. This enzyme is unambiguously expressed in the brain by GABAergic 
neurons. The novel contrast agent serves as a substrate for the enzyme and permits the discrimina-
tion of GABAergic neurons from immature cells based on the decreased T1 relaxation rate.  
Optical cell tracking with bioluminescence has been investigated in the second project. Luciferases, 
e.g. isolated from the firefly Photinus Pyralis, can be expressed in mammalian cells and permit a cell 
viability-dependent readout. A transgenic mouse model of luciferase expression restricted to double-
cortin-positive neurons served as a reference for optical neuroimaging and allowed bioluminescence 
protocol optimization under stable conditions. Luciferase substrate concentrations, injection routes 
and anesthesia effects were investigated. As a major result, an optimized protocol with 2-fold higher 
sensitivity was established. A mouse neural stem cell line was generated and transduced with 4 dif-
ferent luciferases for a quantitative comparison after transplantation into the mouse brain. Firefly 
luciferase Luc2 was selected because of its superior bioluminescence in the brain. Cell grafts were 
imaged with surpassing sensitivity by applying the empirically optimized protocol.  
Based on this evaluation, neural stem cells were genetically modified to express a set of distinct opti-
cal reporters under control of either a constitutive promoter or cell-specific promoter. Glial differen-
tiation has been monitored by the induced expression of firefly luciferase and the fluorescent protein 
mCherry controlled by the GFAP promoter.  
The results presented in this dissertation show the potential of noninvasive approaches for elucidat-
ing key cell features, like viability and differentiation. These methods can be applied for in vivo stud-
ies and provide significantly more details of graft behavior. They enable stem cell induced recovery 
assessment in neurodegenerative disease like stroke without the need of invasive intervention. 
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1. BACKGROUND 
1.1 Noninvasive imaging for stem cell therapy 
1.1.1 Embryonic and neural stem cells 
Stem cells serve as the fundament of body homeostasis, wound healing and immunity. The em-
bryoblast, composed of the blastocyst´s inner cell mass, contains the stem cell origin, which will give 
rise to fetal, neonatal and adult stem cells during development. These embryonic stem (ES) cells are 
capable of reconstituting every cell type independent of the germ layer background, which makes 
them pluripotent. The ES cell isolation and adaption on cell culture conditions in the early 1980s by 
Evans, Kaufman and Martin1,2 marks the breakthrough of experimental stem cell research. Mainte-
nance of pluripotency in vitro is mainly achieved by the cell culture supplement LIF (leukemia-
inhibitory factor), which triggers activation of the transcription factor STAT3 - one of the essential key 
factors of self-renewal. In general, stem cell state in vitro is defined by the potential to divide and 
differentiate into various cell types and the reconstitution of the stem cell pool (self-renewal). In 
contrast to ES cells, the potential of adult stem cells is limited by self-renewal and differentiation into 
the cell types of their host tissue (multipotency). Adult stem cells exist exclusively in tissue specific 
niches for example in the bone marrow, skin and fat3–5. Whereas persistent dividing cells with stem 
cell characteristics in the mammalian brain have been discussed controversely6 until the early 1990s. 
The experiments of Eriksson and colleagues7, finally proved early reports on neural stem cells (NSCs) 
in a human study using the cell division marker BrdU (5-bromo-2'-deoxyuridine). The in vitro charac-
terization of mammalian NSCs was made possible by the neurosphere assay invented by Reynolds 
and Weiss8. Cells from the adult brain tissue are isolated and cultured in the presence of growth fac-
tors to form neurospheres, which consist of cells with NSC properties. The maintenance of multipo-
tency and self-renewal is achieved by the supplementation with the growth factors EGF and b-FGF, 
which specifically stimulate NSC proliferation and enable the continuous passaging, as it was shown 
for human NSCs up to 2 years of sustained culture9. In addition, stable NSC lines have been generated 
by immortalization using retroviral oncogene transfer, as described by Ryder et al.10 for mouse NSCs 
and recently adapted for human NSCs11. The adult mammalian brain constitutes two major neuro-
genic regions, the subependymal (SE) zone ensheating the lateral ventricles12,13 and the subgranular 
zone (SGZ) of the dentate gyrus of the hippocampus14. GFAP-positive cells persist in these regions, 
which retain the potential to proliferate and generate differentiated daughter cells. The cellular 
composition was described by Doetsch and colleagues and proposed to consist of a GFAP positive 
astrocyte within the SE and SGZ. These cells divide into putative precursor cells, that in turn give rise 
to migrating neuroblasts (SE) or new granule neurons (SGZ)15. However, the in vivo identity of NSCs 
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remains still controversial16 because of the lack of definitive markers – e.g. GFAP is insufficient be-
cause it is expressed by non-neural cells (astrocytes) and non-stem cells17. 
1.1.2 Stem cell therapy 
Regeneration of damaged neural tissue and reconstitution of lost neural circuits is hampered by the 
irreversibility and progression of these processes in many human neurological diseases (e.g. Hunting-
ton, Parkinson and Stroke). Although endogenous repair mechanisms include the generation of novel 
neurons from endogenous NSCs, they are not effective enough to restore lost brain tissue complete-
ly. This is meant to be enhanced and supported by the application of exogenous (neural) stem cells. 
Cell replacement therapy initially aimed to replace damaged tissue by spontaneous differentiation 
into the appropriate cell type. However, this attempt is impeded by the differentiation efficiency, low 
neural circuit integration and the graft survival in vivo. Nevertheless, transplantation of stem cells 
from various tissue sources was highly investigated during the last decade and could prove enhanced 
functional recovery and/or tissue reorganization in animal models of neurological disorders18,19. 
More recently, the observed beneficial effects are explained by a combination of immunosuppres-
sive20, neuroprotective21 and neurotrophic effects22. The understanding of mechanisms underlying 
stem cell induced regeneration is at the beginning and strictly dependent on the development of 
noninvasive imaging techniques with the aim of elucidating these processes under in vivo conditions.  
1.1.3 Stem cell transplantation – a novel therapy in stroke 
Stroke is the second leading cause of death23 and the leading cause of long-term disability24. It is 
characterized by an embolic/thrombotic vessel blockage or a hemorrhagic bleeding. The clinical ther-
apy is strictly limited to a small subset of patients, administered with recombinant tissue plasmino-
gen activator (rtPA) for recanalization of the vessels within a strict time limit of 4.5 h after stroke 
onset25.  
Human stroke is experimentally mimicked in rats and mice e.g. by blocking the middle cerebral artery 
(MCAo)26. This results in a substantially reduced blood supply to the cortex and parts of the subcorti-
cal regions, leading to a progressive loss of neurons in cortical and subcortical regions. The aim of 
stem cell therapy in stroke is in the first place to boost the functional recovery (see 1.1.2). Various 
experimental studies supplied evidence for the successful improvement of behavior and motor func-
tions after stem cell therapy27,28. Furthermore, clinical trials are already in progress (e.g. a phase I 
study in Guildford, UK, Id-nr. NCT01151124). Beside the route, timing and side of delivery, various 
types of stem cells are under investigation: ES cells, NSCs and stem cells isolated from bone marrow, 
umbilical cord blood and adipose tissue. Recently human induced pluripotent stem cells were invent-
ed, which serve as an patient-specific source for autologous transplantations29.  
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The conventional experimental approach includes subgroups of animals to reveal the endogenous 
recovery mechanisms from the transplant induced and the influence of the surgery itself for each 
individual time point. The result is a high number of laboratory animals used for one single experi-
ment. Therefore, monitoring of the cell transplant, the stroke tissue evolution and the animal physi-
ology are the main challenges for noninvasive approaches and essential for a successful therapy mon-
itoring28.  
1.1.4 Noninvasive imaging  
Noninvasive imaging offers the exclusive advantage over established invasive methods to observe 
biological processes in the living organism with only mild effects on the physiological homoeostasis 
(Table 1). Conventional histological or electrophysiological approaches require the sacrificing of the 
animal at a distinct time point of the experiment. Therefore, to avoid the loss of the animal specific 
physiological state organotypical slice cultures can be used for a limited time – up to 6 days30. Nonin-
vasive imaging was invented to overcome the limitation of describing only the pathological state by 
enabling the detection of single molecular events (e.g. gene expression) responsible for a certain 
disease31 under in vivo conditions. Various techniques exist for small animal imaging based on radio-
nuclides (e.g. Positron Emission Tomography, PET), based on optical probes (e.g. bioluminescence 
imaging, BLI), and based on magnetic probes (e.g. magnetic resonance imaging, MRI). These methods 
differ in spectral and temporal resolution, sensitivity, signal specificity, and tissue penetration (Figure 
1). Optical methods are limited by the poor spatial resolution, but offer high sensitivity. Radiotracer 
methods are also highly sensitive but offer only slightly higher spatial resolution. Finally, MRI is supe-
rior for spatial resolution near the range of computer tomography (CT), but is limited in sensitivity.     
Table 1: Characteristic properties of invasive and noninvasive methods  
 Invasive Noninvasive 
Complexity - Methods established and cost effective 
- Methods still under development, ex-
pensive equipment 
Methods 
- Have to be performed in separate ses-
sions and multimodality strictly limited 
- Allow multimodal detection the same 
day 
Resolution - Subcellular (microscopic) - Multicellular (macroscopic) 
Animals 
- High group size, Observations limited to 
one point of time 
- Repetitive measurements on the same 
animal, each serves as its control 
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Figure 1: Schematic overview of selected noninvasive imaging modalities illustrating the differences in spatial/temporal 
resolution, penetration depth and sensitivity
31
.  
1.1.5 The imaging reporter concept 
The fast development of noninvasive imaging techniques in the last decade was a prerequisite for a 
novel combination of molecular biology and medical imaging, called Molecular Imaging. Molecular 
Imaging includes the visualization, characterization and quantification of biological processes at the 
cellular and subcellular level within living subjects31. As a basic principle, the gene of interest is moni-
tored by a genetically linked reporter gene or serves itself as an imaging reporter. As a result, pro-
teins/enzymes are expressed and detected with noninvasive imaging techniques. This approach is 
going to revolutionize the search of disease-related biomarkers because novel therapies can be mon-
itored for specific target genes in the living organism in real time. Several prerequisites for an imag-
ing reporter have to be considered: 1) stable, non-toxic, non-immunogenic, 2) high specificity and 3) 
biologically relevant half-life. Furthermore, imaging reporter substrates (e.g. for bioluminescence) 
should have the ability to cross biological barriers and enter the target cells. This dissertation involves 
examples from MRI and OI-based imaging reporterI. 
  
                                                             
I For a comprehensive review of other modalities including radionuclide based approaches, see222. 
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1.2 MRI basics 
1.2.1 Principles of magnetic resonance 
Magnetic resonance imaging (MRI) is one of the most powerful methods in clinical diagnosis and has 
recently emerged as the state-of-the art method in the field of Molecular Imaging. Compared to oth-
er imaging methods, MRI combines high resolution with excellent soft tissue contrast. The underlying 
physical principle of nuclear magnetic resonance (NMR) was discovered by Purcell and Bloch in 1952. 
20 years later, Lauterbur and Mansfield invented NMR for imaging32,33. This chapter will describe 
briefly the physical basics of MRI, including contrast mechanisms and principles for contrast en-
hancement, and introduce MRI for cell tracking. 
The nuclear magnetic resonance effect is based on a specific property of certain atomic nuclei, e.g. of 
the hydrogen nucleus (proton), which have a non-zero nuclear spin. The spin can be imagined as a 
rotation of the nucleus of non-zero electric charge with a specific frequency, which gives rise to a 
magnetic moment  ⃗ , defined as the product of the gyromagnetic ratio γ and the spin   . Under nor-
mal conditions, the proton spins are oriented randomly (Figure 2 A). After applying an external mag-
netic field (B0), the proton spins will preferably align with the external field, which give rise to a mac-
roscopic magnetization (Figure 2 B) and start to precess around the magnetic field axis (MZ) according 
to the external field with a specific larmor frequency (f), which is proportional to the field strength B0: 
                            . 
The MRI signal is generated while applying a radiofrequency pulse with larmor frequency, which in-
duces a flip of the MZ magnetization into the plane transverse to B0. The transversal magnetization 
(MT) is generated, which precess again with larmor frequency (Figure 2C). This rotating magnetization 
can be recorded by a conductive field coil. Once the radiofrequency pulse is removed, the MT com-
ponent will disappear and the nuclei realign until equilibrium MZ state. 
Figure 2:  Schematic representation of the spin model for nuclear magnetic resonance. A) Random spin distribution and 
rotation in magnetic field free environment. B) Spin alignment according to a strong external magnetic field. C) Radiofre-
quency pulse with the nuclear specific larmor frequency leads to flipping of magnetization into the transverse plane to 
B0. This rotating magnetization MT can be recorded by a conductive field coil. The decline of MT with a characteristic 
decay – the free induction decay (FID) – is illustrated.    
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The system reaches equilibrium state by two mechanisms: the decline of the transverse component 
with a characteristic decay – the free induction decay (FID), induced by heterogenous rotation of the 
transversal spins and the increase of MZ until equilibrium state. The signal decay can be used for con-
trast generation, because of the relating tissue specific time constants, called relaxation times. The 
FID decays with the T2* relaxation time, which is based on a dephasing of the MT aligned spins, be-
cause of time-constant inhomogeneities of the surrounding B0, which results in slightly different lar-
mor frequencies and diversification of spin direction. Realignment of MT can be induced by e.g. a 
refocusing pulse – a process called echo generation. This will exclude the impact of constant inhomo-
geneities and the signal decays predominantly by energy transfer between the spins and dephasing, 
resulting in the T2 relaxation (Figure 3 B). 
Figure 3: Illustration of T1 and T2 relaxation time dependency for fat, cerebrospinal fluid (CSF), cortex and white matter of 
the rat brain at 11.7 T (values approximated from
34
). A) T1-weighted images (dotted line indicates strong weighting, 
dashed line weak weighting) results in hyperintense fat (short T1) and hypointense CSF (long T1). B) T2-weighting (strong: 
dotted line, weak: dashed line) results in hypointense fat (short T2) and hyperintense CSF (long T2). 
After the radiofrequency pulse, the spins will realign again with B0 until the MZ equilibrium is reached 
with the time constant T1 (Figure 3 A). The T1 and T2 relaxation is mathematically described by solu-
tions of the Bloch equations35 (Figure 3), which are used for data fitting. Both relaxation times T1 and 
T2 can be used to maximize soft tissue contrast in MR images based on the parameters for image 
acquisition, namely repetition time TR and echo time TE. T1-weighting is induced with short TR/TE, 
resulting in hyperintense fat (short T1) vs hypointense liquids (long T1). In contrast, long TR and TE 
values lead to a T2-weighted image, in which fat will appear dark (short T2) and liquids bright 
(long T2).  
The challenging part of MRI-based cell tracking is to highlight single cells against the host tissue. Nev-
ertheless, cells can be labeled with paramagnetic or superparamagnetic contrast agents to enhance 
the contrast and enable long-term cell tracking36. The following sections will give a short introduction 
into MRI sequences and contrast agents used for cell tracking with MRI.  
A B 
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1.2.2 Basic MRI sequences 
MRI sequences consist of an ordered combination of radiofrequency pulses (to excite the protons) 
and gradient pulses to apply local magnetic field changes, which are used for spatial reconstruction.  
Gradient Echo Sequence (e.g. FLASH, FISP) 
For gradient echo (GE) sequences, a series of radiofrequency pulses is applied separated by the repe-
tition time TR and the data recorded after the echo time TE, phase decoding gradients and during 
frequency decoding gradients. GE sequences allow rapid imaging with low flip angles (less radiofre-
quency power), but are sensitive to B0 inhomogeneities and susceptibility artifacts. By adjusting TE 
and TR, T2*, T1 and proton-density weighted contrast can be achieved. Advanced gradient echo se-
quences include Fast Low Angle Shot (FLASH), which is optimized for low flip angles at TR<T1 and 
allows shortening of acquisition time by spoiling of the remaining transverse magnetization. The re-
sidual transverse magnetization in gradient echo sequences is used by Fast Imaging with Steady-state 
Precession (FISP), in which the remaining transversal magnetization is not spoiled but used for gain-
ing high SNR at TE=TR/2. Independent of the GE sequence, the choice of a correct flip angle is im-
portant for determining T1. For each T1 value an optimal flip angle (“Ernst angle”) exists, which is 
necessary to achieve highest SNR according to                
(
   
  
)
. 
Spin echo sequences (e.g. MSME, RAREVTR) 
The spin echo sequences make use of an additional 180° refocusing pulse halfway between the exci-
tation and the echo, which eliminates differences in spin precession, which are introduced by local 
field inhomogeneities. Therefore, T2*-weighting is eliminated and SE sequences allow true T2-
weighting and high SNR, but require long scan times and use more RF power compared to GEs. For 
T1-weighted images, inversion recovery sequences are often used, which consist of a SE sequence 
that begins with a 180° pulse for inverting the longitudinal magnetization. After a certain time of 
inversion (TI), in which the inverted longitudinal magnetization decreases, the 90° excitation pulse is 
applied. Relaxation during TI is mainly T1 relaxation time dependent, which enables strong T1-
weighting with so called inversion recovery sequences. Multi Slice Multi Echo (MSME) sequences 
consist of an initial 90° pulse and a series of 180° pulses to generate more than one spin echo. For 
each echo an image can be reconstructed. Using slice selection gradients, excitation and refocusing 
pulses are applied in an interleaved manner on different slices in order to speed up the acquisition. 
This can even be accelerated by accumulating over several TE for one image (Rapid Acquistion with 
Relaxation Enhancement, RARE).  
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1.2.3 Superparamagnetic contrast agents 
Iron oxide contrast agents consist of nanoscale superpararamagnetic iron oxide (SPIO) cores encased 
in a hydrophilic coating composed of poly-saccharides (e.g. Dextran) and synthetic polymers (e.g. 
silica, or polyvinyl alcohol)37. Such nanoparticles are categorized according to the diameter: <50 nm 
ultra-small SPIOs (USPIOs) and >50 nm SPIOs38. Due to the magnetic moment of the core in an exter-
nal magnetic field, they are able to reduce predominantly T2 and T2* relaxation time. When SPIOs are 
placed in an external magnetic field their moments align in the direction of the magnetic field. This 
way, substantial disturbances in the local magnetic field are generated, which lead to a rapid dephas-
ing of surrounding protons, thus resulting in a detectable change in MR signal. Iron oxide particles 
are eliminated by the reticuloendothelial (RES) system), particularly of mononuclear phagocytic cells 
in the spleen, liver and lymph nodes and subsequently incorporated into the body´s iron pool39. 
1.2.4 Paramagnetic contrast agents 
Most paramagnetic contrast agents contain the lanthanide ion gadolinium Gd(III), which offers seven 
unpaired electrons resulting in the highest magnetic moment compared to other paramagnetic 
ions40. The Gd(III) is complexed by chemical ligands or chelators to prevent free Gd(III) uptake, which 
has a toxic effect on biological systems. Paramagnetic relaxation of water protons originates from 
dipole-dipole interactions between the nuclear spins of the hydrogen nuclei of water molecules and 
the fluctuating local magnetic field caused by the spins of the unpaired electrons. The resulting effect 
is seen predominantly as a decrease in T1 and strongly decreases with distance
41. Detailed theory is 
provided by the Solomon-Bloembergen equations42. The T1 relaxivity of Gd(III) complexes is primarily 
determined by three factors: a) the number of water molecules in the inner coordination sphere of 
Gd(III) q, b) the residence lifetime of these inner-sphere water molecules (how fast they exchange 
with other water molecules) τM, and the rotational correlation time of the agent (how fast the com-
plex tumbles in solution) τR (Figure 4).  
 
Figure 4: Schematic depiction of the interactions between water molecules and the Gd(III)-based contrast agent. The 
relaxivity is influenced by the longitudinal electron spin relaxation time T1e,  the electron spin-proton distance rGdH, the 
exchange lifetime τM, the number of water molecules q and the and the molecular reorientational time τR
41
. 
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1.2.5 Responsive contrast agents 
Responsive contrast agents are the further development of conventional agents. They possess two 
distinct magnetic states, changed in response to physiological, enzymatic and other metabolic activi-
ties. In one concept lanthanide chelates are chemically modified to have one or more potential coor-
dination sites for water blocked in the inactive state and accessible in the active state, as it was in-
vented for the first time by Moats and colleagues43. The relaxivity of this responsive contrast agent is 
changed by the enzymatic cleavage of a sugar group by the enzyme β-galactosidase, enabling free 
water access to the paramagnetic ion. Several attempts were made to design contrast agents which 
are responsive to changes in pH44,45, intracellular calcium concentration46, or local oxygen pressure 
pO2
47,48 on the in vitro level.   
1.2.6 MRI-based cell tracking 
Cell tracking using MRI has evolved as an indispensible tool to register the grafted cells in space and 
time, while exhibiting no or very low adverse effects on the animal physiology49. The experimental 
setup includes 3 major steps: 1) the labeling of (stem) cells with a MRI contrast agent, 2) transplanta-
tion of the labeled cells, and 3) the imaging protocol specified for the visualization of the contrast 
agent labeled cells. The cell labeling procedure must be optimized for every cell type and contrast 
agent. Potential toxic effects should be monitored.  
For histological evaluation, Prussian blue staining of iron oxide-based contrast agents is possible. 
Additionally, a reliable histological detection is achieved by an internal fluorescent marker (expres-
sion of fluorescent reporter or labeled with intracellular dye). For precise monitoring of a biological 
effect, a sham transplantation is necessary to exclude side effects of the transplantation surgery. Due 
to the needle penetration of the tissue, inflammation and proliferation of glial cells can be induced.  
The highlight of MRI-based cell tracking is the noninvasive monitoring of cell location and migration 
processes over several months. The resulting images offer information about the anatomical envi-
ronment and e.g. the structural changes of the stroke lesion, but key cell features, e.g. viability, func-
tion and differentiation are neglected. One alternative contrast agent-based method is presented in 
this dissertation, which enables the discrimination of a specific neuronal population from the back-
ground (see 3.).  
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1.3 Optical imaging basics 
Optical imaging comprises a variety of methods to visualize cells and molecular processes by the de-
tection of light emitted by biological light sources with highly sensitive charge-coupled device (CCD) 
image sensors. Different physical light properties and light interactions with molecules/tissues, e.g. 
fluorescence, absorption, reflectance or bioluminescence are used for optical imaging. The technical 
equipment, like sensitive optics, filters and detectors are under permanent development. However, 
in vivo imaging is still limited for cell tracking by the low depth resolution in the mm-range and chal-
lenges for signal quantification50. Figure 5 summarizes the penetration depth and time-resolution, 
which differ widely for common optical imaging techniques.    
 
Figure 5: Schematic overview of key-features of selected 
optical imaging techniques. A) Microscopic techniques are 
limited by low penetration depth, but can be used to follow 
fast cellular processes. Fluorescence tomography (FLT), 
fluorescence imaging (FLI) and bioluminescence imaging 
(BLI) enable higher tissue penetration, with a time-
resolution of seconds to minutes
51
.  
 
 
Three dimensional reconstruction and quantitative determination of the signal source are challenged 
by the natural barrier for light propagation in a living animal leading producing light absorbance, 
scattering and autofluorescence. Absorption in the imaging wavelength range (400-1000 nm) is main-
ly driven by pigments/chromophores (hemoglobin and bilirubin in the blood, myoglobin in the mus-
cles, pheo- and eumelanin in the skin) and also by water and by lipids (Figure 6). A naturally existing 
window of low absorption appears, which is characterized as the near-infrared (NIR) window (ap-
prox. 700-850 nm)52. A further impairment is induced by light scattering at inter- and intracellular 
membrane boundaries due to differences in the refractive index. Light propagation in optically dense 
media is reduced by the refractive index n (ratio of the speed of light in vacuum and speed of light in 
the material), ranging from 1.335 (extracellular fluid) to 1.491 (triglycerides)53. These physical effects 
are of particular importance for optical brain imaging. A multilayer barrier consisting of meninges, 
bone and skin is covering the brain tissue. Hemoglobin absorption is enhanced because of the high 
blood to tissue content54. The human brain accounts for 2% of the total weight but make use of 20% 
of total blood flow. Light scattering is induced between grey matter and white matter because of a 
different refractive index.  
In conclusion, the signal intensity in optical imaging is strictly dependent on 1) source depth in the 
tissue, 2) photons emitted per second, and 3) the wavelength of emitted photons. This results in 
sensitivity differences for FLI compared to BLI: 1015–1017 mol/L and 109– 1012 mol/L respectively55.  
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Figure 6: Illustration of the wavelength dependence of the extinction coefficienct for hemoglobin and water. Blue to 
orange light is strongly absorbed by hemoglobin and the infrared range by water leading to a window of low absorption 
in the near-infrared range optimal for in vivo imaging (original data, see
56–60
).  
1.3.1 Fluorescence imaging 
The green fluorescent protein (GFP) was first isolated form Aequorea Victoria in 196261 and cloned in 
199262,63. The discovery of GFP by Shimomura, Chalfie and Tsien paved the way for the universal use 
of fluorescence imaging because of the novel unique possibility to visualize structures and processes 
in living cells and organisms in real-time (Nobel prize in chemistry, 2008). A variety of GFP-like pro-
teins were discovered (Figure 7) from distant species like crustaceans or mutated for different spec-
tral emission64. In general, nearly all GFP-like proteins form very stable homotetramers. This naturally 
occurring oligomerization limits the use as (multicolor) imaging reporter, thus the recently discov-
ered monomeric fluorescent proteins are preferable. The chromophore formation and spectral tun-
ing is strictly dependent on amino acid side chains inside the FP β-barrel, which can be genetically 
mutated with a single amino acid substitute resulting in a substantial wavelength shift65. Neverthe-
less, the potential for in vivo application is not only dependent on the excitation/emission wave-
length, but also on the brightness being determined by quantum yield (QY, the ratio of photons emit-
ted to photons absorbed), the extinction coefficient (EC, determining how strongly light is absorbed), 
the maturation rate, photostability, pH stability and aggregation potential. EC and QY can be modi-
fied by random or site-directed mutagenesis, restricted by the physical barriers of the GFP-like chro-
mophore. The maturation half-time for most fluorescent proteins is between 40 min to 1-2 h, suffi-
cient for the majority of imaging experiments. The photostability defines the time span for imaging 
and is influenced by the applied imaging method (light intensity, frequency, wavelength). The pH 
dependence differs for classes from high for yellow, middle for green and low for blue and red emit-
ting proteins. 
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Figure 7: Schematic comparison of selected FPs ranked after the emission maxima in relation to their relative brightness 
(original values from
31
 and manufacturer´s website). To make the fluorescence brightness comparable, quantum yield 
(QY) and molar extinction coefficient (EC) were multiplied and normalized to EGFP (EC= 55,000 M
-1
cm
-1
, QY= 0.6).    
1.3.2 Bioluminescence imaging 
The bioluminescence effect can be used for imaging thanks to the discovery of the enzyme luciferase 
from the firefly Photinus pyralis in 1978 and successful cloning into mammalian cells . In a naturally 
occurring form of chemiluminescence, the luciferase (Luc, Photinus-luciferin 4-monooxygenase) oxi-
dizes in an ATP-dependent two-step process the substrate D-LuciferinII (Figure 8).  
 
Figure 8: Simplified reaction scheme for the firefly luciferase
66
. In an initial reaction, the enzyme-bound luciferyl adenyl-
ate is formed in the presence of Mg
2+
 and ATP. In the second step, an oxygenation of LH2-AMP leads to the excited state 
of oxyluciferin, which degrades to the ground state by emission of light in the last reaction step.    
Applications for BLI were first developed for in vitro biochemical and molecular assays for fast quan-
titative measurements of protein interactions and enzyme reactions67. Since the first in vivo applica-
tion for visualizing luciferase gene expression in vivo68, the method was continuously developed69.  A 
potpourri of different luciferases has emerged from various species and exhibiting different proper-
ties (required substrate, wavelength, need or lack of ATP-dependence) (Table 2). Technical and com-
putational advancements enable spectral unmixing of luciferases emitting at different wavelengths, a 
method which is also applicable in vivo70.  
                                                             
II D-Luciferin: (S)-2-(6´-hydroxy-2´-benzothiazolyl)-2-thiazoline-4-carboxylic acid 
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BLI is beneficial for cell tracking approaches (compared to FLI) because the localization is achieved by 
the unambiguous light emission from genetically modified cells, and the ATP-dependent enzyme 
reaction serves as an indicator for cell viability. In addition, quantification is possible based on the 
relationship between enzyme-substrate complex and photon emission. BLI has been proven in vari-
ous studies as a valuable imaging reporter for noninvasive monitoring of tumor cells and stem cells in 
various disease models71–74. In vivo BLI approaches are strictly determined by biological factors (e.g. 
substrate availability) and physical factors (e.g. wavelength), which will be discussed in chapter 4.  
Table 2: Properties of luciferases from different species 
Luciferase Species 
Emission 
in vitro 
Emission 
in vivo  
Quantum 
Yield 
Substrate  
Protein 
Size 
Energy 
Source 
Cofac-
tor 
Refer-
ence 
Luc2 Photinus pyralis 562 nm 616 nm 0.44 D-Luciferin 61 kDa ATP Mg
2+
 
76
 
PpYRE9 Photinus pyralis 617 nm 617 nm N.A. D-Luciferin 61 kDa ATP Mg
2+
 
77
 
CBG99 
Pyrophorus plagi-
ophthalamus 
546 nm 546 nm 0.62 D-Luciferin 61 kDa ATP O2 
78
 
GLuc Gaussia princeps 485 nm 485 nm N.A. CTZ-h 20 kDa substrate - 
79
 
hRLuc Renilla reniformis 480 nm 480 nm 0.06 CTZ-h 34 kDa substrate - 
80
 
Vluc 
Vargula hilgen-
dorfii 
462 nm 462 nm 0.28 Vargulin 68 kDa substrate O2 
81,82
 
Cluc 
Cypridina noctilu-
ca 
465 nm 465 nm N.A. Vargulin 68 kDa substrate O2 
83
 
1.3.3 Optical imaging-based cell tracking  
An optical imaging-based cell tracking approach can be subdivided into 3 experimental steps: 1) gen-
eration of transgenic cells expressing a luciferase and/or fluorescent protein, 2) in vitro cell charac-
terization of the optical properties and the impact of the transgene, and 3) the in vivo application, 
e.g. transplantation of the cells and subsequent optical tracking in the mouse brain. Following this 
approach, numerous applications have been reported for bioluminescence-based cell tracking to 
glioblastomas84, ischemic lesions85 and multiple sclerosis inflammatory regions86. For fluorescent-
based brain applications the recent discovery of near-infrared proteins enabled first applications 87,88. 
The GFP fluorescent protein is not suitable for in vivo imaging in the brain and detection ex vivo is 
limited due to high green tissue autofluorescence and low GFP stability/persistence against histologi-
cal treatment. The fluorescence proteins used for experiments described in this work belong to a 
new generation of enhanced green or red fluorescence proteins, exhibiting strong signal also for ex 
vivo detection. As was pointed out before (1.3), optical imaging in the brain is challenged by the spe-
cial anatomical compartment and therefore dependent on an optical reporter with highest sensitivi-
ty. A complete investigation of optical reporters suitable to meet brain imaging has not been done. 
The following experimental section will highlight which luciferase works best for optical cell tracking 
and how fluorescent proteins can be coupled efficiently to serve as histological landmarks.  
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2. MATERIAL & METHODS 
2.1 Devices 
Table 3 summarizes the devices for each experimental category (cell culture, molecular biology, pro-
tein biochemistry, histology and animal experiments).  
Table 3: List of devices sorted according to experimental categories.  
Device Name Supplier 
Cell culture 
Liquid nitrogen tank Arpege 170  VWR 
Electroporator GenePulser Xcell Biorad 
Incubator HERA cell 150 ThermoScientific 
Centrifuge Himac CT6E VWR 
Confocal microscope TCS SP2 Leica 
Fluorescence microscope BZ-9000 Keyence 
Laminar cabine Kojair Biowizard and MSC-Advantage ThermoScientific 
Hotplate stirrer L-81 Hartenstein 
Microplate Reader Sunrise/ Mithras LB 940 Tecan/Berthold 
Light Microscope Axiovert 4CFL and Axiovert 135 Zeiss 
Molecular biology 
Centrifuge 2415/Multifuge 1 S-R Sigma-Aldrich/Heraeus 
Electrophoresis EasyPhor Midi Biozym 
Gel documentation Gel Doc XR Bio-Rad 
PCR GeneAmp PCR System 2400 Perkin-Elmer 
qPCR TProfessional Thermocycler Biometra 
Spectrometer BioSpectrometer basic Eppendorf 
Thermomixer Thermomixer comfort Eppendorf 
Protein biochemistry 
SDS electrophoresis X-Cell Surelock Mini-Cell Invitrogen 
Western blot X-Cell II blot module Invitrogen 
Histology 
Cryostat CM3050 Leica 
Microscope/ Confocal Microscope BZ-9000/ TCS SP2 
 
Keyence/ Leica 
Animal experiments   
4.7, 7.0 and 11.7 T animal MRI scanner Biospec47/30, 70/30, 117/16 Bruker BioSpin 
BLI camera system Photon Imager/IVIS spectrum Biospace/PerkinElmer 
Stereotactical instrument Cat. No. 51600 Stoelting 
Mouse Adapter Cat. No. 51625 Stoelting 
Temperature controller - medres 
Electric Driller Technobox 810 Bien-Air 
Digital navigation system  Cat. No. 51904 Stoelting 
Digital injection controller Micro 4 World Precision Instruments 
Hamilton syringe 5µl with 26 G needle Cat. No. 7634-01, 7732-06 Hamilton 
Surgical instruments (scissors, forceps) Various FST 
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2.2 Consumables 
The following table summarizes consumables used for the highlighted experiments. Chemicals, which 
are not listed were purchased exclusively from Sigma-Aldrich and Merck. Standard buffer (PBS, TBS, 
Tris-HCL were prepared in aqua bidest according to established recipes89. Dilutions of stock solutions 
for animal experiments were prepared in physiological saline to facilitate physiological distribution. 
All solutions for cell culture and animal experiments were sterile filtered (0.2 µm filter, VWR). Con-
sumables were stored according to manufacturer recommendations.  
Table 4: List of consumables for cell culture, molecular biology, protein biochemistry and animal experiments 
Name Product nr. Supplier 
Cell culture   
Agarose Typ VII-A low-gelling A0701 Sigma-Aldrich-Aldrich 
Agarose A9539 Sigma-Aldrich-Aldrich 
Accutase L11-007 PAA 
B27 Supplement (50x) 17504 Gibco 
beta-mercaptoethanol  (50mM) 31350, 50 mM Gibco 
BSA K31-011 PAA 
Cell culture plates, flasks, (Pasteur) 
pipettes, pipet tips, filter, eppis,  
various Brand, Greiner, Nunc, Sarstedt and 
VWR D-Luciferin sodium salt, 99%  
 
bc218 
 
Synchem 
 DMEM high Glucose (4,5g/l) E15-883 PAA 
DMEM/F12 (1:1) 31330-038 Gibco 
Dotarem® - Guerbet 
EZ-PCR Mycoplasma kit 20-700-10 WKS Diagnostik 
EGF-human AF-100-15 PreproTech 
Euromed ECL-ECM0883L Biozol 
FBS/FBS  ES-cell tested A15-101/ Lot 751710 PAA/Gibco 
FGF-human AF-100-18B PreproTech 
G418 (Neomycin) P25-011 PAA 
Gelatine 2% G1393 Sigma-Aldrich 
Glutamin  M11-004, 200 mM PAA 
GMEM 1x 21710025 Gibco 
HBSS 1x 14170 Gibco 
Insulin human, rekombinant (10mg/ml) I9278 Sigma-Aldrich 
ITS (100x) I3146-5ml Sigma-Aldrich 
Laminin (1mg/2ml) 11 243 217 001 Roche 
LIF (10
6
 Units) ESG1106, 106units/ml Millipore 
Lipofectamin LTX + Plus Reagent Kit 15338-100 Invitrogen 
N2-Supplement (100x) 17502-048 Gibco 
Mycoplasma Test Kit 20-700-20 Biological Industries 
NEAA (100x) M11-003 PAA 
Neurobasal 21103 Gibco 
Nickel 72247 Sigma-Aldrich 
Optimem 11058-021 Gibco 
Penicillin/Streptomycin P11-010 PAA 
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Name Product nr. Supplier 
Cell culture   
PBS with Mg
2+
/Ca
2+
 H15-001 PAA 
PBS w/o Mg
2+
/Ca
2+
 H15-002 PAA 
Poly-L-Ornithin  P4957 Sigma-Aldrich 
PrestoBlue A-13261 
 
Invitrogen 
Sodium pyruvate  P3662 Sigma-Aldrich 
Trypan blue 93595 Sigma-Aldrich 
Trypsin/EDTA 11-004 PAA 
Zeocin R250-01 Invitrogen 
Molecular biology 
DEPC K028.2 Roth 
DNA Polymerization Mix 10 (dNTPs) GC-013-004 GeneCraft  
dTT R0861 Fermentas 
FastDigest restriction enzymes various Fermentas 
Gel Extraction Kit 287704 Qiagen 
LE Agarose 840004 Biozym 
LB Medium A6666 AppliChem 
Mass Ruler 6x loading dye RO621 Fermentas 
Mass Ruler DNA ladder SMO403 Fermentas 
Midori Green 617002 Biozym 
Nucleo Spin Gelextractin Kit  74060950 Machery-Nagel 
Nucleo Spin RNA ll  74095550 Machery-Nagel 
Oligo dT 79237 Qiagen 
Omniscript RT Kit 
 
205111 Qiagen 
Phusion Hot Start Polymerase F540s Finnzymes 
Plasmid Midi Kit  12243 Qiagen 
Plasmid Mini Kit 27106 Qiagen 
Rapid Dephos + Ligation Kit 4898117001 Roche 
SensiMix No-Rox OT650-05 Bioline 
T4- DNA-Ligase 10716359001 Roche 
Protein biochemistry 
AOAA C13408 Sigma-Aldrich 
Amersham Hyperfilm ECL 28906839 GE Healthcare 
BCA protein assay 23221 Thermo-Scientific 
Cell Lysis Buffer 9803 Cell Signaling 
Complete protease inhibitor cocktail 04 693 159 001 Roche 
ECL solution RPN2209 GE Healthcare 
M-PER lysis buffer 78503 Thermo-Scientific 
Novex 8-16% Tris-Glycine Mini Gels EC6045BOX Invitrogen 
PageRuler Plus SM1811 Fermentas 
Protran Nitrocellulose Membrane 10402506 Whatman 
PLP P9255 Sigma-Aldrich 
Restore Plus Stripping buffer 10016433 Thermo-Scientific 
TBS-Tween tablets 524753-1EA Merck Chemicals 
1 
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Name Product nr. Supplier 
Histology   
Alkaline Phosphatase Detection Kit SCR004 Millipore 
Glass ware various VWR 
Mounting Medium Aqua-mount Thermo-Scientific 
Microscope Slides 4951PLUS Thermo-Scientific 
Animal experiments 
Carprofen Rimadyl® Pfizer 
Coelenteratazine-h, RediJect 760506 PerkinElmer 
D-Luciferin, sodium salt bc218 Synchem 
Isoflurane Isoflurane Abbott 
Hamilton syringe 5µl with 23 G needle 7634-01, 7732-06 Hamilton 
Ketamine Ketavet Pfizer 
Physiological saline NaCl 0.9% Braun 
Pentobarbital PTB-537-NA Lipomed 
Surgical instruments (scissors, forceps) Various FST 
Suture (non-colored) PGA Resoquick 5/0 USP Resorba 
Syringes and needles various Braun 
Xylazine Rompun® Bayer 
   
2.3 Molecular Biology 
2.3.1 Cloning of imaging reporter plasmids 
Lenti- and retroviral plasmids (Table 5) were cloned by amplification of the gene of interest with spe-
cific primer (Table 5) with Phusion DNA Polymerase designed to fit the FastDigest restriction enzymes 
necessary for ligation with the plasmid backbone (protocols used according to manufacturer´s speci-
fications). The following plasmids were donated or purchased: pBabe-neo-GIT (generous gift of A. 
Jacobs, European Institute for Molecular Imaging, Münster, Germany), pcDH and pPACKH1 (Biocat, 
Heidelberg, Germany), pGL (Promega, Madison, USA) pGex and phu (generous gift of L. Mezzanotte 
and E. Kaijzel, Leiden University Medical Center, Leiden, Netherlands), pDRIVE (Invivogen, San Diego, 
USA) and pCH (generous gift of Rob Hoeben, Leiden University Medical Center, Leiden, Netherlands). 
The HIV-1 derived lentiviral vector included the following parts:  
 Multiple Cloning Site (MCS) 
 EF1alpha promoter - constitutive promoter for highly efficient expression90 
 T2A - self-cleaving 2A-like peptide sequence for efficient multicistronic reporter expression 
 WPRE element - enhances stability and translation 
 SV40 polyadenylation signal - enables efficient termination of transcription 
 Hybrid RSV/5LTR promoter - provides high level of expression of full-length viral transcript 
 Genetic elements (cPPT, gag, env, LTRs) - necessary for packaging, transducing, and integrat-
ing of the viral expression construct into genomic DNA 
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 SV40 origin - for stable propagation of the pCDH plasmid in mammalian cells 
 pUC origin - for high copy replication and maintenance of the plasmid in E.coli cells 
 Ampicillin resistance gene - for selection in E.coli cells.  
The lentiviral expression vectors are combined with the pPACKH1 plasmid mix containing 3 plasmids 
for the structural (gag), replication (pol), regulatory protein (rev) and the envelope glycoprotein of 
vesicular stomatitis virus (VSV-G)91. By combination of the expression vector and the pPACKH1 mix 
during the transduction process, pseudoviral particles are produced, which can infect mammalian 
and non-mammalian target cells (amphotropic virus) but cannot replicate (biosafety level 2). 
The retroviral expression vector pBabe is derived from Moloney murine leukemia virus (MMLV) and 
produces only in combination with the packaging cell line Plat-E92 (bearing the viral structural genes) 
pseudoviral particles. Based on the MMLV envelope protein, these particles have a limited host range 
(mouse) and refer to an ecotropic virus (biosafety level 1).   
The following cDNAs were used to modify the backbone plasmids: the human GFAP promoter, the 
luciferases (Luc2, PpyRe9, CBG99 and hRluc) and the fluorescent proteins mCherry from Discosoma 
sp. and copGFP from Pontenilla plumata. Modified plasmids were verified by sequencing (GATC Bio-
tech, Konstanz, Germany) with primer pairs flanking the gene of insert. All generated imaging report-
er plasmids are listed in Table 5 with the associated PCR primer pairs used for cloning in Table 6.  
Table 5: Overview of cloning strategy for imaging reporter plasmids 
Plasmid Insert Backbone origin Insert origin Restriction 
pcDH-pBabe-Luc2-T2A-copGFP-Neo Luc2 pBabe-Neo-GIT 
pcDH-EF1-Luc2-T2A-
copGFP 
EcoRI/SalI 
pcDH-EF1-Luc2-T2A-copGFP Luc2 EF1-MCS-T2A-copGFP pGL4.14 BamHI/NotI 
pcDH-EF1-PpyRe9-T2A-copGFP PpyRe9 EF1-MCS-T2A-copGFP pGex-Pret9 BamHI/NotI 
pcDH-EF1-CBG99-T2A-copGFP CBG99 EF1-MCS-T2A-copGFP pGL3 CBG99 NotI/BamHI 
pcDH-EF1-hRluc-T2A-copGFP hRLuc EF1-MCS-T2A-copGFP 
hRluc PCR (from pGL4 
hRluc) 
XbaI/BamHI 
pcDH-EF1-Luc2-T2A-mCherry mCherry EF1-Luc2-T2A-cop GFP 
mCherry PCR (from 
phu-DCX 3509-
mCherry) 
BspEI / SalI 
pCDH-GFAP-T2A-Puro GFAP 
promoter 
EF1-MCS-T2A-Puro 
GFAP PCR (from 
pDRIVE-hGFAP) 
ClaI/XbaI 
pcDH-GFAP-P2A-T2A-Puro P2A GFAP-T2A-Puro 
pCH-CMV-eGFP-P2A-
fLuc 
EcoR1/BamH1 
pcDH-GFAP-Luc2-P2A-mCherry-T2A-Puro Luc2 GFAP-P2A-T2A-
mCherry-Puro 
Luc2 PCR (from 
pGL4.14) 
EcoRI/XbaI 
pcDH-GFAP-Luc2-T2A-mCherry GFAP 
promoter 
EF1-Luc2-T2A-mCherry 
pcDH-GFAP-MCS-T2A-
cop GFP 
ClaI/XbaI 
pcDH-GFAP-Luc2-T2A-mCherry-SV40-Zeo SV40-Zeo GFAP-Luc2-T2A-
mCherry 
pBabe-SV40-Zeo KpnI 
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Table 6: PCR primer pairs for cloning  
Name Sequence 5'-3' Length (bp) CG-content (%) Tm (°C) 
Luc2_BamHI_for AAGGGAAAGGATCCGCCACCatggaagatgccaaaaacattaag 44 46 73 
Luc2_NotI_rev AAATTTGCGGCCGCcacggcgatcttgc 28 61 71 
PpyRe9_BamHI_for AAGGAAAAAGGATCCGCCACCatggaggacgccaag 36 56 74 
PpyRe9_NotI_rev AAATTTGCGGCCGCgatcttgccgccc 27 63 71 
CBG99_BamHI_for AAG GGA AAA GGA TCC GCC ACC atg gtg aag cgt gag 36 56 74 
CBG99_NotI_rev TAAAA GCGGCCGC acc gcc ggc 22 73 70 
hRluc_XbaI_for AAG GGA AAA TCTAGA GCC ACC atg gct tcc aag 33 49 64 
hRluc_BamHI_rev TAAAAGCC GGATCC ctg ctc gtt ctt cag 29 52 68 
mCherry_BamHI_for AAGGGAAAAAGGATCCAATGgtgagcaagg 30 47 63 
mCherry_BamHI_rev AAATTCTCGGATCCCTTGTACAGCTCGTCC 30 50 64 
mCherry_BspEI_for AAGGGAAAAATCCGGAAtg gtg agc aag 28 46 61 
mCherry_SalI_rev TAAAAGCCGTCGACttacttgtacagctcg 30 47 61 
P2A_EcoRI_for AAGGGAAAAAGAATTCGGTGGTGGCTCGG 29 52 64 
P2A_BamHI_rev TAATTGCGGGATCCTGGTCCGGGATTCTC 29 55 64 
GFAP_ClaI_for AAGGGAAAAAATCGATgtctgcaagcagacctgg 34 47 70 
GFAP_XbaI_rev TAAAAGCCTCTAGAatgctctggctctgctcg 32 50 70 
SV40-Zeo_KpnI_for ATGGGATATATGGTACCcctgtggaatgtg 30 
 
46 62 
SV40-Zeo_KpnI_rev TAATTGCCGGTACCtcgatcggtcag 26 53 63 
2.3.2 Qualitative identification of gene expression with PCR 
The primer pairs for PCR were designed using the Primer-Blast tool from the National Center for Bio-
technology Information (NCBI, Bethesda, USA) – whenever possible selected primer pairs span exon-
exon junctions in the reference sequence (Table 7). Actin was used as reference. Lineage marker 
were selected according to manufacturer´s recommendation and literature data93.    
Table 7: Properties of PCR primer pairs for identification of gene expression in mouse cells.  
Name Sequence 5'-3' 
Length 
(bp) 
GC-content 
(%) 
Tm (°C) 
Product 
(bp) 
Accession Nr. 
5T4  for AACTGCCGAGTCTCAGATACC 21 52 53 
506 NM_011627.4 
5T4 rev ATGATACCCTTCCATGTGATCC 22 46 51 
Actin for CAGGTCATCACTATTGGCAA 20 45 49 
574 NM_007393.3 
Actin rev ATCGTACTCCTGCTTGCTGA 20 50 50 
Brachyury for TGCTTTCCCGAGACCCAGTT 
 
20 55 61 
303 NM_009309.2 
Brachyury rev CCGGTGGTTCCTTAGAGCTG 
 
20 60 60 
BLBP for ATGAAAGCTCTGGGCGTGGGC 21 62 60 
322 NM_021272.3 
BLBP rev AGCGAACAGCAACGATATCCCCA 23 52 59 
DCX for TTTCTACCGCAATGGGGACC 20 55 60 
897 AF045547.1 
DCX rev AATGACAGCGGCAGGTACAG 20 55 60 
Galc  for CGTGAGCACCGCTTCACGCT 20 65 60 
130 NM_008079.3 
Galc  rev ATGTTGGTCCAGTGGTGATCGCC 23 56 59 
GATA6 for AAACTGAGCCCCTTCGCGGC 20 65 60 
765 NM_010258 
GATA6 rev GGAGCCGCAGTTCACGCACT 20 65 60 
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Name Sequence 5'-3' 
Length 
(bp) 
GC-content 
(%) 
Tm (°C) 
Product 
(bp) 
Accession Nr. 
GFAP for AAGAGACAGAGGAGTGGTAT 20 45 49 
518 NM_010277.3 
GFAP rev GTCCTTAATGACCTCACCAT 20 45 49 
Musashi1 for ATGCCTTCATGCTGGGTATT 20 45 57 118 
 
NM_008629.1 
Musashi1 rev CGGAATTCGGGGAACTGGTA 20 55 60 
Nanog for TGCTCTTTCTGTGGGAAGGCTGC 23 56 60 
899 NM_028016.2 
Nanog rev AGCATTCCAAGGCTGGCCGTT 21 57 60 
Nestin for TGTCAAGGTCCAGGATGTCA 20 50 58 
335 NM_016701.3 
Nestin rev GCTCTAGTCCATTCTCCATC 20 50 55 
NeuroD1 for TTCGCCCACGCAGAAGGCAA 20 60 60 
653 NM_010894.2 
NeuroD1 rev CAGGCAGCCGGCGACCAAAT 20 65 60 
NF-h for TCTGAACGACCGCTTCGCGG 20 65 60 
587 NM_010904.3 
NF-h rev GGTCCAACCTCACTCGGAACCAC 23 60 60 
Oct4 for GCCCTGCAGAAGGAGCTAGAAC 22 59 63 
459 NM_013633.1 
Oct4 rev GGAATACTCAATACTTGATCT 21 33 50 
Olig2 for ACAGACCGAGCCAACACCAGCGC 23 65 63 
546 NM_016967.2 
Olig2 rev CCCGTGCGCGTAAGGCATGAC 21 66 61 
Pax6 for GGCAACCCACGCAAGATGGC 20 65 60 
454 NM_013627.4 
Pax6 rev GCGGTGTCTGTTCGGCCCAA 20 65 60 
Prominin 1 for  TCCTGTGCAGCAATCACTGA 20 54 60 
445 
NM_008935.2 
 Prominin 1 rev CACAGTCTCAACATCGTCGT 20 52 60 
Rex-1 for TGACCCTAAAGCAAGACG 18 50 54 
 
414 NM_009556.3 
Rex-1 rev ATAAGACACCACAGTACACACC 22 45.5 57 
S100beta for AGCAGCAAAGGTGACCAG-
GAGCTCC 
25 60 62 
555 NM_009115.3 
S100beta rev G ACCAGTCAGCTCACGGGA 21 67 60 
Sox1 for TTACTTCCCGCCAGCTCTTC 20 55 54 
555 
NM_009233.3 
 Sox1 rev TGATGCATTTTGGGGGTATCTCTC 24 46 55 
Sox2 for TGCTGCCTCTTTAAGACTAGGGCT 24 50 57 
506 NM_011443.3 
Sox2 rev CTGCCCCCGGGACCATACCA 20 70 60 
Synaptophysin for 
mouse for 
GCCTGTCTCCTTGAACACGAAC 22 55 65 
287 NM_009305.2 
Synaptophysin rev TACCGAGAGAACAACAAAGGGC 22 50 64 
 
The protocol for conventional detection of 
gene expression by RT-PCR included 1) the 
total RNA extraction, 2) single strand cDNA 
synthesis with 5 μg of purified total RNA, 3) 
the PCR reaction mix (Table 8), 4) the PCR 
run (initial denaturation 98°C 30 s, 35 cycles 
of Denaturation 98°C 5 s – Annealing 
TM=55-60°C 30 s – extension 72°C 30 s and 
the final extension 72°C 10 min) and 5) the 
evaluation after electrophoresis (1% agarose gel, TrisHCL, 100 V, 45 min). 
Table 8: PCR mix 
 
  
Component 
Final concen-
tration 
Volume 
(µl) 
H2O, PCR grade - 10.8 
MgCl2 (stock 25 mM) 3 mM 0 
PCR primer forward (stock 10 µM) 500 nM 1 
PCR primer reverse (stock 10 µM) 500 nM 1 
5x Phusion HF buffer 1x 4 
dNTPs (stock 10 mM) 200 µM 0.4 
DMSO 
 
0.6 
Phusion 
 
0.2 
total volume 
 
18 
mix 2 µl DNA (100 ng) with 18 µl the reaction mix 
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2.3.3 Quantification of gene expression with qPCR 
The qPCR primer pairs were selected with the QuantPrime94 software and selected for high specificity 
based on NCBI mouse reference sequences. GAPDH was chosen as housekeeping gene, because of 
the reported stable expression in mouse embryonic stem cells and neural differentiation protocols95. 
Table 9: Properties of qPCR primer pairs for quantification of gene expression in mouse cells. 
Name Sequence 5'-3' Length 
(bp) 
CG-content 
(%) 
Tm (°C) Accession Nr. 
qDCX for TGGAAACAGCCCACCCTTTCTG 22 55 56.7 NM_001110222 
qDCX rev ACCATGCATTTACTCTCCAAAGGC 24 46 55.7  
qGAD1 for CAGCCAGACAAGCAGTATGACG  22 55 57 NM_008077.4 
 qGAD1 rev TTGCTTTCCACATCAGCCAGAAC 23 48 57  
qGAD2 for ACCACAATGGTCAGCTACCAACC 23 52 57 NM_008078.2 
qGAD2 rev TTTGAGATGACCATGCGGAAGAAG 24 46 56  
qGAPDH for CATGGCCTTCCGTGTTCCTA  20 55 54 NM_008084.2 
qGAPDH rev GCGGCACGTCAGATCCA 17 65 52  
qGFAP for TCAATGCTGGCTTCAAGGAGAC 22 50 54.8 NM_010277.3 
 qGFAP rev CATTGAGCTCCATCATCTCTGCAC 24 50 57.4  
qGlast for TTGGCATTGGCAGAGGACCAAC 22 54.5 62.9 NM_148938.3 
qGlast rev AGTAGAGGAGATCAGCCTCCTGTC 24 54.2 60.4  
qMAP2 for AGCAGGATGACGGGCTGAAATC 22 54.4 63.3 NM_001039934.1 
 qMAP2 rev AGCTACCTTCAGCCAAACTGAGC 23 52.2 63.4   
qNestin for AGTGGCTACATACAGGACTCTGC 23 52 57.1 NM_016701.3 
  qNestin rev TTCTTCCAGGTGTCTGCAAGCG 22 55 56.7   
qOct4 for TGTTTCTGAAGTGCCCGAAGCC 22 55 56.7 NM_013633.3 
qOct4 rev CCAAGCTGATTGGCGATGTGAG 22 55 56.7   
qS100beta for TGGCTGCGGAAGTTGAGATTCAC 23 52.2 62.4 NM_009115.3 
qS100beta rev TCCCAGCAGCTAAAGGACACAC 22 54.5 62.1  
qSynaptophysin for CCAGAACGGACATAACCTGGGAAG 24 54.2 63.3 NM_009305.2 
qSynaptophysin rev ACATTTCGCTCACCCTCCAAACC 23 52.2 63.9  
qTubb3 for ATGAGGCCTCCTCTCACAAGTATG 24 50 57.4 NM_023279.2 
 qTubb3 rev TTCCAGGTTCCAAGTCCACCAG 22 55 56.7  
 
The protocol for quantification of gene expression consisted of the 1) cDNA preparation (see 1.3.2), 
2) the reaction mix (Table 10) with the SensiMix SYBR No-ROX kit including a dilution series of cDNA-
mix from all samples for determining primer-specific PCR efficiency (2.5-100 ng) and the single cDNAs 
(100 ng per reaction) in triplicate and 3) the PCR run (initial denaturation 95°C 10 min, 40 cycles of 
denaturation 95°C 15 s – Annealing TM=58-62°C optimized for each primer pair for 15 s – extension 
72°C, melting curve at the end of the amplification from 65 to 99°C with ΔT=1°C, heating rate=1°C/s). 
Data was evaluated using the software PCRsoft V1.1 and the Relative Expression Software Tool 
V2.0.1396. Relative quantification based on the ∆∆CT method was achieved by determining the PCR 
efficiencies for each primer pair with the cycle threshold (CT) values from the cDNA-mix and CT val-
ues for each specific gene. Results were calculated in relation to the housekeeping gene GAPDH.  
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Table 10: qPCR reaction mix 
Component Final concentration Volume (µl) 
H2O, PCR grade - 7 
MgCl2, stock solution, 25 
mM 
3 mM 0 
PCR primer forward, 10 µM 500 nM 1 
PCR primer reverse, 10 µM 500 nM 1 
DNA master mix 2x 1x 9 
total volume 
 
18 
mix 2 µl cDNA (100 ng) with the reaction mix 
 
2.3.4 Protein Biochemistry 
Western blot 
Western blot analysis was performed using as standardized setup with commercially available con-
sumables (see Table 4)III. For cell lysates, 2-3x106 cells were washed with ice-cold PBS and scraped 
from the plate with 4 ml/cm2 with complete lysis buffer (10 ml stock: 9 ml 1x Cell Lysis Buffer + 5 µl 
PMSF + Protease inhibitor cocktail tablet). The mixture was kept on ice for 30 min and vortexed occa-
sionally, followed by 20 min centrifugation (20,000 xg, 4°C). The resultant supernatant contained the 
proteins, which were measured with the BCA protein assay at 570 nm in 96-well plates. For each 
protein analysis, 30 µg of total lysate protein were subjected to SDS-polyacrylamide gel electropho-
resis and transferred to nitrocellulose membranes 97. Membranes were blocked with 5% non-fat dry 
milk in TBST for 1 h. Immunolabeling of the blots occurred overnight at 4°C with the primary anti-
body, followed by the HRP-coupled secondary antibody for 1 h at RT (Table 11). Immunolabeling was 
detected on an X-ray film using the ECL developer solution. For evaluation of the X-ray films, ImageJ 
was used (Version 1.42q; National Institutes of Health) to determine the integrated density of the 
protein-of-interest bands in relation to the actin or alpha-tubulin bands as loading control.  
Table 11: List of antibodies used for western blot analysis 
Antigen Host Dilution Product-nr. Supplier 
alpha-Tubulin Mouse 1:5000 CP06 Calbiochem 
beta-Actin Rabbit 1:5000 PM053 MBL 
copGFP Rabbit 1:10000 AB501-EV Biocat 
Goat anti mouse HRP Goat 1:5000 12-349 Millipore 
Goat anti rabbit HRP Goat 1:5000 7074 Cell Signaling 
Goat anti rat HRP goat 1:5000 AP136P Millipore 
Rluc Mouse  MAB4410 Millipore 
GAD65/67 Rabbit 1:750 ab1511 PAA 
                                                             
III Western blot of tissue lysates were obtained according to a modified-protocol including a different lysis buff-
er, for details see114. 
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Tissue lysates for contrast agent assessment 
For contrast agent activation tests with lysates, rat tissues (liver, cortex and cerebellum) were me-
chanically homogenized, and lysed with M-PER lysis reagent according to the manufacturer´s proto-
col. M-PER is a nondenaturating agent, preserving protein structure, which makes it compatible with 
enzyme assays. The protein content was determined and lysates subsequently frozen at -80°C to 
avoid protein degradation. Equal amounts of total protein (3-3.5 mg) were incubated with the con-
trast agent and 0.05 mM of the cofactor pyridoxal-5´-phosphate (PLP) in PBS buffered solution. For 
selective inhibition of the GAD enzyme, the carbonyl-trapping agent aminooxyacetic acid was used at 
250 µM concentration.  
2.4 Cell culture 
2.4.1 Cell lines 
All cell lines were stored in liquid nitrogen tanks and tested regularly for the contamination with my-
coplasma using the mycoplasma test kit according to manufacturer´s protocol. Table 12 gives a short 
overview of cell lines used for the experiments including the references of the first description in the 
literature. A morphological comparison of the major cell lines is visualized in Figure 9 and Figure 10. 
The CGR8 cells were a generous gift from A. Sachinidis (University Cologne, Germany), the D3WT 
from T. Saric (University Cologne, Germany) and the GL261 from A. Jacobs (EIMI, University Münster, 
Germany).  
Table 12: List of experimentally used cell lines 
Name Species Description Reference 
HEK-293(T) Human Embryonic kidney cells, immortalized with sheared adenovirus  
98
 
C17.2 Mouse Neural stem cell line, immortalized by retrovirus-mediated v-myc transfer 
99
 
CGR8 Mouse Embryonic stem cells (129/Ola derived) 
100
 
D3WT Mouse Embryonic stem cells (129S2/SvPas derived) 
101
 
D3WT_N2Euro#4 Mouse Neural stem cells, derived from D3WT - 
GL261 Mouse Glioblastoma cell line (C57BL/6 derived) 
102
 
 
Plat-E Human Packaging cell line optimized for high efficient packaging of retroviruses 
92
 
U373 Human Glioblastoma-astrocytoma - grade III- cell line derived from human 
(Caucasian, male, 61 years old) 
103
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Figure 9: Morphological characterization of tumor cell lines. 293T, GL261 and U373 show unique morphology under 
phase contrast microscopy (scale bar 100 µm). B) ICC for α-tubulin (green) counterstained with Hoechst reveal cytoarchi-
tectural differences (scale bar 20 µm).   
 
Figure 10: Morphological characterization of embryonic and neural stem cell lines. A) CGR8 cells and D3WT exhibit the 
unique embryonic stem cell colony formation – a dense package of homogeneous round cells growing on gelatin coating 
and feeder layer, respectively. Small framed pictures show the alkaline phosphatase staining, which specifically high-
lights embryonic stem cells as red/purple cells. B) The neural stem cell lines D3WT_N2Euro#4 and C17.2 are characterized 
by a bipolar and epithelial morphology, respectively (scale bar 100 µm).   
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2.4.2 Cell culture media, supplements and coatings 
The following tables summarize the composition for each cell culture media (Table 13, calculations 
for a total volume of 50 ml) and cell culture plate coatings (Table 14), indicated by a characteristic 
short name, which is used throughout the text. The media containing growth factors or instable sup-
plements (e.g. N2) were freshly prepared before use and stored not longer than 1 week at 4°C. Sup-
plementation with antibiotics Penicillin/Streptomycin (P/S) was not used for stem cell culture media 
except selection of transduced cells with zeocin (250 µg/ml), or G418 (200 µg/ml). 
Table 13: Cell culture media composition 
Component Final concentration Volume Component Final concentration Volume 
 GMEM FCS*  DMEM FCS 
GMEM  44.0 ml DMEM  44.5 ml 
FCS* (ES-cell tested) 10% (v/v) 5.0 ml FCS 10% (v/v) 5.0 ml 
L-Glutamine  2 mM 0.5 ml L-Glutamine  2 mM 0.5 ml 
LIF  100 units/ml 5.0 µl 
50 l 
P/S 1x 0.5 ml 
beta-mercaptoethanol  50 µM 50.0 µl    
DMEM FCS* N2/B27 
DMEM  41.4 ml Neurobasal  24.2 ml 
NEAA  1x 0.5 ml DMEM/F12  24.45 ml 
L-Glutamine 2 mM 0.5 ml B27 1x 0.5 ml 
FCS* (ES-cell tested) 15% (v/v) 7.5 ml N2 1x 0.25 ml 
LIF  1000 units/ml 50.0 µl L-Glutamine 2 mM 0.5 ml 
beta-mercaptoethanol  50 µM 50.0 µl beta-
mercaptoethanol  
100 µM 100.0 µl 
ITSFN DMEM FCS/HS 
DMEM/F12  49 ml FCS 10% (v/v) 5.0 ml 
L-Glutamine 2 mM 0.5 ml HS 5% (v/v) 2.5 ml 
ITS  1x 0.5 ml L-Glutamine 2 mM 0.5 ml 
   Sodium pyruvate 1x 0.5 ml 
D3N2Euro D3N2Euro FCS 
Euromed  48.275 ml Euromed  47.875 ml 
L-Glutamine 2 mM 0.5 ml L-Glutamine 2 mM 0.5 ml 
N2 1x 0.5 ml N2 1x 0.5 ml 
BSA  50 µg/ml 0.5 ml BSA  0.5 µg/ml 0.5 ml 
Insulin 25 µg/ml 125.0 µl Insulin 25 µg/ml 125.0 µl 
b-FGF  10 ng/ml 5.0 µl FCS 1% (v/v) 0.5 ml 
EGF  10 ng/ml 5.0 µl    
Table 14: Coating procedure for cell culture plates 
Coating Material Procedure 
Gelatine 0.2% in PBS (with Ca
2+
/Mg
2+
)  
Incubate plate with 100 µl/cm
2
 at 37°C 
min. 30 min, wash 1x with PBS 
Poly-L-Ornithin/Laminin (POLA) 
178.6 µl/ml PO, LA 1:100 in PBS (with 
Ca
2+
/Mg
2+
) 
Incubate plate with 100 µl/cm
2
 at 37°C 
min. 4 h, wash 1x with PBS 
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2.4.3 Cell culture protocols 
Cells were incubated under humidified atmosphere with 5% CO2 with exception of those experiments 
under hypoxia (2% O2). Cell counting was done using a Neubauer chamber and the Trypan blue dye 
with respect to the formula: cells/ml=10,000*mean number of cells per large square*trypan blue 
dilution factor*medium dilution factor.  
293T, Plat-E, U373 and C17.2 cells 
Cells were splitted at 80% confluence by washing 1x with PBS (w/o Ca2+, Mg2+) and detachment with 
50 µl/cm2 Trypsin for approx. 2 min at 37°C. Trypsin reaction was stopped with 1-3 ml medium, cells 
collected and centrifuged for 3 min at 1,000 rpm. The pellet was resuspended in 1-3 ml medium and 
the cells counted and subsequently plated (approx. 30,000 cells/cm2). The following complete media 
were used: 293T, Plat-E, U373 (DMEM FCS), C17.2 (DMEM FCS/HS) 
CGR8 and D3WT cells 
The ES cell lines CGR8 and D3WT cells depend on gelatine coating and feeder layers (γ-irradiated 
mouse fibroblast culture, obtained from Dr. Saric Dept. Neurophysiology, University of Cologne), 
respectively. The cells were splitted before reaching 80% confluence (approx. every 2nd day) by wash-
ing 1x with PBS (w/o Ca2+,Mg2+) and detached with 50 µl/cm2 Trypsin for approx. 2 min at 37°C. Tryp-
sin reaction was stopped with 1-3 ml medium, cells collected and centrifuged for 3 min at 1000 rpm 
(except for the EBs, which were centrifuged for 3 min at 500 rpm). The pellet was resuspended in 1-3 
ml medium, the cells counted and subsequently plated (approx. 18,000 cells/cm2). The maintenance 
of pluripotent state needs to be checked regularly for these cells, e.g. by morphological analysis and 
staining for alkaline phosphatase – an enzyme elevated in stem cells (Figure 10).   
Derivation and culture of D3WT_N2Euro#4 
The radial glia-like NSCs were derived after a modified protocol from Conti et al.93: the D3WT cells 
(see above) were seeded on bacteriological grade plates (approx. 2,000/cm2) in DMEM FCS* (w/o LIF) 
for 4 d and subsequently passaged in N2/B27 medium for additional 10-14 d. The developing neuro-
sphere-like EBs were plated on gelatine coated plates and attached on the surface for 1 d. After-
wards, the medium was changed to D3N2Euro, which induced proliferation of FGF- and EGF-
responding cells. The proliferating, adherent cell subgroup was further passaged using Accutase in-
stead of Trypsin for detachment and cultured additional 10 d until the stable cell line develops. For 
further passaging D3N2Euro medium, Aaccutase and gelatine coated plates were essential to main-
tain NSC state. The neuronal differentiation was induced by plating 50,000 cells/cm2 on POLA coating 
in the D3N2Euro media without EGF for 3 d. The cells were further cultured for 7 d in N2/B27 media. 
The glial differentiation was induced by plating 50,000 cells/cm2 on POLA coating and culture in 
D3N2Euro FCS media for 7 d.    
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2.4.4 Transfection protocols 
Cell transfection was used for short-term gene expression analysis and functionality tests of the 
cloned plasmids in 24-well plates (with glas slides and 0.2% gelatine coating for IHC) or black 96-well 
plates for BLI. The day before transfection, cells were seeded at 25,000/cm2 (NSCs) and 17,500/cm2 
(tumor cells) in the complete media. 24 h later, 0.25 µg/cm2 plasmid DNA was diluted in 50 µl/cm2 
OptiMem and mixed with 0.5 µl/cm2 Plus Reagent. After initial incubation at RT for 5 min, 1 µl/cm2 
Lipofectamine LTX was added, mixed and incubated for 30 min to allow lipo-DNA complex formation. 
Afterwards, cell media was exchanged by 50 µl/cm2 lipo complex and incubated for 4 h at 37°C. After 
lipofection, media was refreshed with complete growth media and the cells were further cultured for 
up to 48 h prior testing of transgene expression. In case of experiments with U373 cells, 24 h after 
transfection, cells were additionally stimulated by adding 1.5-5.0 mM valproic acid or 10-50 mM eth-
anol to the media to enhance GFAP expression104,105.  
2.4.5 Transduction protocols 
Ecotrop transduction 
For retroviral packaging, Plat-E cells were plated 24 h prior to transfection at 1x105/cm2 in 
0.25 ml/cm2 DMEM FCS (w/o antibiotics). The transfection was achieved by mixing 0.2 µg/cm2 plas-
mid DNA diluted in 20 µl/cm2 Optimem plus 0.2 µl/cm2 Lipofectamine Plus Reagent and incubating 
for 5 min at RT. Afterwards, 0.25 µl/cm2 Lipofectamine were added and incubated for 30 min to allow 
DNA-lipo complex formation. Before adding the transfection mix, cells were washed 3x with Opti-
mem and supplement with 0.1 ml/cm2 Optimem containing Chloroquine (final conc.: 25 µM). Finally, 
the DNA mixture was added dropwise to the cells, mixed gently by shaking the plate and incubated at 
37°C overnight. 24 h post transfection, the medium was exchanged. The virus collection started 48 
hours post transfection, by centrifugation of the supernatant at 1,500 rpm/4°C for 5 min to pellet cell 
debris. The virus was stored long-term at -80°C. For retroviral infection of proliferating target cells 
(not confluent culture in 24-well plate), medium was exchanged by 200 µl Optimem containing 7.5 
ng/ml Polybrene and 200 µl virus-supernatant. After 24 h of incubation at 37°C, media was ex-
changed. At 48 hours post infection selection with antibiotics or cell sorting via FACS started.  
Amphitrop transduction 
The amphitrop transduction is based on 3 steps: 1) production of pseudoviral particles in a packaging 
cell line (e.g. 293T) by co-transfection of the expression plasmid and packaging vectors, 2) Collection 
of pseudoviral particles from producer cells, and 3) transduction of the target cells with pseudoviral 
particles, which will drive transgene integration into the host genome by reverse transcription. The 
3rd generation lentivector expression system is based on the expression vector, which contains the 
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genetic elements required for packaging, transduction, stable integration of the viral expression con-
struct into genomic DNA, and expression of the reporter, but is lacking genes coding for viral replica-
tion. The structural replication and integration proteins are provided by the packaging plasmids 
pPACKH1-GAG, pPACKH1-REV and pVSV-G. The resulting pseudoviral particles are limited by infection 
and stable transgene transfer into the target cells – the production of new infectious virus particles is 
blocked.  For lentiviral packaging und Biosafety Level 2 criteria, 293T cells were plated 24 h prior to 
transfection at 8.8 x 105 cells/cm2 in 0.2 ml/cm2 DMEM FCS (w/o antibiotics). The transfection mix 
consisted of 1) 2.25 µg pPACKH1 packaging plasmid mix and 1 µg target vector in 100 µl Optimem, 2) 
mixed with 4 µl Lipofectamine Plus Reagent and incubated for 5 min at RT, and 3) the addition of 8 µl 
Lipofectamine LTX, mix and incubation for 30 min at RT to allow DNA-lipo complex formation. Before 
adding the transfection mix, cells were washed 3x with Optimem. Transfection mix plus 4.0 ml Opti-
mem was added and incubated 37°C for 12-15 h. The day after medium was changed and cells fur-
ther incubated at 32°C and 5% CO2 to facilitate transfection process. 48 h post transfection, the first 
virus supernatant was collected and stored overnight at 4°C. This procedure was repeated 24 h later 
and both virus samples were centrifuged at 1,250 rpm for 10 min and aliquoted for long-term stor-
age at -80°C. For lentiviral infection, target cells were prepared the day before by plating on 24-well 
plates at 4,000 cells/cm2 and incubation overnight. The virus mix contained 8 µg/ml polybrene in 
200 µl medium and 200 µl virus stock for each wellIV. The expression of reporter genes was moni-
tored in the target cells the next 2-3 days and medium changed or cells passaged if necessary. If the 
cells exhibited transgene expression during at least 3 passages, cell culture was transferred to Bi-
osafety Level 1 area and selection process (via antibiotics or FACS) started.  
2.4.6 Cell labeling with contrast agents 
The cell labeling procedures were adapted based on previously described protocols. In general, trans-
fection methods are commonly to introduce foreign DNA (see 2.4.4). Moreover, most of the tech-
niques are also able to facilitate uptake of MRI contrast agents dependent on the particle size and 
polarity. Several methods were compared with regard to uptake and influence on cell viabil-
ity/survival using the commercially available paramagnetic contrast agent Dotarem®, which shares 
the chemical structure of the Gd(III) chelate with Gd-DO3A-GAD. The tested methods are 1) Pinocy-
tosis (Pino): a process of spontaneous uptake of contrast agent supplemented to the cell culture me-
dia by the unspecific and random pinocytosis/endocytosis , 2) calcium phosphate precipitation (CaP): 
contrast agent binds to calcium phosphate which crystallizes in a mixture of calcium chloride and 
sodium phosphate and is taken up by endocytosis98, 3) lipofection (Lipo): the contrast agent is coated 
                                                             
IV For transduction of (neural) stem cells supplementation with growth factors is recommend. 
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by a positively charged phospholipid bilayer which induces fusion with the cell membrane106, and 4) 
electroporation (EP), which induces the reversible formation of small pores in the cell membrane 
upon an electrical discharge107. Cells were prepared as follows: undifferentiated CGR8 cells were 
detached with 0.05% trypsin/0.02% EDTA (PAA), centrifuged at 250 xg for 3 min and counted. Differ-
entiated CGR8 cells were detached and dissociated with accutase (PAA) by careful titration, centri-
fuged at 250 xg for 3 min and counted. Pinocytosis was achieved by incubating the cells for 2 h in the 
presence of 50 mM Dotarem®. For lipofection a custom-made transfection agent similar to lipofec-
tamine 108 was used in a lipo:contrast agent ratio of 1:2, preincubated for 30 min, followed by 2 h 
incubation with the cells in complete medium. The CaP transfection mixture was prepared as de-
scribed by 109. Briefly, 2× BES-buffered saline (BBS), 0.25 M CaCl2 and 50 mM Gd-DOTA were mixed in 
a ratio of 2:1 and treated like the lipofection samples. For electroporation 50 mM Gd-DOTA were 
mixed with ice-cold Hanks Balanced Salt Solution (HBSS) and directly electroporated using the 
Genepulser with a 100 V square pulse for 20 s. After EP, cells were placed on ice for 5 min. Independ-
ent of the labeling method, cells were finally washed twice with PBS to remove excessive contrast 
agent and counted by the trypan blue exclusion assay to determine viability and survival rate 
(see 2.4.8). The electroporation protocol was applied to undifferentiated and differentiated cells with 
10 mM Gd-DO3A-GAD. The cells were subsequently plated for 6 h and collected by centrifugation at 
250 ×g for 3 min. Labeled cells were washed and counted as described above. Cell pellets were di-
rectly used for cell implantations by adjusting the cell number to 1.875×105 cells/μl in HBSS or either 
fixed with PFA for 15 min at RT for MRI phantoms.  
2.4.7 Phantom preparation for MRI 
For MRI on cells and lysates a MRI compatible setup was used, which allowed positioning of the 
probes on the MRI animal holder without introducing additional susceptibility artefacts and permit-
ted the long-term storage of the imaging probes. Phantoms for MRI experiments at 4.7 T consisted of 
plastic PCR tubes containing a mixture of cells/tissue lysates and 0.5% low melting agarose covered 
and embedded in 1% agarose (Figure 11A, B).  
The measurements at 1.0 and 7.0 T (at University of Torino) were conducted on cell pellets in glass 
capillaries embedded in a 10 mm glass tube filled with 1% agarose. The agarose phantoms were 
cooled down to room temperature for MRI experiments or cooled down to 4°C for long-term stor-
age. For the quantitative comparison of T1 scans (see section 3.2), two specific phantoms were used: 
a T1 reference phantom (Figure 11) and a PCR tube phantom with distinct concentrations of Gd-DTPA 
(Magnevist®, Bayer) ranging from 0.5-25 mM.  
The reference phantom was prepared according to previous reports110,111: it consists of 9 different 
nickel chloride (NiCl2) concentrations ranging from 0.2 to 1.9 mM in aqua dest, mixed with deuterium 
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oxide (D2O) and agarose in 15 ml falcon tubes (Table 15, Figure 11C). Compared to Gd(III), Ni(II) 
doped agarose is much less temperature and magnetic field strength dependent and exhibits stable 
T1 relaxation times under various experimental conditions.   
Table 15: Composition of the reference phantom tubes.  
Sample NiCl2 (mM) NiCl2 (ml) H2O (ml) D2O (ml) Agarose (g) 
1 1.88 8.30 1.70 0.00 0.06 
2 0.12 0.55 9.45 0.00 0.02 
3 0.24 1.05 8.45 0.50 0.08 
4 0.50 2.20 6.30 1.50 0.13 
5 0.27 1.20 7.30 1.50 0.11 
6 0.91 4.00 5.00 1.00 0.22 
7 0.50 2.20 5.80 2.00 0.25 
8 1.61 7.10 0.40 2.50 0.20 
9 0.58 2.55 5.00 2.50 0.15 
 
 
Figure 11: MRI phantom composition: A) PCR tube phantom for lysate and cell analysis. B) Composition of the PCR tube 
phantom containing three layers of agarose. C) Reference phantom placed in helmholtz coil setup for receive/transmit. 
Pictures illustrate views from the left, top, and a representative RAREVTR scan image with the sample assembly.   
2.4.8 Characterization of labeled cells and transduced cells  
Cell viability and survival rate measured with the trypan blue exclusion assay 
Based on the standard method for cell counting with the trypan blue exclusion assay for cell passag-
ing (see 0), this test was adapted to count the number of viable (transparent) and dead (blue) cells 
per treatment. The resulting number of viable cells in percent gives a “snapshot” information on the 
treatment impact (viability = viable cells/total cell number x 100%). In addition for cell labeling exper-
iments, the number of viable cells was compared to an untreated control group (n=3). This measure 
is capable of reflecting the number of cells, which died because of the labeling – a very important 
measure reflecting the contrast agent toxicity: survival rate = viable cellstreated /viable cellsuntreated x 
100%).  
PrestoBlue live-cell viability assay 
The PrestoBlue assay solves the challenge to determine cell viability quantitatively in short time 
without cell impairment. This assay was used to identify changes in cell viability between transduced 
and wildtype cells. The PrestoBlue reagent is a resazurin-based solution, which is blue and nonfluo-
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rescent, but subsequently turns red and fluorescent (emission max. 586 nm) after cell-endogenous 
reduction processes take place. The fluorescent measurement is quantitative due to the proportional 
relation between conversion and number of metabolically active cells. 24 h before PrestoBlue test, 
5,000 cells/well were plated in 100 µl (96 well). The next day, medium was removed, centrifuged at 
1,000 rpm for 3 min and later used for background correction. Finally, 10 µl and 90 µl complete me-
dia was added to each well and incubated for 2 h at 37°C. The fluorescence was measured using the 
plate reader (adjustments: duration: 0.5 s, lamp Energy: 14,000, excitation: 530 nm; emission: 600 
nm). If luciferase expressing cells were used, bioluminescence could be measured in the same well 
after washing 2x with PBS, adding new media and 1 mM 2 µg/µl D-Luciferin (adjustments: shake for 
10 s, acquisition for 2 s). 
Cell proliferation 
The determination of cell proliferation was achieved by at least 5 subsequent measurements. On the 
first day, 5x 60 mm dishes of each cell line/treatment were prepared in dublicate (approx. 1 x 105 
cells) and counted for the following 5 days. The cell density at day 0 and on the following days was 
used to determine the doubling time – h/generation: doubling time = (log (cell number day x) – log 
(cell number day 0) / log 2 ) / hoursday 0 to x.   
2.5 Histology 
For histological analysis, mice were perfused with 0.1 M PBS and 4% PFA, the brains were removed 
and subsequently frozen in -40°C cold methanol. Longterm stored brains (-80°C) were sliced 10-20 
µm thin using a cryostat and directly used for histology. Conventional histological stainings (e.g. Nissl, 
Hoechst, etc.) and the alkaline phosphatase detection assay for ESCs were performed according to 
established protocols89 and manufacturer´s protocols. Prior to histology, cells were fixed with 4% PFA 
for 15 min at RT and washed 2x with 0.1 M PBS. For immunohistochemistry (IHC) and immunocyto-
chemistry (ICC) analysis, a standard protocol consisting of 1) permeabilization with 0.025% (ICC) or 
0.25 % (IHC) Trition-X-100 in TBS for 10 min, 2) unspecific antigen blocking by 5% BSA in TBS for 60 
min, 3) primary antibody binding in 0.8% BSA for 2 h, 4) coupling of the primary specific secondary 
antibody (Dylight 488 or 549, made in goat, dilution 1:1000, Pierce) in 0.8% for 60 min and counter-
staining of the cell nuclei with Hoechst dye 33342 for 10 min. In between the protocol steps and after 
the last step, cells were carefully washed at least 2x with TBS. The glass slides or object slides were 
mounted with Aquamount and long-term stored at 4°C in the dark.       
Table 16: List of antibodies used for IHC and ICC 
Antigen Host Dilution Product-nr. Supplier 
Alpha tubulin Mouse 1:500 CP06 Calbiochem 
betaIII tubulin Mouse 1:300 T8660 Sigma-Aldrich 
betaIII tubulin Rabbit 1:200 PRB-435P Covance 
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DCX Rabbit 1:500 4604 CellSignaling 
DyLight488 anti-mouse Goat 1:1000 35502 Pierce 
DyLight488 anti-rabbit Goat 1:1000 35552 Pierce 
DyLight549 anti-mouse Goat 1:1000 35507 Pierce 
DyLight549 anti-rabbit Goat 1:1000 35557 Pierce 
GABA Rabbit 1:1000 A2052 Sigma-Aldrich 
GAD65/67 Rabbit 1:200 AB1511 Abcam 
GFAP Mouse 1:750 G3893 Sigma-Aldrich 
GFAP Rabbit 1:200 Z0334 Dako 
Living Colors DsRed 
 
Rabbit 1:500 632496 
 
Clontech 
 Nestin Rabbit 1:500 Ab5968 Abcam 
Nestin Mouse 1:500 MAB353 Millipore 
Oct4 Rabbit 1:200 SC8066 SantaCruz 
 
2.6 Animal experimental protocol 
2.6.1 Animal handling and anesthesia 
All animal experiments were conducted according to the guidelines laid out in the German Animal 
Welfare Act, in accordance with the European Communities Council Directive 86/609/EEC, and were 
approved by the local authorities (Landesamt für Natur, Umwelt und Verbraucherschutz North 
Rhine-Westphalia, reference number 8.87-51.04.20.09.362 and A123). Mice and rats were purchased 
from Janvier (Saint Berthevin Cedex, France). Animals were housed in individually ventilated cages at 
25°C with regulated day-night cycle and handled in relation to the guidelines of the German council 
for laboratory animal use (GF-SOLAS, http://www.gv-solas.de/index.html). The anesthesia protocols 
were adapted from previously described versions37,112.  
For MR measurements, mice were fixed with a tooth bar and ear bars in a custom-made animal 
holder (medres, Cologne, Germany) for stable animal fixation. The holder was coupled to a warming 
pad system for heating. The respiration rate was monitored with a pressure sensitive pad under the 
thorax using DASYlab (Measurement Computing, Norton, USA) software. This setup allowed imaging 
under physiological conditions for several hours. For BLI measurements animals were not fixed (be-
cause of the lower image resolution not necessary), but also warmed to 37°C. In both setups, inhala-
tion anesthesia was conducted by nose caps with constant 2% Isoflurane supply at approx. 1 bar in 
O2:N2O (30:70%). Nitrous oxide is used in this carrier gas-mixture, because of its anesthetic and anal-
getic effect. Isoflurane is one of the most common inhalation anesthetics, exhibiting an analgetic 
effect, reducing muscle tonus and inducing vasodilation. For injection anesthesia, Ketamine/Xylazine 
anesthesia was induced by intraperitoneal (ip) injection of 100 mg/kg ketamine and 10 mg/kg 
Xylazine, resulting in a sleeping time of approx. 45 min. Ketamine is a NMDA-receptor antagonist and 
induces analgesia, anesthesia, hallucinations, elevated blood pressure and bronchodilation. It is 
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combined with the α2 agonist Xylazine for muscle relaxation. Furthermore, Pentobarbital anesthesia 
was applied by injecting 45 mg/kg ip, which resulted in a sleeping time of approx. 45 min. As a barbi-
turate, Pentobarbital induces sedation and anesthesia.  
2.6.2 Intracerebral transplantation 
Cell preparation 
For intracerebral transplantations, cells are cultured for at least 2 passages in advance to allow bal-
anced gene expression and high cell viability. On the day of surgery, cells are detached and counted 
(see cell specific protocols, 0). The cell amount is adjusted carefully to result in a total injection vol-
ume of 2 µl (e.g. 150,000 cells/µl for the injection of 300,000 cells) in HBSS buffer. Cells have to be 
kept on ice until transplantation to ensure high viability. 
Surgery  
Mice were anaesthetized with Isoflurane in O2:N2O (30:70%) and fixed in the stereotactic frame, 
equipped with a warming pad and temperature feedback control for efficient control of the physio-
logical state. For analgesia, Carprofen was injected subcutaneously (sc) using a 2 ml syringe with a 
30g needle (4 mg/kg sc). The skull was exposed by a small incision and hole(s) were drilled at the 
following coordinates relative to bregma: AP+0.5; L±2.0; DV−2.5 using a stereotactical instrument. 
The homogeneous cell suspension was injected into the brain through a Hamilton syringe using a 
micropump system with flow rates of 1,500 nl/min (withdraw) and 500 nl/min (injection). Before 
removing the syringe, it was left in place for 5 min to allow the cells to diffuse locally. The wound was 
sutured and the animal woke up under controlled conditions in an incubation chamber at 30°C.  
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Figure 12: The technical setup for stereotactical injections included a driller, the stereotactical mouse holder equipped 
with a motorized injection for Hamilton syringes, a microinjection controller and digital navigation system. Animals were 
kept under Isoflurane anesthesia by using a vaporizer and O2/N2O 30:70% at physiological conditions by heating with 
warming pad controlled by a temperature probe.  
 
2.7 Experimental imaging setup 
2.7.1 Evaluation of MRI sequences for determining T1 relaxation 
A precise determination of T1 relaxation is a prerequisite for experiments with a paramagnetic con-
trast agent, which is designed for T1 contrast weighted MRI. Spin echo with inversion recovery 
(MSME_IR) serves as the NMR reference, hampered for in vivo imaging by the long aquisition time. 
Therefore, a variety of different MRI sequences comprising different physical principles for determin-
ing T1 were tested in order to select a short and stable method, which fits to in vitro and in vivo con-
ditions: 1) variation of the repetition time with fixed echo time (TE) and flip angle (FA), 2) variation of 
inversion time (TI) with fixed TE, TR and FA. The sequences were either gradient echo (FLASH) or spin 
echo based (MSME, RAREVTR). The signal intensity per voxel was plotted against the variable time 
constant or flip angle and fitted with the Bloch equations (see 1.2) per voxel using an in-house soft-
ware (see 2.7.4).  
These measurements were conducted with the Nickel standard phantom (Table 17), the Gd-DTPA 
phantom (Table 18) and applied for in vivo tests on mice and rats (Table 19).  
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Table 17: MRI parameter for optimizing T1 relaxometry in vitro with the Nickel standard phantom 
Nickel standard phantom 
 FLASH_TR FLASH_IR MSME_TR MSME_IR RAREVTR 
TR/TI (ms) 14x (50 – 10000) 15x (20 – 5000) 16x (65 – 10000) 13x (75 – 5000) 12x (100 – 5000) 
TE (ms) 4 4 13.5 13.5 12 
FA 30° 90° 90° 90° 90° 
FOV (mm) 70x70 70x70 70x70 70x70 70x70 
Matrix 128x128 128x128 128x128 128x128 128x128 
Resolution (mm) 0.547x0.547 0.547x0.547 0.547x0.547 0.547x0.547 0.547x0.547 
Slice (mm) 2 2 2 2 2 
Averages 4 4 4 4 4 
Acquisition time (h) 9 13 9 11 1 
 
Table 18: MRI parameter for optimizing T1 relaxometry in vitro with the Gd-DTPA phantom 
Gd-DTPA phantom 
 FLASH_TR FLASH_IR MSME_TR MSME_IR RAREVTR 
TR/TI (ms) 14x 12.5 - 5000 19x (25 – 5000) 12x (20-10000) 19x (30-5000) 12x (30-10000) 
TE (ms) 4 4 13.5 13.5 12 
FA 30 90 90 90 90 
FOV (mm) 30x30 30x30 30x30 30x30 30x30 
Matrix 128x128 128x128 128x128 128x128 128x128 
Resolution (mm) 0.234x0.234 0.234x0.234 0.234x0.234 0.234x0.234 0.234x0.234 
Slice (mm) 2 2 2 2 2 
Averages 1 1 1 1 1 
Acquisition (total) 0.5 5 3 4.5 0.75 
 
Table 19: RAREVTR parameter for in vivo validation 
In vivo tests 
 RAREVTR (rat) RAREVTR (mouse) RAREVTR (mouse) 11.7 T 
TR/TI (ms) 12x (250-5000) 12x (30-5000) 12x (200-9000) 
TE (ms) 12 12 12 
FA 90 90 90 
FOV (mm) 30x30 30x30 30x30 
Matrix 128x128 128x128 128x128 
Resolution (mm) 0.234x0.234 0.234x0.234 0.234x0.234 
Slice (mm) 2 2 2 
Averages 2 2 1 
Acquisition (total) 0.5 0.75 0.5 
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2.7.3 In vitro and in vivo MRI protocols 
MRI phantom PCR tubes measured at 4.7 T 
MRI experiments with tissue lysates and for the optimization of cell labeling were conducted on a 
Biospec 4.7 T (Bruker BioSpin, Ettlingen, Germany) with a transmit Helmholtz coil (120 mm diameter) 
and a receive surface coil (28 mm diameter) for receive. T1 maps were acquired with a RAREVTR se-
quence using the following parameters: 12 variable TR=116.640, 258.513, 415.220, 590.230, 788.388, 
1,016.768, 1,286.274, 1,615.045, 2,036.712, 2,625.391, 3,608.035, 7,500.000 ms, effective TE=12.0 
ms, Rare factor 2, field of view (FOV)=30.0×30.0 mm, slice thickness 2.0 mm, matrix=128×128, reso-
lution=0.234×0.234 mm, number of averages=2, with a total acquisition time (TA) of 46 min.  
MRI phantom measured at 1.0 and 7.1 T  
MRI experiments on cell pellets were acquired on an Avance300 spectrometer (Bruker) operating at 
7.1 T equipped with a microimaging probe using a standard T1-weighted MSME sequence (TR=250 
ms, TE=3.3 ms, NEX=6, FOV=0.115×0.115 cm2, 1 slice, slice thickness=1 mm) and on an Aspect M2 
system (Aspect Imaging, Shoam, Israel) operating at 1.0 T equipped with a horizontal bore MRI mag-
net using a standard T1-weighted multi-slice spin-echo sequence (TR=250 ms, TE=7.0 ms, NEX=30, 
FOV=0.17×0.17 cm2, 1 slice,slice thickness=1.5 mm). T1 values were measured using a saturation 
recovery spin-echo sequence (at 7 T: TE=2.6 ms, 16 variable TR ranging from 40 to 6,000 ms, NEX=1, 
FOV=0.115x0.115 cm2, 1 slice, slice thickness=1mm; at 1 T: TE=7.0 ms, 12 variable TR ranging from 50 
to 4,000 ms, NEX=1, FOV=0.17×0.17 cm2, 1 slice, slice thickness=2 mm). For relaxometric determina-
tion of intracellular Gd(III)-content, cell pellets were treated as described elsewhere 113.  
Determination of R1 field dependence 
The proton R1 NMRD profiles of tissue lysates were measured at 25°C on a fast field-cycling Stelar 
relaxometer (Stelar, Mede Pavia, Italy) over a continuum of magnetic field strengths from 0.00024 to 
0.47 T (corresponding to 0.01–20 MHz proton Larmor frequencies). The relaxometer operates under 
computer control with an absolute uncertainty in R1 of ±1%. Additional data points in the range of 
20–70 MHz were obtained on a Stelar Spinmaster relaxometer tunable to the different frequencies. 
The temperature was controlled with a Stelar VTC-91 air-flow heater equipped with a copper con-
stantan thermocouple to 25°C±0.1.  
In vivo MRI at 7.0 T 
The in vivo MRI data was acquired on a Biospec 7.0 T (Bruker) using a 8 cm diameter transmit Helm-
holtz coil and a 16 mm diameter receive surface coil for detection under Isoflurane (2%) anesthesia 
(O2:N2O, 30:70 %) and lasted approximately 35 min. For a general overview and the coregistration, a 
T2-weighted RARE sequence was used (TR=6,500 ms, TE=13.0 ms, FOV=14.0×14.0 mm2, 30 slices, 
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slice thickness=0.5 mm, 128×128 matrix, i.e. a resolution of 109×109×500 μm3). The T1 maps were 
acquired with a RAREVTR sequence (12 variable TR 189.708, 331.527, 488.167, 663.094, 861.146, 
1,089.384, 1,358.693, 1,687.171, 2,108.355, 2,696.085, 3,676.028, 7,500.000 ms, effective TE=12.0 
ms, Rare factor=2,  FOV=20.0×20.0 mm2, 6 slices, slice thickness=1.0 mm, 128×128 matrix, i.e. a reso-
lution of 156×156×1000 μm3) 114. 
2.7.4 MRI postprocessing 
T1 maps were calculated on a voxel basis with monoexponential fits using a custom-made program 
developed in IDL, which includes an initial signal-to-noise (SNR) cut-off for each voxel at SNR < 5 115. 
For RAREVTR measurements, the MRI signal S(TR) was fitted with the following function: 
 (  )     (   
 
  
  ) or  (  )     (     
 
  
  ) with equilibrium signal S0, relaxation time T1, 
repetition time TR and inversion time TI.  
MR images were visualized and processed with ImageJ (Version 1.42q; National Institutes of Health). 
Region of interest (ROI) analysis based on the quantitative maps was used to determine T1 values for 
phantom tubes or cell graft. In case of MRI phantoms, circular ROIs with identical diameter were 
drawn manually. For the in vivo measurements, two ROIs were drawn manually along the grafting 
canal in one animal and applied to all scans, yielding T1 values for the phantom samples and the cell 
grafts, respectively.  
Changes in relaxation rate ΔR1 induced by the contrast agent were calculated by: 
    (    (              ))  (  (  (                )) 
This calculation minimizes the impact of fluctuating background T1 values for each sample and allows 
comparison of T1 maps from different scans. The relaxivity r1 was determined from T1 maps of dilu-
tion series of NiCl2 and Gd-DTPA in different concentrations (c) as the slope of the linear fits accord-
ing to:           . Further processing of the in vivo MRI data was done by converting the raw 
data into 32-bit NIFTI format (Neuroimaging Informatics Technology Initiative; 
http://nifti.nimh.nih.gov) and scaling up the voxel size by a factor of 10. For brain extraction and af-
fine coregistration with 12 degrees of freedom, FSL tools were used (FMRIB Software Library; 
http://www.fmrib.ox.ac.uk/fsl). The data was processed according to a 4-step protocol: 1) RARE 
scans of all animals were registered and averaged to yield a brain template, 2) the RAREVTR scans of 
every time point were coregistered to the template brain, 3) the resulting transformation was ap-
plied to the T1 maps accordingly and 4) for visualization, brain maps were masked manually to ex-
clude non-brain tissue114. 
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2.7.6 Optical imaging  
Technical setup 
BLI was conducted using the Photon IMAGERTM – a BLI camera equipped with an f/1.4 numerical ap-
erture lens for light collection and a 3rd generation (Gallium Arsenide PhotoCathode) dual multichan-
nel plate intensifier tube coupled through an optical fiber to a charge coupled-device (CCD) chip for 
light detection. The object is placed on a stage, which is heated up to 37°C and can be adjusted in 
height revealing a FOV ranging from 18x24 cm to 6x8 cm. The camera equipment is caged in a light 
proof hood (low level of 30 photons/s background radiation). The detection of photons is achieved 
by several steps, involving the collection of photons by the lens, the amplification by the dual channel 
plate intensifier by a factor of 105 and detection by the CCD chip. Optical resolution is limited by the 
separation of 2 spots in 100 µm distance (stage top position) and 300 µm (stage base position). Cal-
culation of the photon flux (ph/s/cm2/sr) is achieved by the software-automated calculations, which 
include the conversion of photodetector counts to photons per s and cm2, the correction for light 
source placement and the noise introduced by cosmic radiation. For selection of emission/excitation 
wavelengths, a set of six long-pass filters (515-800 nm) and continuous wavelength excitation filter (5 
nm accuracy, 400-740 nm range). The Photon IMAGERTM is equipped with gas and vaporizer for inha-
lation anesthesia and a PC for image acquisition (Photon Imager software Version 2.7.5.1) and evalu-
ation (M3 Vision software Version 1.5 rev.1076). In addition to the Biospace system, an IVIS Spec-
trum imager was used in the collaboration with Prof. Löwik (LUMC Leiden, The Netherlands). The IVIS 
camera contains the same major components, but offers additional filters for excitation (18 filter 30 
nm bandwidth) and emission filter (20 filter 20 nm bandwidth), which allow acquisition and separa-
tion of light spectra and finally spectral unmixing e.g. of luciferases emitting light at different wave-
lengths and the reduction of autofluorescence.  
 
 
Figure 13: The experimental setup for biolumines-
cence imaging includes the Photon Imager with a 
PC for acquisition and analysis and equipment for 
inhalation anesthesia (anesthesia box and vaporiz-
er).   
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Acquisition parameter 
The video/photo was acquired by adjusting the illumination to 10-20% and setting the aperture to 
22.6. In the BL mode, aperture was adjusted to 1.4, which results in an open diaphragm and allows 
more photons to hit the photomultiplier plate.   
In vitro BLI was conducted on cells seeded in 96 black well plates (to reduce light scattering and re-
flection) by adding the appropriate substrate directly prior to measurement. The plate was carefully 
moved to disperse substrate equally and placed centrally on the stage in top position. The stage was 
heated to 37°C to allow comparison to in vivo conditions. BLI signals were recorded for 1 min. 
For in vivo BLI, stage height was adjusted to fit the FOV covering all animals (1-4) and fixed between 
same experiments. The standard imaging protocol included i.p. injection of 150 mg/kg D-Luciferin in 
the pre-anaesthetized animal and subsequent measurement for 15-60 min.  
Optical imaging postprocessing 
BLI raw data was analyzed using the M3Vision software. Time profiles were extracted with 5 s and 
60 s time frame for each ROI (with constant size between different measurements) with the fixed 
unit ph/s/cm2/sr. Background ROIs were only necessary for the transgenic DCX-Luc mice (on the 
shaved back, ROI size equal to brain ROI) to subtract unspecific signal correlating with substrate in-
jection dose and for hRluc transgenic cells vs. control cells to normalize for the coelenterazine auto-
oxidation and the resulting unspecific photon emission. For in vitro data, no time profiles were ac-
quired, but the ROI means for 1 min acquisition were used to calculate mean and standard deviation 
for e.g. a particular cell line (at least in triplicate). From cell dilution series (in triplicate) the photon 
flux per (photons/cell) were calculated by dividing the ROI ph/s/cm2/sr by the cell number plated in 
each well. The in vivo time profiles were exported to Excel (Version 2010, Microsoft Corporation, 
Redmond, USA) and evaluated with user-written macros according to Keyaerts et al.37: the 95th per-
centile (5s time frame) referring to maximum photon emission (“PEmax”) and the “time-to-peak” (60 s 
time frame) referring to the time needed after substrate injection to reach maximum photon emis-
sion. Time curves were preprocessed by correction for the actual acquisition start by addition of the 
time between substrate injection and acquisition start, to correct for interindividual differences. The 
95th percentile of N ordered values (e.g. 360 time frames for 30 min acquisition) is obtained by calcu-
lating the rank n:               . The result is rounded to the nearest integer and the photon 
emission corresponding to n represents the PEmax. For calculation of time-to-peak the maximum pho-
ton emission in the 60 s time frame curves was determined. The signal-to-noise ratio (SNR) on optical 
data was calculated by dividing mean photon flux (ph/s/cm2/sr) by the standard deviation of the 
noise. For accurate calculation of the noise, the mean of 3 randomly chosen ROIs outside the mouse 
was calculated.  
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2.7.7 Microscopy 
Bright field images were acquired using the Zeiss Axiovert, confocal fluorescence images with the 
Leica TCS SP2 microscope equipped with a supplementary CCD camera and the Keyence BZ-9000 
microscope. Microscopic images were acquired by keeping brightness/contrast and illumination con-
stant for each project to allow a qualitative comparison. Phase contrast images were acquired at 10 
and 20x magnification; fluorescence images at 20, 40 and 63x magnification (ocular 10x magnifica-
tion). IHC and IHH images were preprocessed using the manufacturer microscopic software and final-
ly modified with the ImageJ software by adjusting brightness/contrast accordingly for each experi-
mental setup. Quantification of cell differentiation was achieved by counting GABA, GAD, beta III-
tubulin, DCX or GFAP-positive cells based on the specific immunostaining. This cell number was di-
vided by the total cell number represented by the counting the Hoechst-stained cell nuclei. This 
counting procedure was done for 5 randomly chosen fields of view at 40x magnification.  
The relative ICC signal intensity was calculated by measuring the image intensity with ImageJ and 
dividing this mean value by the number of cells on the image. At least 3 separate images were ana-
lyzed for each condition. The brightness was adjusted on the microscope software for every acquisi-
tion equally. Acquisitions with the Leica TCS SP2 were adjusted to GFAP 0-45,000 a.u.; copGFP 0-
25,000 a.u. and Hoechst 0-25,000 a.u.; for the Keyence BZ-9000, excitation for copGFP and Hoechst 
were set to 1 s and 1/150 s, respectively. 
2.8 Statistics 
All data are represented as mean ± SD. Unpaired t test was used to compare means of 2 groups for in 
vitro experiments (GraphPad QuickCalcs, GraphPad Software, La Jolla, USA).  
In vivo BLI data was analyzed using a repeated measures ANOVA for each individual test regime (con-
centration, injection route, anesthesia, time of injection). Post hoc comparisons were corrected for 
multiple comparisons using Sidak correction (SPSS version 20, IBM SPSS statistics, Ehningen, Germa-
ny). If not specified, a p-value ≤ 0.05 was considered to be significant and highlighted by *, in addi-
tion a p≤0.005 was marked by **. 
1 
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3. IMAGING GABAERGIC NEURONS BY MRI 
3.1 Project aim and experimental setup 
MRI-based tracking of contrast agent labeled stem cells grafted in the rodent brain has become the 
noninvasive imaging method of choice because of the high spatial resolution and the possibility for 
repeated, noninvasive measurements. Nevertheless, this method is lacking information about stem 
cell fate and viability. Furthermore, the unambiguous detection of neuronal subtypes - which poten-
tially develop out of a stem cell graft, cannot be imaged selectively with MRI.  
The aim of this project was to design and evaluate a novel molecular probe (in cooperation with the 
group of Prof. Silvio Aime, University of Torino, Italy), which allows the detection of neurons with 
MRI. As a potential target, we selected the glutamic acid decarboxylase (GAD) enzyme, which exists 
in two isoforms encoded by two separate genes: GAD65 and GAD67 with different intracellular dis-
tribution and activity. We focused on GAD because of 1) the unambiguous expression in GABAergic 
neurons (and beta-cells of the pancreas), 2) the importance of this enzyme in synthesis of the major 
inhibitory neuronal transmitter, which comprises approx. 30-40% of all neurons in the brain, and 
finally, 3) because of the pivotal role of GABAergic neurons in neuronal network homeostasis and 
neurological disorders such as stroke and Huntington´s disease116–118. The GAD-specific decarboxyla-
tion of glutamate was used as a motive, which is mimicked by the responsive contrast agent to facili-
tate a highly specific change in relaxivity.  
The experimental schedule included the following subprojects:  
1) Comparison of MRI sequences for stable and reliable determination of T1 relaxation rates.  
2) Evaluation of Gd-DO3A-GAD relaxivity in tissue lysates.   
3) Setting up a GABAergic cell system based on the differentiation of embryonic stem cells, 
which allows relaxometry on cell pellets.  
4) Optimization of the cell labeling procedure, based on a comparison of different method (pino-
cytosis, lipofection, Calciumphosphate precipitation and electroporation).   
5) Characterisation of relaxivity changes induced by the GAD enzyme in the cellular compart-
ment by applying the optimized labeling protocol. 
6) Proof-of-concept study of imaging GABAergic neurons with MRI.  
The results of this section are available in the following publications:  
Aswendt M, Gianolio E, Pariani G, Napolitano R, Fedeli F, Himmelreich U, Aime S, Hoehn M (2012) In 
vivo imaging of inhibitory, GABAergic neurons by MRI. NeuroImage 62(3):1685-93.  
Napolitano R, Pariani G, Fedeli F, Aswendt M, Aime S, Gianolio E (2013) Synthesis and Relaxometric 
Characterization of a MRI Gd-based probe responsive to GAD enzymatic activity. Journal of Medicinal 
Chemistry (Epub ahead of print).   
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3.2 Results 
3.2.1 MRI sequence validation 
For a quantitative comparison of T1 relaxation rates, the nickel standard phantom was measured with 
3 different MRI sequences, comprising the variation of TR (RAREVTR, MSME_TR and FLASH_TR) and 
TI (MSME_TI, FLASH_TI). The data fitting was optimized for each sequence to yield reliable r1 (Figure 
14), which were compared to the expected values at 4.7 T (Figure 15A). These measurements re-
vealed stable relaxivities for all sequences, except for FLASH with variable TR, with best fitting to the 
expected r1 for the MSME_TR and RAREVTR sequence. The MRI sequences were adapted to the Gd-
DTPA phantom and r1 was again determined (Figure 15B) revealing comparable values for all se-
quences. The RAREVTR sequence was chosen for further tests because of its superior time-efficiency, 
and reproducibility between both separate MRI sessions and Gd-DTPA phantoms (Figure 15C and D).  
 
Figure 14: Schematic overview of the monoexponential fit for determining T1 relaxation. Representative fits are dis-
played for the central image pixel. The resulting T1 maps are depicted on the upper left of each graph with equal scaling 
for 0-1750 ms T1, illustrating the apparent differences in the resulting T1 map.  
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Figure 15: Evaluation of MRI sequences for T1 relaxivity. A) Comparison of different sequenes on the Nickel standard 
phantom at 4.7 T (representative T1 map, upper right) revealing relaxivity values for MSME_IR and RAREVTR close to the 
expected values
119
 (expressed as relaxivity ± standard deviation). B) Same sequences were used to determine Gd-DTPA 
relaxivity at 4.7 T with a phantom consisting of a Gd-DTPA dilution series (representative T1 map, upper right). C) Stability 
of RAREVTR scans on the same Nickel standard phantom – separate scan on separate days revealed robust determina-
tion of T1. D) Stability of RAREVTR scans for determining T1 on different phantoms. 
Finally, the RAREVTR sequence was validated for robust in vivo measurements by comparing rat and 
mouse values at low field strength (4.7 T) and high field strength (11.7 T). According to the field 
strength-dependent relaxivity of paramagnetic contrast agents, the T1 values for the rat brain in-
creased with magnetic field strength (e.g. rat cortex approx. 200 ms difference). The measured T1 
values at 11.7 T were in good agreement with data reported by de Graaf et al.34 (Figure 16). 
 
Figure 16: In vivo verification of the RAREVTR sequence. A) ROI analysis on coronal brain images was used to extract T1 
values from B) T1 maps in anatomical brain regions. C) RAREVTR was suitable to determine T1 on mouse and rat brains. D) 
Previously published T1 values of the rat brain
34
 correlated highly with the experimentally acquired using the RAREVTR 
sequence at 11.7 T.   
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3.2.2 Novel responsive contrast agent for detection of GAD activity 
The chemical basis of the novel responsive contrast agent Gd-DO3A-GADV is a Gd-DO3A moiety bear-
ing a long, highly flexible substituent that ends up with two glutamate residues on which the GAD 
enzyme is intended to decarboxylate. The two glutamate moieties are expected to compete with 
water for the two axial Gd(III) coordination sites, and thus their presence results in a low relaxivity 
system. The removal of the carboxylates by GAD yields an increase in the observed relaxivity. To 
avoid the cleavage of the peptidic bonds by endo-peptidases, the amidic nitrogens formed upon con-
jugation of the glutamate residues have been selectively methylated. In order to avoid steric con-
strain in the access to GAD active site, the glutamate moieties have been separated from the Gd-
chelate by a long and flexible linker (Figure 17). 
 
Figure 17: Schematic representation of Gd-DO3A-GAD structure and processing by the GAD enzyme. A) The chemical 
structure of Gd-DO3A-GAD reveals the core chelate DO3A structure and the long linker arms bearing the 2 glutamate 
moieties. B) Enzymatic reaction converting glutamate into GABA driven by GAD. C) Schematic representation of Gd-
DO3A-GAD structure and processing by the GAD enzyme, which releases Gd coordination by the glutamate residues and 
enables free water access, resulting in an increased relaxivity
114
.  
3.2.3 Characterization of GAD-dependent contrast agent activation in tissue lysates 
For the initial test of GAD-dependent relaxivity changes upon contrast agent activation, crude tissue 
lysates with a specific buffer to preserve enzyme activity were incubated for 24 h at 37°C in the pres-
ence of Gd-DO3A-GAD, and subsequently T1 relaxation times were acquired. Western Blot analysis 
was used to identify GAD65/67 in tissue lysates (Figure 18 A). Rat brain lysates from the cortex and 
cerebellum exhibit strong GAD65/67 protein expression, in contrast, the in the liver the enzyme is 
absent. This is reflected in the T1 maps: a decrease in T1 relaxation time was only detectable in the 
                                                             
V Gd-DO3A-GAD: 1-[5-[[N,N′-bis-[3,10,17-triaza-4,11,18-trioxo-21-carboxyl-21-aminoeinecosane]]-N-
methylaminocarbonyl]pentyl]-1,4,7,10-tetraazacyclododecane-4,7,10-triacetate (3-) gadolinate 
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presence of GAD65/67 in cortex and cerebellum (Figure 18 B). Based on the T1 maps, a quantitative 
comparison was made to extract changes in relaxation rates before and after addition of Gd-DO3A-
GAD, which revealed a 2-fold higher ΔR1 in the brain samples compared to the liver sample (Figure 
18 C). The relaxivity behaviour was further studied at different magnetic field strengths by acquiring 
NMRD profiles, which exhibited the highest relaxivity shift useful for MRI at 1 T (or 40 MHz). The 
NMRD profiles were also obtained for identifying the specificity of GAD mediated contrast agent 
activation by addition of the GAD specific inhibitor AOAA to the brain lysates (Figure 18D).  
 
Figure 18: GAD-dependent relaxivity increase in tissue lysates. A) Confirmation of GAD65/67 in brain lysates expression 
by western blotting, alpha-tubulin as loading control. B) T1 map acquired for MRI phantom of tissue lysates revealed a 
decrease in T1 relaxation time after incubation with Gd-DO3A-GAD compared to the control situation. B) This MRI phan-
tom was used for quantitative analysis. ∆R1 was increased for brain lysate compared to liver lysate. D) NMRD profile 
revealing the paramagnetic characteristic relaxivity field dependence and the specificity of Gd-DO3A-GAD activation. 
Upon addition of the GAD-specific inhibitor AOAA, relaxivity decreased substantially. 
3.2.4 Differentiation protocol for GABAergic neurons from embryonic stem cells 
Relaxometry studies on a cellular level require a substantial amount of cells for labeling and subse-
quent MRI measurements. In case of GABAergic neurons, this is hampered by the absence of stable 
and commercially available cell lines. Therefore, a protocol was set up, which allows the robust gen-
eration of several million of GABAergic neurons in approx. 10 days by differentiation of the embryon-
ic stem cell line CGR8. The novel three-step protocol consists of 1) formation of embryoid bodies 
(EBs), 2) selection of neural precursor cells (NPCs) in chemically defined medium, and 3) differentia-
tion of NPCs into inhibitory neurons (Figure 19 A). The presence of the GAD65/67 proteins, was con-
firmed by western blot and by ICC (Figure 19 B, D). The final proportion of betaIII tubulin and 
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GAD65/67 positive neurons was 31% and 27%, respectively. Neuronal differentiation was not im-
paired in the prescence of Gd-DO3A-GAD, as labeled stem cells exhibited only slightly reduced pro-
portion of GABAergic neurons (Figure 19 C). Marker up- and downregulation reflecting the transition 
from pluripotency to mature neurons was studied with qPCR for every protocol step. Relative gene 
expression in relation to expression of the housekeeping gene GAPDH in CGR8 cells revealed 1) the 
downregulation of the pluripotency marker Oct4, 2) the maximum Nestin expression under NPC se-
lection conditions, and 3) the selective upregulation of the mature neuronal marker betaIII tubulin in 
conjunction with GABAergic specific GAD1 and GAD2 in the final step (Figure 19 E). 
 
Figure 19: Evaluation of the GABAergic differentiation protocol: A) Principle of the 3-step protocol lasting for 10 days 
illustrated by bright-field microscopy of the EB formation, selection of NPCs and the differentiation of NPCs. (scale bar 
100 µm). B) Existence of GABA and GAD65/67 coexpressed by majority of cells after differentiation protocol proven by 
IHC (scale bar 20 µm). C) Detailed quantitative analysis of marker expression in differentiated cultures revealed high 
proportion of GAD65/67 expressing neurons. Labeling of cells prior to differentiation resulted in only slightly (not signifi-
cant) decresed GABAergic differentiation. D) Western blotting revealed GAD65/67 only present in differentiated cul-
tures. E) qPCR analysis reflects protocol step dependent upregulation of neuronal marker (betaIII, GAD) and downregula-
tion of pluripotency marker (Oct4).  
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3.2.5 Evaluation of the optimal Gd-chelate labeling procedure 
Stem cell labeling with MRI contrast agents depends on specific protocol optimization for minimizing 
toxicity effecting pluripotency and differentiation potential. In order to determine the best method, 4 
different approaches were compared using the clinically used contrast agent Dotarem®, which shares 
the Gd(III) chelate chemical structure with Gd-DO3A-Gad: 1) unspecific endocytosis/pinocytosis (pi-
no), 2) calcium phosphate precipitation (CaP), 3) lipofection (Lipo), and 4) electroporation (EP). Via-
bility and survival rate were assessed for each method, revealing no effect for endocytosis. In con-
trast, calcium phosphate, lipofection and electroporation lead to a decreased survival rate without 
affecting viability of the cells, indicating a detrimental effect of the incorporated contrast agent 
(Figure 20 A). The efficiency of contrast agent uptake was determined by ROI analysis on T1 maps of 
MRI phantoms containing labeled cells at 4.7 T. The ΔR1 values indicate a minimal unspecific uptake 
of contrast agent by endocytosis and calcium phosphate precipitation. Higher contrast agent uptake, 
as indicated by stronger changes in ΔR1 (factor 2.4) was observed for lipofection and electroporation 
treatment (Figure 20 B). Although electroporation served as the most convenient method for stable 
and high contrast agent uptake, the influence on viability/survival needed to be minimized by a spe-
cific protocol, which includes HBSS buffer and a single square wave at 100 V with a pulse length of 20 
ms. This final protocol was applied to the undifferentiated and differentiated CGR8 cells in the pres-
ence of Gd-DO3A-GAD without impact on viability and low impact on cell survival (decreased to 53–
72% ) (Figure 20 C). IHC analysis showed no difference in potential of these labeled cells to constitute 
a GABAergic culture (see Figure 19 C). 
Figure 20: Optimization of cell labeling approaches with paramagnetic contrast agents. A) Cell viability was not impaired 
by the labeling procedure. The survival rate for Calciumphosphate precipitation (CaP), lipofectio (Lipo) and electro-
poration (EP) decreased due to impact of the labeling procedure, but not due to the Gd-DTPA. B) High contrast agent 
uptake was only possible with Lipo and EP, as confirmed by the changes in relaxation rate of labeled cell vs. unlabeled 
cell pellets. C) An optimized EP protocol was applied to the undifferentiated and differentiated ES lableing with Gd-
DO3A-GAD. Independent on the cell status, viability was not impaired, but the survival rate decreased slightly compared 
to Gd-DTPA
114
.   
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3.2.6 GABAergic neuron-specific contrast in vitro   
Applying the optimized labeling protocol permitted the discrimination of native and differentiated ES 
cells based on the T1 relaxation rates. Labeled cells were incubated for 6 h to allow complete activa-
tion of Gd-DO3A-GAD and subsequently measured in MRI phantoms at 1 and 7 T (Figure 21). At both 
field strengths, independent experiments proved the substantial difference between ES cells and 
GABAergic neurons based on the measured T1 values. Notably, such experiments showed high fluc-
tuations and averaging depends on prior normalization, either by considering the actual number of 
vital cells or the Gd(III) content. The correction of the actual contrast agent uptake turned out to fit 
better the expected high difference between low- and high field (see NMRD profile, predicting relax-
ivity behavior for low and high field, Figure 18). Nevertheless, all in vitro experiments predicted a T1 
difference at 7 T still ≥100 ms, which promised an in vivo application at high field strength. 
Figure 21: Relaxometric discrimination of native ES cells and GABAergic neurons based on the relaxivity change of Gd-
DO3A-GAD in the presence of GAD. A) T1 maps of a MRI phantom containing PBS (1), ES cells (2) and neurons (3) acquired 
at 1 and 7 T. B and C) Changes in relaxation rate calculated for 3 independent labeling experiments at 1 T and 7 T. At both 
field strengths, the T1 difference was sufficient to discriminate between undifferentiated and differentiated cells. D) The 
normalization of these relaxation rate changes based on the actual cell number for each experiment or the Gd(III) con-
tent per mg protein, revealed a stronger effect for the second method
114
.  
3.2.7 In vivo cell imaging at high field strength 
The in vitro experiment was transferred to in vivo conditions, by grafting 750,000 pre-labeled undif-
ferentiated and differentiated cells into the left and right striatum of nude mice, respectively (n=2). 
MRI was performed at 7 T directly after transplantation and followed for up to 1 week. T1 maps were 
evaluated to calculate the change in relaxation rate between the ES cell graft and the differentiated 
graft (Figure 22).  The T1-weighted image and the T1 map at 0.5 h after transplantation clearly depict 
the substantial image contrast difference between the two cell grafts. Further analysis at each time 
point revealed a strong T1 difference > 100 ms, as predicted from the in vitro experiments. This con-
trast was lost by day 7. The final histological evaluation of graft location revealed a symmetric distri-
bution corresponding to the MR images (Figure 22 D). 
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Figure 22: In vivo application of Gd-DO3A-GAD to discriminate grafted GABAergic neurons from ES cells. A) Representa-
tive T1-weighted image at 0.5 h after implantation of pre-labeled GABAergic neurons (right striatum) and ES cells (left 
striatum). B) Corresponding T1 map revealing substantially lower T1 values for the neuronal implant. C) Quantitative 
evaluation of the ΔT1 between both cell grafts from 2 animals monitored for up to 7 days reflects a decrease of contrast 
over time. D) HE-staining for histological localization of the cell grafts 7 days after transplantation
114
.   
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3.3 Discussion 
Molecular probes bioengineered to respond to processes, which are directly coupled to neuronal cell 
function are under strong investigation and intended to bridge noninvasive observation of molecular 
events with pathophysiological processes during disease state120. The GAD-responsive probe, pre-
sented here, marks the first development of a MRI contrast agent, which is selectively activated by a 
neuron-specific enzyme, and is proven to discriminate GABAergic neurons based on T1 relaxation 
changes.   
3.3.1 Validation of RAREVTR sequences for stable and reliable T1 determination   
The best MR sequence for measuring T1 relaxation for both in vitro MR phantoms and in vivo condi-
tions was empirically determined by comparing gradient echo (FLASH) and spin echo (MSME, 
RAREVTR) sequences, with variable TR or TI. In a first step, the sequences were applied to the nickel 
standard phantom, which contains defined concentration of NiCl2, H2O, D2O and agarose with known 
T1 relaxation rates. In these experiments, the r1 determined by the inversion recovery sequence 
MSME_IR correlated best with expected values. The RAREVTR sequence gave similar results within 
1/10 the acquisition time. Based on these results, sequences were optimized in terms of resolution 
(234 µm in plane) and imaging time (fastest method: FLASH_TR 30 min). Again the RAREVTR se-
quence was best in terms of acquisition time and precise r1. Further tests on the RAREVTR stability 
for separate scan sessions and on different Gd-DTPA phantoms revealed strongly coherent data lim-
ited only by the general MR imaging noise and the phantom preparation. Finally, the RAREVTR se-
quence was also tested under in vivo conditions. The sequence was used to obtain T1 relaxation 
times of rat and mouse brain at low magnetic field 4.7 T. However, also at high magnetic field 
(11.7 T), the acquired values for the rat brain are in accordance with literature values34. In conclusion, 
the RAREVTR sequence enabled stable determination of T1 for in vitro and various in vivo applica-
tions.   
3.3.2 Contrast agent mechanism 
The design of Gd-DO3A-GAD is a further development of established responsive probes, namely the 
first reported enzyme-activated gadolinium chelate by Moats, Fraser and Meade43. According to the 
concept described there, Gd-DO3A-GAD has been made responsive to the GAD-decarboxylation by 
two glutamate groups, which block free water access to Gd(III) and suppress the relaxivity. These 
masking groups are cleaved specifically by the enzyme GAD leading to an increased relaxivity based 
on the elevated access of water molecules to the paramagnetic core. This contrast agent processing, 
accompanied with a relaxivity shift, was proven in GAD-containing tissue lysates and could be dimin-
ished by addition of a GAD-specific inhibitor. The enzyme co-factor PLP plays a crucial role in efficient 
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contrast agent processing, because the GAD inhibitor AOAA, selectively traps PLP. Therefore, lysates 
were supplemented with additional PLP to facilitate the reaction. Based on the acquired NMRD pro-
files the representative field dependence relationship for r1 relaxivity was observed, where devia-
tions are most likely due to the crude lysate mixture, substantially different to ideal water solutions. 
Further chemical analysis of the contrast agent processing and potential unspecific complexing of the 
agent to macromolecules, especially in lysates, is reported elsewhere (Napolitano et al., in revision).  
3.3.3 GABAergic differentiation protocol 
To establish a cell model for relaxometric tests of Gd-DO3A-GAD, a differentiation protocol was most 
suitable to generate several millions of cells, required for one MRI phantom experiment. Based on 
previous reports, the ES cell line CGR8 was chosen, which grows feeder-layer independent and is able 
to generate GABAergic neurons in vitro121. The novel differentiation protocol described here, is based 
on the five-stage method introduced by Okabe122, but generates comparable number of GABAergic 
neurons (approx. 30% neurons of which 89% were GABAergic) in 10 days instead of 2-3 weeks. The 
simplified 3-step protocol was proven by western blot and qPCR to produce neurons with the 
GAD65/67 enzyme. Furthermore, the qPCR profile reflects each protocol step, namely the increased 
Nestin expression during NPC selective conditions, the decrease of the pluripotency marker Oct4 
over time, and finally, the onset of GAD1 and GAD2 expression in the last step.  
3.3.4 Labeling of stem cells and derivatives with paramagnetic agents 
Appropriate to the differentiation procedure, the labeling protocol had to be developed for the ES 
cells and the differentiated neurons. Four different methods were chosen based on previous reports 
proving the usefulness when using superparamagnetic contrast agents, and compared relating to cell 
viability and labeling efficiency: pinocytosis, lipofection, calcium phosphate precipitation and elec-
troporation. Pinocytosis describes the unspecific uptake of contrast agent and turned out to be not 
effective at all for labeling. Lipofection and CaP were already used for labeling of ES cells and NPCs 
with ironoxide-based contrast agents123 and Gd(III) chelates124. In the experiments reported here, 
lipofection facilitated contrast agent uptake better than CaP, without effecting viability. The uptake 
variability is probably due to the random process of contrast agent complexing with the liposome. 
The contrast agent is finally stored in intracellular vesicles, which can change relaxivity125. Electro-
poration induces direct intracellular contrast agent uptake by the formation of small pores in the 
membrane and was selected for the labelin with Gd-DO3AGAD. The method was already applied for 
incorporation of iron oxide particles, as well as Gd(III) chelates125,126. For the experiments reported 
here, the protocol was optimized to yield ≥92% viability and ≥62% survival rate in the presence of 
50 mM Gd-DOTA, which was only slightly decreased by Gd-DO3A-GAD.  
 58 
IMAGING GABAERGIC NEURONS BY MRI  
3.3.5 T1 relaxation dependent discrimination of GABAergic neurons   
In a first application step, undifferentiated and differentiated cells were labeled with Gd-DO3A-GAD 
and imaged for T1-dependent contrast differences at 1 and 7 T. Quantitative T1 maps confirmed high-
er relaxation rates at low field compared to high field strength, in agreement with the theory. Fur-
thermore, the GAD-specific activation of Gd-DO3A-GAD could be proven in three independent exper-
iments by the strong increase in ΔR1. Because of the multi-step process, these values tend to vary 
and should be normalized to the cell number, or even better, to be more precise, normalized to the 
Gd(III)/protein content. The comparison of both correction methods revealed a stronger field-
dependence for the Gd(III) content calculation, which is most likely due to variable amount of con-
trast agent taken up by individual cells. However, these results promised the usefulness of Gd-DO3A-
GAD for cell tracking at high magnetic fields, which was investigated in the final in vivo experiment. 
Until now, only a minority of novel responsive contrast agents have been used for in vivo 
imaging127,128, although various biological processes were already targeted in vitro129. However, in the 
present study the first proof-of-principle discrimination between grafted stem cells jand differentiat-
ed cells was achieved using in vivo MRI. In line with the in vitro experiments, predicting a change in T1 
relaxation rate ≥200 ms, the in vivo analysis revealed ≥100 ms, still enough for robust discrimination 
of labeled ES cells and GABAergic neurons. Although, normalization seems to be important for quan-
titative analysis, until now a similar procedure cannot be applied in vivo130. Nevertheless, such a 
method would be important in order to determine quantitatively the proportion of pre-labeled stem 
cells differentiating into GABAergic neurons and simultaneously changing relaxivity of Gd-DO3A-GAD.  
3.4 Conclusion and Outlook 
In this study, cell specific MR imaging was shown based on a novel contrast agent responsive to the 
GAD enzyme in GABAergic neurons. This contrast agent based method is in line with the first reports 
on imaging neurotransmitter131 and brain-specific receptor132, which will definitely expand the poten-
tial of MRI for a functional readout on the cellular level. The responsive probe presented here, 
proved for the first time a neuronal enzyme-specific MRI signal. The contrast agent chemistry is still 
developing rapidly, e.g. generating cell-penetrating probes with increased intracellular retention. 
Such improvements could facilitate molecular probes, as Gd-DO3AGAD, for the longitudinal monitor-
ing of GABAergic differentiation in “real time”. The validation of a responsive probe for ES cells and 
neurons, set the basis for future transplantation studies and will enable the functional readout re-
quired to monitor the success in stem cell therapy of neurodegenerative disease, like Huntington´s 
disease or stroke.   
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4. BOOSTING BIOLUMINESCENCE FOR SENSITIVE NEUROIMAGING 
4.1 Project aim and experimental setup 
Optical monitoring of stem cell based therapies is strictly limited by imaging sensitivity. Being superi-
or to fluorescence imaging, in vivo bioluminescence imaging (BLI) has become the optical method of 
choice for quantitative tracking of (stem) cells in real-time with high signal-to-noise. Nevertheless, 
BLI of grafted NSCs needs adaption to the complex brain application - like the selective substrate 
uptake through the blood-brain-barrier, light scattering and attenuation by the multilayer tissue bar-
rier. The numerous reports on BLI in the mouse brain used nearly exclusively tumor cells73,133,134, im-
mortalized neural stem cells135, mesenchymal stem cells136 or lentiviral in vivo gene transfer137 for a 
qualitative measurement of reporter gene expression.  
The project reported here was initiated in cooperation with Laura Mezzanotte and Clemens Löwik 
(Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands), Rob Hoeben 
(Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands) 
and Sébastien Couillard-Després (Institute of Molecular Regenerative Medicine, Paracelsus Medical 
Private University, Salzburg, Austria). The in vivo performance of 4 luciferases was tested by overex-
pression in HEK-293 and NSCs after transplantation into the mouse brain. The standard BLI protocol 
was revised by analyzing the effect of anesthesia, substrate concentration and injection route using 
the DCX-Luc transgenic mouse model for brain specific BLI. Results were finally translated to intrac-
erebrally transplantated Luc2+ NSCs, which could be detected with surpassing sensitivity. 
The experimental schedule included the following subprojects:  
1) Establishing a mouse NSC line  
2) Cloning of bimodal imaging reporter for lentiviral vector-mediated expression of Luc2, 
PpyRE9, CBG99 or hRluc coupled to copGFP in HEK-293 and NSCs 
3) In vitro and in vivo characterization of BLI sensitivity of transgenic HEK-293 and NSCs  
4) In vivo BLI protocol optimization (substrate concentration, injection route and anesthesia)   
5) Determination of the sensitivity limit for transplanted Luc2+ NSCs in the mouse brain using 
the optimized protocol.   
 
The results of this thesis section are part of the following publications:  
Aswendt M*, Adamczak J*, Couillard-Després S, Hoehn M (2013) Boosting Bioluminescence Neu-
roimaging: An Optimized Protocol for Brain Studies. PLoS ONE 8(2):e55662. 
Mezzanotte L*, Aswendt M*, Tennstaedt A, Hoeben R, Hoehn M, Löwik C (2013) Quantitative evalua-
tion of luciferases for in vivo bioluminescence imaging of neural stem cells. CMMI (in revision). 
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4.2 Results 
4.2.1 D3WT_N2Euro – a radial glia-like neural stem cell line 
Based on previous reports about the generation of NSCs from ES  cells93, a novel protocol wa estab-
lished. The murine ES cells D3WT were treated according to a 3-step protocol: 1) formation of neuro-
sphere-like EBs under non-adherent conditions, 2) selection of adherent cells from the neurospheres 
on gelatin-coating, and 3) expansion of the EGF and b-FGF responsive cell population (Figure 23). The 
complete protocol lasts for approx. 25 days (days in vitro, DIV), followed by an additional passaging 
of the cells, during which 3 out of 20 colonies were selected for further characterization.   
Figure 23: Protocol steps for generation of NSCs from the ES cells D3WT by chemically defined media composition and 
surface coatings in approx. 25 days in vitro (DIV). Phase contrast microscopy illustrates the 3-step process and the final 
cell morphology at DIV25 (10x magnification, scale bar 50 µm).  
Cell clone #1, 2 and 4 shared the homogenous bipolar morphology and stable propagation until 
DIV37 (Figure 24 A). All clones expressed homogenously Nestin in the absence of GFAP with excep-
tion of clone #1, which contained single GFAP positive cells (indicated by arrow on Figure 24 B). Fur-
thermore, clone #1 contained DCX positive neurons and clone #2 and #4 showed weak unspecific 
immunoreactivity for DCX (Figure 24 C). During the further cell passaging, only clone #4 showed per-
sistent proliferation under EGF and b-FGF supplementation and was therefore selected as potential 
NSC line and further characterized.  
Extensive gene profile analysis via RT-PCR of 20 genes for identification of ES cells, NSCs, NPCs, neu-
rons, astrocytes, mesodermal cells and endodermal cells, was performed (Table 20, Figure 27). The 
immortalized NSC line C17.2 WT and data published by Conti et al.93 were used as reference. Most 
importantly, cells derived from D3WT were found to lack the pluripotency marker (Oct4, Rex1, 
Nanog) and non-ectodermal marker (Brachyury and Gata6), but positive for NSC marker like Nestin, 
Musashi-1, Pax6 and Sox2. Markers for radial glia cells were also detectable (BLBP and 5T4). Based on 
this gene profile analysis, which revealed good accordance with previously identified marker sets93, 
clone 4 was identified as neural stem cell line and further passaged. The cell line was termed 
D3WT_N2Euro cells, according to the cells of origin, the media component N2 and the culture medi-
um Euromed. Notably, marker expression differed from the reference cell line C17.2 WT. 
Retained stem cell properties were tested by culturing the cell line >33 passages (approx. 6 months 
of continuous culturing). Neural differentiation of these cells was driven either by cell culture sup-
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plementation with 1% FCS (glial differentiation) or by culturing for 3 days in FGF only media and 7 
days in N2/B27 media (neuronal differentiation). The ICC analysis of differentiated cells revealed a 
cell passage-independent strong expression of either glial (GFAP) or neuronal (DCX) proteins (Figure 
25). A detailed qPCR analysis revealed differentiation protocol-dependent regulation of neuronal 
(DCX, betaIII, Map2, Synaptophysin), glial (GFAP, Glast, S100b) markers (Figure 25 B, D). Differentia-
tion into the neuronal lineage resulted in 12x higher DCX, 2x higher MAP2 and 5x higher betaIII tubu-
lin values compared to the glial differentiation. In contrast to pro-neuronal conditions, 1% FCS in-
duced the up-regulation of glia-specific marker, e.g. Glast (2.8x-fold). Controversially, neuronal dif-
ferentiation resulted in S100b 1.9x-fold and glial differentiation in 2.8x-fold Synaptophysin expres-
sion.    
 
Figure 24: Morphological and immunocytochemical characterization of NSCs derived from D3WT ES cells. A) Phase con-
trast image showing homogenous bipolar structure of adherent cells (50 µm scale). B) Fluorescence microscopy of Nestin 
(red), GFAP (green) counterstained with Hoechst. C) Fluorescence microscopy of DCX (red), betaIII tubulin (green) coun-
terstained with Hoechst (scale bar B and C 20 µm, 40x magnification).  
 62 
BOOSTING BIOLUMINESCENCE FOR SENSITIVE NEUROIMAGING  
 
 
Figure 25: Differentiation of D3WT_N2Euro cells resulted in expression of neuron- and glia-specific marker. A) Neuronal 
differentiation into DCX-positive neurons for low and high cell passage. B) qPCR profile for the neuronal differentiation. 
C) Glial differentiation highlighted by ICC for high GFAP expression in low and high cell passage. D) qPCR profile for the 
glial differentiation (fluorescence microscopy, 40x magnification, zoomed pictures upper right, scale bar 50 µm).  
 
Table 20 and Figure 26: Gene marker profile for D3WT_N2Euro compared to C17.2 and data published by Conti et al.
93 
 Marker D3WT_N2
Euro 
C17.2 Conti et al.  
Pluripotent embry-
onic stem cells 
Oct3/4 - - - 
Rex-1 - - x 
Nanog - - - 
Neural stem cells 
Nestin + + + 
Pax6 + - + 
GFAP - + - 
Sox1 - - - 
Sox2 + + + 
Musashi-1 + + x 
Neural progenitor 
cells 
DCX - - x 
Prominin-1 + - x 
Olig2 + - + 
NeuroD1 + - x 
Mature (neural) cells 
5T4 + + + 
BLBP + - + 
S100ß - - x 
NF-H - - x 
Synaptophy-
sin 
- - x 
Galc + + x 
Mesoderm Brachyury - - x 
Endoderm Gata6 - - x 
Control Actin + + + 
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4.2.2 In vitro bioluminescence comparison in D3WT_N2Euro and HEK-293 
HEK-293 and D3WT_N2Euro cells were stably transduced with self-inactivating lentiviral plasmids 
(EF1-Luciferase-T2A-copGFP) for expression of the luciferases Luc2, PpyRE9, CBG99 or hRluc coupled 
to the fluorescent reporter copGFP. The transduction resulted in approx. 80% positive HEK-293 and 
30% positive NSCs. A FACS selection of a high expressing population (>103 counts) was only possible 
for the HEK-293 cells, whereas for the NSC only a middle expressing population could be selected 
(102-103 counts). All attempts to isolate cells with higher levels of copGFP failed, because of a pro-
gressive cell death. A comparable expression of the different luciferases within one cell type was 
achieved by FACS normalized to copGFP, whose expression is equimolar to the luciferase genes, due 
to the “self-cleaving” T2A sequence. After sorting, equal copGFP expression was validated by fluores-
cence microscopy and fluorescence measurements using a plate reader (Figure 27).  
The in vitro sensitivity was determined by BLI of cell dilution series for HEK-293 and NSCs (Figure 28). 
In both cell lines, the luciferase signal was increased from PpyRE9 to CBG99 and Luc2 with highest 
signal for hRluc. The expected quantitative relationship between cell number and photon flux was 
detectable for both cell lines and every luciferase in vitro, by linear fitting with R2=0.99. From this 
dilution series a ph/s/cell value was calculated for Luc2 (3,412±189), PpyRE9 (837±78), CBG99 
(3,119±179) and hRluc (68,276±18,077). As expected from the different FACS gating and the copGFP 
expression, the luciferase expression differed substantially between both cell types – visible by the 4-
6 fold increased photon flux of 1x103 HEK-293 compared to NSCs.  
 
Figure 27: Transduced cells after FACS with equal expression of copGFP. A, B) Representative fluorescence microscopy 
images of HEK-293 and D3WT_N2Euro cells (scale bar 50 µm). C) Fluorescence imaging of 1x10
3
 cells confirmed the 
equimolar expression of copGFP in the sorted and stably transduced cell lines with a mean radiation efficiency of 9.45± 
0.13. 
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Figure 28: In vitro bioluminescence sensitivity determined by cell dilution series for all cell lines in two independent 
experiments. A) Representative image of a HEK-293 cell dilution series (1,000, 2,500, 5,000 and 10,0000 cells). B) Corre-
sponding quantitative relationship for D3WT_N2Euro cells. C) Photon flux comparison for D3WT_N2Euro and HEK-293 
cells revealing higher BLI signal for HEK-293 cells independent of the luciferase type.   
4.2.3 Bioluminescence imaging of cells grafted into the mouse brain 
Initially the Luciferin- and Coelenterazine-dependent kinetic was investigated by acquiring every 20 
min the luciferase signal for 30 s. Independent of the different kinetics in vitro, under in vivo condi-
tions the signal from HEK-293-hRluc and -Luc2 cell grafts increased with a comparable curve until a 
time-to-peak of 15 and 16 min (n=3), as it is shown for a representative animal data set in Figure 29 
A. On average for both substrates, time-to-peak values were between 12 and 16 min post ip injec-
tion. NSCs were transplanted in different amounts into nude mouse striatum (1x105 left, 3x105 right 
hemisphere, n=3) and recorded with BLI 24 h later for 1 min – 15 min after substrate administration 
(150 mg/kg D-Luciferin or 1.5 mg/kg CTZ-h). Superior signal was detectable for Luc2 followed by 
CBG99 and PpyRE9 with a detection limit of 1x105 (Luc2, CBG99) and 3x105 (PpyRE9). In contrast, 
neither 1x105 nor 3x105 hRluc cells were detectable (Figure 29 B). For a quantitative comparison of 
the luciferase performance in 3 transplanted animals, only the 3x105 cell graft revealed reliable data 
(Figure 29 C). BLI of hRluc expressing cells was only possible with transplanted HEK-293 cells (data 
not shown, only 1 animal), where 2x105 cells exhibited a photon flux of 92,600±12,347 ph/s.   
 
Figure 29: In vivo comparison of luciferases. A) Similar BLI time curves were acquired for Coelenterazine- and Luciferin-
dependent luciferases with HEK-293. B) Representative images for nude mice grafted with 1x10
5
 and 3x10
5
 luciferase 
expressing NSCs. C) Quantitative analysis was done for 3x10
5
 cells and revealed superior photon emission for Luc2 fol-
lowed by CBG99 and PpyRE9 – the hRluc signal was not detectable.   
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4.2.4 Spectral luciferase analysis in vivo 
For spectral analysis of in vivo BLI signals, a series of 20 nm bandpass filters was used, covering the 
luciferase emission spectra (520-680 nm). With this setup the emission spectra of D3WT_N2Euro 
cells expressing CBG99, Luc2 and PpyRE9 transplanted at 3 mm depth were compared.  Luc2 and 
PpyRE9 spectra remain nearly stable for lower transplantation depths, but CBG99 becomes bimodal 
due to stronger absorption of light in the green region of the spectrum and better tissue penetration 
of light at red wavelengths. In an additional experiment, CBG99 cells were transplanted at 4 mm 
depth, which resulted in an increase in the red part of the spectrum, shifting almost completely.  
 
4.2.5 BLI protocol optimization  
Validation of transgenic mouse model of neuroblast-specific BLI 
Transgenic mice (n=4, 3-6 months) expressing luciferase under control of the neuronal doublecortin 
promoter DCX were used to optimize protocol parameters for brain-specific BLI. The animals were 
shaved prior to BLI on the head and back to reduce signal scattering and masking by the fur. To make 
measurements from different days and imaging conditions comparable, the unspecific signal from 
the back was subtracted from the brain signal (Figure 31). This weak unspecific signal appears most 
probably due to spontaneous oxidation of D-Luciferin. According to previous experiments, differ-
ences in this signal between animals reflect variations in substrate administration and Luc2 expres-
sion.  
Figure 31: Background correction for the 4 DCX-Luc mice. A) BLI image of the ROI positions for measuring the background 
(ROI 1) and brain signal (ROI 2). B) The kinetic values obtained in ROI 1 were subtracted from ROI 2 for every animal 
(indicated by different colors) to normalize for variations in substrate injection/delivery in each imaging session.   
Figure 30: Emission spectra of Luc2, PpyRE9 and 
CBG99 under in vivo conditions acquired with a 
set of 20 nm bandpass filter. Luc2 and PpyRE9 
show strong overlap and emission maxima 
merge at approx. 630 nm. Notably, the CBG99 
emission peak shifts and the spectrum changed 
with implantation depth, serving as a specific 
predictor of graft location from the brain sur-
face.    
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Photon flux dependence on substrate concentration 
In order to measure the substrate-dose dependency of in vivo luciferase activity in DCX-Luc mice, 
different concentrations of D-Luciferin (15, 150, 300, 750 mg/kg) were injected ip after 2% Isoflurane 
anesthesia and BL was recorded for 30 min. The D-Luciferin concentration had a significant effect on 
PEmax (F(1.006, 3.017)=72.862 p=0.003), AUC (F(1.005, 3.016)=66.988) p=0.004) and time-to-peak 
(F(3, 9)=28.693, p<0.001). Interestingly, the increase in PEmax followed a monoexponential curve 
(Figure 32 A). The concentration increase from 150 mg/kg to 750 mg/kg resulted in approx. the 10-
fold PEmax/AUC value (Figure 32 B). Nevertheless, at high concentrations the standard deviation was 
also increased. The strong signal enhancement was accompanied by higher slope values in the initial 
inflow phase following also the exponential relationship (1.1x105-2.9x106) and a prolonged time-to-
peak for high substrate concentrations (Figure 32 C, D).    
 
Figure 32: Dose-dependency of luciferase activity in DCX-Luc mice. A) Exponential PEmax increase for substrate concentra-
tions 15-750 mg/kg. B) Illustration of AUC and PEmax values normalized to 150 mg/kg D-Luciferin (red dotted line). C) D-
Luciferin concentration dependent modulation of luciferase time activity curves acquired for 30 min (left y-axis for 750 
mg/kg, right y-axis for 15-300 mg/kg). D) The increased substrate concentration delays time-to-peak (* indicates statisti-
cally significant difference with p≤0.05 to 150 mg/kg in post-hoc comparison).  
D-Luciferin injection route comparison 
Here, the impact of different injection routes ip (intraperitoneal), vs. intravenous (iv) and subcutane-
ous (sc) was evaluated. DCX-Luc mice (n=4) received 150 mg/kg D-Luciferin ip, iv, or sc post Isoflu-
rane anesthesia followed by acquisition for 30 min. Considering ip as the standard injection route, iv 
and sc had a significant effect on PEmax (F(2, 6)=75.048 p<0.001), AUC (F(2, 6)=126.935 p<0.001) and 
on time-to-peak (F(2, 6)=71.148 p<0.001). The PEmax for sc injections reached approx. 40 % of the ip 
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experiment, whereas iv resulted in approx. 450% PEmax. The AUC values showed a similar behavior 
with a minor effect for iv - approx. 260% (Figure 33 A). The D-Luciferin absorption kinetic was reflect-
ed by the luciferase time-activity curves with a smaller slope for sc vs. ip (6.1x104±2.2x103 vs. 
2.2x105±8.6x103). In case of iv injections, absorption into the blood system is not the rate-limiting 
step, as reflected by the highest slope (5.1x105±6.2x104) (Figure 33 B). The D-Luciferin biodistribution 
contributed to significant smaller time-to-peak values for iv injections (8.7 min shorter than ip, 
p=0.017) and a significant delay in time-to-peak for sc (additional 4.4 min compared to ip, p=0.011) (  
Figure 33 C).  
  
Figure 33: Brain-specific BLI is strongly affected by the D-Luciferin injection route. A) Compared to ip injections, PEmax 
and AUC were significantly reduced for sc and enhanced for iv injections. B) Kinetic of D-Luciferin biodistribution is re-
flected by the time-activity-curves. C) This results in significantly longer time-to-peak values for sc (red) and faster signal 
maturation for iv (blue) injections compared to ip (* indicates statistically significant difference with p≤0.05 to 150 mg/kg 
ip in post-hoc comparison). 
 
Effect of anesthesia on photon flux 
In a further set of experiments, the impact of type and timing of anesthesia was evaluated. Beside 
the commonly used Isoflurane anesthesia, which was reported to exhibit inhibitory effects on the 
luciferase enzyme, Pentobarbital and Ketamine/Xylazine were compared. The 4 DCX-Luc mice re-
ceived different concentrations of D-Luciferin ip (15, 150 and 300 mg/kg) prior to and post Isoflurane 
anesthesia in order to determine the influence of a pre-inhibited enzyme. D-Luciferin injection prior 
to Isoflurane anesthesia resulted in significantly increased PEmax (F(1, 3)=51.585 p=0.006) and AUC 
(F(1, 3)=44.488 p=0.007).  
By increasing the substrate concentration the maximum and total amount of photon flux difference 
for pre to post condition was significantly increased (300 mg/kg to 150 mg/kg pre iso: PEmax p=0.01, 
AUC p=0.009) (Figure 34 A, B). The time-to-peak suggested a similar D-Luciferin concentration-
dependent effect, however did not reach the level of statistical significance (Figure 34 C).  
In a second set of experiments, DCX-Luc signal was compared for different anesthetics revealing an 
overall effect on PEmax (F(2, 6)=5.935 p=0.038) but no significant change compared to Isoflurane an-
esthesia in post-hoc pairwise comparison (Ketamine/Xylazine: p=0.058, Pentobarbital: p=0.742). A 
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significantly lower AUC value for Ketamine/Xylazine compared to Isoflurane (F(2, 6)=22.738 p=0.002; 
post-hoc p=0.005) (Figure 35) was observed. Time-to-peak values for Isoflurane and Pentobarbital 
were not different.  
 
Figure 34: Luciferase inhibition by Isoflurane is D-Luciferin dose-dependent. A and B) PEmax and AUC differed were in-
creased for the pre Isoflurane condition. This effect could be increased by higher substrate concentrations (*=statistically 
significant to 150 mg/kg post-Iso, +=statistically significant between pre and post condition, p≤0.05). C) There was no 
effect on the time-to-peak value. 
 
Figure 35: DCX-Luc BLI is modulated by the type of anesthesia. A) PEmax and AUC were slightly decreased under Keta-
mine/Xylazine conditions and increased under Pentobarbital anesthesia, without reaching statistical significance (except 
for AUC Ketamine/Xylazine compared to 150 mg/kg post-Iso, p=0.005, indicated by *). B and C) Representative time 
activity curves showing the anesthesia dependent signal behavior leading to delayed time-to-peak for Keta-
mine/Xylazine, but no difference for Isoflurane to Pentobarbital anesthesia.  
4.2.6 Generation of advanced Luc2+ NSCs 
The first generation of D3WT_N2Euro cells was transduced using a lentiviral approach. In order to 
generate advanced luciferase expressing cells, the Luc2-T2A-copGFP cassette was cloned into a ret-
roviral vector, which included the internal LTR promoter and the neomycin resistance cassette, driv-
en by an additional SV40 promoter (Figure 36 A). This enabled a double selection strategy – by the 
copGFP expression and the antiobitic resistance – resulting in approx. 90% transduced cells which 
were subsequently selected. Initially a FACS high (>103 counts) and middle (5x102-103 counts) cell line 
was derived in order to determine the impact of high gene reporter expression (Figure 36 B, C). There 
was a significant reduced viability detectable for the high vs. middle copGFP expressing cells (Figure 
36D). 
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Figure 36: Retroviral generation of NSCs expressing Luc2 and copGFP. A) Retroviral plasmid used for transduction con-
tains Luc2 coupled to copGFP and Neomycin resistance driven by the SV40 promoter. B) Transduced cells were sorted for 
a middle (P6) and high count regime (P5) for copGFP. C) Representative fluorescence images of the sorted cell lines (20x 
magnification, scale bar 50 µm). C) Cell viability was significantly decreased for the FACS high cells (p<0.005). for differ-
ences in cell viability with the PrestoBlue assay.  
 
However, the FACS high cell line dom-
inated strongly in BLI performance (7 
vs. 2 photons/cell). In order to gain 
maximal sensitivity, the high cell line 
was chosen for further experiments. 
The cell numbers intended for trans-
plantation and in vivo sensitivity de-
termination were also tested in vitro. 
For this purpose, a cell dilution series 
(each cell number n=4) was measured 
for 1 min under substrate excess conditions (1 mM) and the SNR was calculated (Figure 37 A). Under 
these conditions, the photon emission is linearly correlated with the amount of luciferase enzyme 
(represented by number of cells) (Figure 37 B) and results in a reliable detection of 6,000 cells with a 
mean SNR of 4.4.  
The FACS high D3WT_N2Euro cells expressing Luc2 and copGFP were further characterized in relation 
to the non-transduced cells by Western blot, RT-PCR and ICC. The immunoblotting proved the exclu-
sive expression of the reporter gene Luc2 in the transduced cells. A alleviative effect on the Nestin 
expression was detected by 5 % (approximated only for a single experiment). Furthermore, an exten-
sive qualitative comparison of gene expression between transduced cells and WT cells was carried 
out (Figure 38). According to the equal bands for WT and transduced cells, there was no difference in 
gene expression induced by the transgene expression (excluding weak detection of Synaptophysin in 
transduced cells).  
 
Figure 37: In vitro characterization of NSC bioluminescence. A) BL signal 
obtained for a cell dilution series ranging from 3,000 – 300,000 cells. B) 
Photon emission and cell number are linearly correlated as indicated by 
linear fit.  
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As an additional prove of no contaminating pluripotent cells, tumorigenicity was assessed in vivo. 
Luc2-positive cells were transplanted into nude mice (n=2) and BLI was conducted over 1 month. 
According to the decrease in BLI signal, cell death occurs after transplantation. On day 27 after trans-
plantation, BLI signal from the cell graft reached the skin background level. A long-term tumor for-
mation was excluded by the histological staining, which showed no sign of tumor cell proliferation 
(Figure 39).    
 
Figure 38: Characterization of D3WT_N2Euro cells transduced with EF1-Luc2-T2A-copGFP-SV40-Neo. A) Western blot 
verification of Luc2 (61 kDa) expression and maintained level of Nestin (200 kDa) compared to WT cells – Actin as loading 
control (42 kDa). B) Proliferation rate for Luc2-positive cells compared to WT obtained in two independent experiments. 
C) RT-PCR marker profile comparison for retroviral-vector transduced D3WT_N2Euro cells and WT cells. D) Neural differ-
entiation potential of transduced cells differed significantly from WT cells (DCX p=0.006, GFAP p=0.001).   
 
 
Figure 39: Long-term tracking of Luc2 expressing D3WT_N2Euro cells. A) Animal 27544 and 27545 received 30,000 cells 
into the left striatum and were monitored over 1 month. B) According to the homogenous cell structure visible in the 
H&E staining at 4x and 20x magnification, no tumor formation occurred (scale bar 500 and 50 µm).     
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4.2.7 Detection of small number of grafted NSCs with the advanced protocol 
Based on the empirical data obtained in 4.2.5, 300 mg/kg pre Isoflu-
rane anesthesia was chosen for a further in vivo application: the 
sensitivity determination for grafted NSCs. For this, different 
amounts of the Luc2 expressing D3WT_N2Euro cell line (see 4.2.6) 
were transplanted into the striatum of nude mice (3,000, 6,000, 
30,000 or 300,000 cells, each cell amount n=3). BLI was performed 
24 h later. The advanced protocol was applied in comparison to the 
standard protocol (150 mg/kg post Isoflurane and 300 mg/kg pre 
Isoflurane – 6 h time separation) for 30 min. The BLI detection limit 
was calculated assuming a SNR≥3 for a reliably detectable signal. A 
summary of all BLI images acquired under both protocol conditions 
is shown in Figure 41. This evaluation revealed the primarily the advantage of the new protocol, 
which facilitated the detection of 3,000 cells in vivo. The standard protocol required at least 30,000 
cells to generate a SNR>3. Based on the calculated mean PEmax values for all cell grafts, a correlation 
between cell number and photon emission was plotted and fitted to a linear equation (Figure 40).    
 
Figure 41: Sensitivity comparison of 150 mg/kg post-Iso and 300 mg/kg pre-Iso D-Luciferin injected ip. Based on the SNR 
calculations 3000 cells were reliably detectable with the advanced protocol, but at least 30,000 cells were necessary to 
generate a SNR > 3 acquired with the standard protocol.   
Figure 40: Linear correlation between 
photon emission and cell number for 
both BLI protocols.  
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4.3 Discussion  
Optical cell tracking with bioluminescence enables researchers to observe various firefly, Gaussia and 
Renilla luciferases upon injection of the appropriate substrate without an additional light source. 
Luciferase variants were recently engineered to enable different emission spectra, to increase quality 
of emission and expression in mammalian cells by codon-optimization (see 1.3.2). These improve-
ments paved the way for dual color70 and dual substrate138 imaging using different luciferases. Never-
theless, most of these luciferases have not been validated for neuroimaging approaches. Especially 
the quantitative detection limits cell grafts in the mouse brain  missing. In the experiments of this 
dissertation, the genetically improved firefly Luc2, the red-shifted PpyRE9, the green-emitting Click 
beetle Luciferase CBG99 and the Coelenterazine-dependent Renilla luciferase hRluc were compared 
in terms of detectability under in vivo conditions. The results emphasize the impact of luciferase 
quantum yield superior to the wavelength-dependent tissue penetration. For dual color imaging 
based on different substrates, Luc2 coupled with hRluc are preferable and CBG99/PpYRE9 remain the 
best couple for spectral discrimination based on the different emission maxima. Based on the superi-
or properties of Luc2 for neuroimaging purposes, the next experimental step involved the empirical 
optimization of imaging parameter with a transgenic mouse line for brain specific BLI. The advanced 
protocol proved two-times higher sensitivity for the detection of grafted Luc2-expressing NSCs.  
4.3.1 Mouse neural stem cell line derived from embryonic stem cells 
The mouse NSC line generated according to an adapted protocol (termed D3WT_N2Euro) fits pre-
cisely to the radial-glia like NSCs – a well described type of NSCs, obtainable under in vitro condi-
tions139. Nevertheless, the molecular fingerprint of such in vitro cells cannot directly be assigned to 
one of the NSCs characterized in the adult mammalian brain in vivo. Based on the expression of 
GFAP, NSCs in the SVZ are divided into GFAP-positive type B cells and transit-amplifying type C cells, 
which are GFAP-negative but positive for NG2 and Dlx-2140–142. But the cellular correlate for 
D3WT_N2Euro cells is better represented by radial glia cells, which serve in the developing brain as 
neural progenitors and as scaffolds for migrating newborn neurons. The in vitro generation of radial 
glia cells seems to be a common step induced by the culture conditions143.The radial glia-like NSC 
identity of D3WT_N2Euro cells is supported by the mouse radial glia set BLBP+/GFAP-144 and the NSC 
pattern Nestin+/Pax6+/Sox1-/Sox2+/Musashi1+/Prominin-1+145–150. In addition D3WT_N2Euro cells 
match the radial glia-like NSC pattern described by Conti et al.93 (Sox1-/BLBP+/Pax6+/Olig2+/Mu-
sashi1+). The oligodendrogenic marker Olig2 and GalC (galactosylceramide)151 is explained by a phe-
notypic deregulation of cultured neural cells as reported by Dromard and colleagues16. The cerebellar 
immortalized NSC line C17.2 (initially derived from 4 day old mice), here used as a reference, showed 
a distinctive marker profile: GFAP+/Nestin+/Sox1-/Sox2+/Olig2-/GalC+. Previous reports have charac-
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terized C17.2 accordingly, except for GFAP and Sox2, which were possibly acquired during extensive 
passaging (the cell line is already ˃ 12 years old)10. However, C17.2 cells differ significantly from other 
NSCs, which limits the extrapolation from data acquired with C17.2 as Mi and colleagues pointed 
out152.  
D3WT_N2Euro cells differentiate efficiently upon stimulation into the neuronal and glial lineage as it 
was proven by ICC and qPCR. In contrast to data by Conti et al.93, expression of early neuronal marker 
(DCX) was more frequently (approx. 40% of all cells) than marker for mature neurons (e.g. Map2, 
Synaptophysin), according to the qPCR analysis. The efficient generation of betaIII tubulin-positive 
cells was not reached. Optimization of the protocol by hypoxia culture conditions (2% O2), which can 
facilitate neuronal differentiation153, could not improve the ICC results (data not shown). These re-
sults indicate that neuronal differentiation potential of D3WT_N2Euro cells is limited and would need 
further cell culture optimization. However, D3WT_N2Euro cells differentiate reliably into astrocytes 
(GFAP, Glast) and Oligodendrocytes.     
In conclusion, the protocol described here, follows the model of embryonic stem cell differentiation 
as described by Pollard and colleagues139, in which a transient Sox1-positive pan-neural progenitor 
population (analogous to mouse E8.5-10.5) contains mature Sox1-negative cells, which can be stably 
maintained and expanded using EGF plus b-FGF. As indicated by the absence of pluriptency marker 
(Oct4, Rex-1 and Nanog), D3WT_N2Euro cells lack residual embryonic stem cells, which could lead to 
a putative tumorigenicity after transplantation154,155. By observing these cells over 4 weeks after 
transplantation into the striatum by BLI and histology, tumor formation or cell proliferation was ex-
cluded. The longterm passaging of D3WT_N2Euro cells revealed no differences in marker expression 
and differentiation potential as verified by RT-PCR and ICC. As an exception, weak amplification of 
Sox1 was detectable in the high passage, which would need further validation by qPCR to be verified 
as a sign of switch to neuroectodermal precursors156. Nevertheless, D3WT_N2Euro cells meet the 
criteria of long-term, self-renewing and multipotent NSCs143 as resource for further experiments. 
4.3.2 Imaging reporter expression 
Lentiviral vector-mediated imaging reporter expression in HEK-293 and D3WT_N2Euro cells  
The cloning strategy for introducing the 4 different luciferases made use of the strong EF1 promoter, 
which was shown to be beneficial in terms of transgene stability especially in stem cells 90. Each lucif-
erase was coupled to copGFP via the self-cleaving T2A sequence, which allows equimolar expression 
of both reporter genes and overcomes limitations of conventional linker elements like viral IRES ele-
ments (internal ribosomal entry site) 157. The transduction of HEK-293 and D3WT_N2Euro cells re-
vealed the substantial difference in transduction efficiency and transgene integration/expression 
rate. Based on this observation, the HEK-293 cells were sorted using a higher FACS gate without long-
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term proliferation effects. In contrast, NSCs represent a group of cells, which are much more difficult 
to transduce and are more vulnerable for genetic modification. Notably, NSCs required sorting with a 
lower gate to reveal stable, proliferating cell lines. The generally lower efficiency of gene delivery and 
suppression of exogenous genes integrated into the (embryonic) stem cell genome has been de-
scribed158,159. In a recent study by Dhara and colleagues160, lentiviral transduction was compared with 
transfection and electroporation. Lentiviral transduction was found to be the most efficient method 
in terms of transgene expression and long-term GFP reporter expression in human neural progenitor 
cells. Because of the focus on the most efficient luciferase for in vivo neuroimaging applications, an 
extensive characterization of lentiviral-induced effects on (stem) cell behavior was not conducted. 
Nevertheless, various reports have proven the safety of lentiviral transduction especially for (neural) 
stem cells in terms of cell viability, proliferation, retained stem cell properties and no influence on 
the proteome160–162. 
Retroviral vector-mediated imaging reporter expression in D3WT_N2Euro cells 
One drawback of the lentiviral approach is the size of the plasmids carrying the EF1 promoter and 
two reporter genes, which can exceed 10 kb – a critical size for efficient viral packaging. Therefore, 
D3WT_N2Euro cells were also infected by an ecotropic retrovirus, which contains Luc2-T2A-copGFP 
under control of LTR and Neomycin-resistance gene under control of a separate SV40 promoter (total 
size 7.7 kb). The antibiotic resistance in combination with the copGFP FACS revealed to be a highly 
efficient method to sort for stable cell clones with high reporter gene expression. Furthermore, these 
cells showed no difference in marker expression and differentiation potential. In these experiments 
the long-term stability of transgene expression was not as important but should be considered for 
future longitudinal studies. Retroviral vector systems are potentially hampered by transgene stability, 
which was reported to be stable for up to 3 months in vivo assessed by a LacZ expressing NSC trans-
planted into the mouse brain163 and strongly reduced after differentiation164.   
4.3.3 Quantitative in vitro and in vivo luciferase comparison 
Our neuroimaging experiments improve and complete previous reports comparing luciferases under 
in vivo conditions135,165,166. Under in vitro conditions, the hRluc, Luc2 followed by CBG99 were superi-
or to PpyRE9 luciferase with 10-times lower detectability for HEK-293 compared to NSCs. Under in 
vivo conditions, we detected a significant difference between CBG99 and Luc2 in line with the in vitro 
results (Table 21). However, the ratio between Luc2 and PpyRE9 decreased (3.7±0.3 fold difference 
between Luc2 and PpyRE9 signals), indicating an advantage of the red shifted spectrum for in vivo 
imaging. Nevertheless, the spectral advantages were diminished by the low quantum yield, which 
leads to a benefit for the green-shifted CBG99.  
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Table 21: Quantitative comparison of luciferase performance in vitro and in vivo 
Luciferase       In vitro In vivo 
  D3WT_N2
Euro 
D3WT_N2Euro 
Luc2  50 100,000 
PpyRE9  500 300,000 
CBG99  50 100,000 
hRluc  50 ˃300,000 
 
In contrast to the well-known flash-kinetic of Renilla luciferases in vitro, this BLI signal normalized to 
the luciferin kinetic with peak emissions between 12-16 min after substrate administration. Coelen-
terazine-h diffusion into the brain parenchyma is strictly limited by the multidrug-resistance specific 
transport back in the blood system, which is most probably the reason for the time delay in signal 
increase. In our experiments, only the pre-formulated Coelenterazine-h RediJect (Caliper) was a suit-
able Renilla substrate. Coelenterazine-h from different supplier could not be solved efficiently and 
degraded rapidly by spontaneous oxidation (leading to unspecific photon emission). This Renilla-
specific setting enabled the detection of 6x104 HEK-293 in the brain, but not 3x105 NSCs. This discrim-
ination is most prominent due to the fact that HEK-293 cells generated nearly 6 fold brighter signals 
in vitro. Optimization of hRluc expression in NSCs is therefore required for future studies.  
The luciferase with second highest photon emission in vitro – Luc2 – was superior in vivo, which is in 
line with recent reports on liver imaging167. The Luc2 benefits from the optical properties, but also 
from the extensive gene modifications to optimize its expression in mammalian cells168. CBG99 re-
vealed second highest photon emission in vivo and the most prominent spectral shift in relation to 
the transplantation depth, which can be used as a precise predictor.  
Tissue depth-dependent spectral emission changes 
Detection of BLI signals from brain transplantations is strictly dependent on the transmission proper-
ties of the brain tissue, determined mainly by light absorption due to hemoglobin52,169 and light scat-
tering at myelin/cell boarders53,170. The spectral shift in relation to the transplantation depth was 
most prominent for the click beetle luciferase CBG99. In this case the emission maximum is directly 
shifted by the stronger absorption/scattering with increasing transplantation depth. Similar results 
were obtained by Zhao and colleagues171, who described depth-dependent spectral changes most 
prominent for the green-emitting click beetle luciferase CBG68. The emission of the red-shifted Luc2 
and CBGr68 was diminished in the lung and liver but not the emission maximum. The pronounced 
shift in emission maximum for the experiments reported here could serve as a noninvasive control 
for the cell graft location for example in longitudinal studies in which migration of stem cells is as-
sumed. In this case, spectral unmixing of the CBG99 signal would resolve the emission maximung, 
which could be translated to a certain transplantation depth.  
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Notably, dual color approaches with PpyRE9 and CBG9970, would be hampered by the spectral shifts 
of CBG99 in the brain. Under in vitro conditions and if the cells are transplanted subcutaneously, the 
initial separation is 60 nm. This is diminished to 20 nm in case of 3 mm deep transplanted cell grafts 
in the mouse brain. In this respect novel Luc2 substrates for shifting the emission maximum of Luc2 
about 40 nm could improve spectral unmixing172.  
4.3.4 Revision of the standard protocol for bioluminescence neuroimaging 
While conducting the BLI comparison of different luciferases, Keyaerts and colleagues37 published an 
article about the anesthesia-dependent inhibition of the firefly luciferase. In a subcutaneous tumor 
model, the inhalation gas Isoflurane diminished the BLI signal about %. A publication record on 21 
recent reports about BLI of transplanted (stem) cells and transgenic animals revealed the lack of a 
consistent standard protocol, with a tendency to 150 mg/kg D-Luciferin (62%) injected ip (86%), post 
anesthesia (57%) by Isoflurane (91%) (Table 22).  
This protocol does not necessarily meet the special requirements of brain imaging, as it has been 
proven useful primarily in qualitative tumor studies. Therefore, in this study basic factors affecting 
the BLI in vivo were empirically evaluated for the first time on a mouse model for brain-specific BLI – 
the transgenic DCX Luc mice. The impact of substrate concentration, route/timing of substrate ad-
ministration and the type of anesthesia were evaluated quantitatively. An advanced protocol was 
identified, which results in a 2-fold BLI signal increase, while remaining user-friendly, fast applicable 
and cost-effective. The advantage of the new protocol relies on the boosting of the sensitivity for 
optical cell tracking in the mouse brain by a factor of 2, which enabled for the first time the detection 
of down to 3,000 transplanted NSCs in vivo.  
Concentration dependent increase in photon flux 
The intracellular kinetics of firefly luciferase were recently characterized186. Under in vitro conditions 
the intracellular half-life is over 24 hours and the KM value (representing the concentration for half 
the maximal enzyme velocity) was found to be 1 mM. However, the in vivo situation – especially for 
brain specific BLI is not well characterized. Interestingly, the experiments with different concentra-
tions showed that 750 mg/kg did still not result in a saturating photon emission level as it was pro-
posed for 450 mg/kg D-Luciferin187. Furthermore, the photon emission increased with concentration 
by an exponential curve. This effect is probably due to a critical blood plasma concentration, which 
facilitates substrate absorption through the blood brain-barrier188. This is supported by the nearly 10-
fold higher slope, which can serve as a measure for the substrate inflow dependent photon emission 
in the first 5 min of acquisition. 
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Table 22: List of BLI protocol conditions for recent publications from 2008-2012. Injection of D-Luciferin pre or post anes-
thesia, the type of anesthesia (Isoflurane – Iso, Ketamine/Xylazine – Ket/Xyl) and the injection route (ip, iv, sc) were 
compared. The D-Luciferin concentration for rats (*) was divided by a factor 5 to match the mouse weight.   
Model 
D-Luciferin 
(mg/kg) 
pre or post 
anesthesia 
Anesthesia 
Injection 
route 
Reference 
Optimized protocol 300 Pre Iso ip - 
NSCs in a demyelination mouse model 300 pre Iso ip 
173
 
Intracerebral gliobastoma 150 pre Iso ip 
134
 
Cardiac cell transplant 75 (rats)* pre Iso ip 
174
 
GFAP-Luc transgenic mice 150 pre Iso ip 
175
 
TLR2-Luc transgenic mice 150 pre Iso ip 
176
 
Imaging SVZ-neurons with Luc lentivirus 126 post Iso ip 
74
 
Human NSCs in ischemic rat brain 75 (rats)* post Iso ip 
177
 
Subcutaneous tumor model 150 post Iso ip 
178
 
DCX-Luc transgenic mice 300 post Iso ip 
71
 
Brain infiltration by MSCs 150 pre Iso ip 
179
 
Renilla vs click beetle luciferase 150 post Iso ip 
165
 
Brain infiltration by MSCs 150 post Iso ip 
180
 
Subcutaneous tumor model 30 post Iso ip, iv 
181
 
Luc2 vs PpyRE9 150 pre Iso ip 
135
 
Subcutaneous tumor model 75 post Iso sc, ip 
182
 
Intracerebral tumor model 125 pre Iso ip 
183
 
Subcutaneous tumor model 150 post Iso ip 
37
 
Brain infiltration by bone marrow cells 150 post Ket/Xyl ip 
184
 
Intracerebral NSC model 150 pre Iso ip 
185
 
Subcutaneous tumor model 150 post Ket/Xyl ip 
70
 
Intracerebral MSCs graft 150 post Iso Iv 
136
 
 62 % 150 57% post 91 %  Iso 86 % ip  
 
Assuming a 20 g mouse with 2 ml of total blood volume and neglecting substrate metabolism and 
elimination, the injection of 30 mg/kg D-Luciferin should reach already the in vitro KM of 1 mM. Nev-
ertheless, the D-Luciferin titration experiments revealed higher PEmax and contradict to previous as-
sumptions, that the enzyme is already saturated at low substrate concentrations (5 µl of 100 mM) for 
subcutaneous applications in vivo68. Pharmacokinetic modeling as it was established for the tumor by 
Sim and colleagues189 would be necessary to understand the brain-specific mechanisms of influx and 
efflux D-Luciferin kinetics. According to a calculation by Berger and colleagues190 only 5% of the blood 
plasma level D-Luciferin will enter the brain parenchyma. The remarkable substrate restriction pro-
vides an indication of the persistent luciferase activity at substrate concentrations exceeding KM un-
der in vitro conditions. Interestingly, the time-to-peak is significantly delayed at high substrate con-
centrations. Under in vitro conditions, this would clearly be reflected in the conformational change of 
the luciferase enzyme, temporarily reducing the catalytic rate191. However, this observation is in all 
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probability due to the prolonged concentration gradient between blood plasma and brain tissue at 
high concentrations of D-Luciferin facilitating a continued concentration increase. D-Luciferin-
dependent toxicity effects are not expected, as the majority of studies have reported no adverse 
effects68,192–195. 
Influence of injection route 
D-Luciferin is advantageous as an imaging substrate because of its ability to distribute rapidly in the 
blood system, pass cell membranes and enter every organ (even through the placenta and blood 
brain-barrier)68,73,196. In this study, previous reports for the injection route182 were complemented by 
comparing the impact of sc, ip and iv on the brain specific BL signal. For every condition, 4 DCX-Luc 
mice were injected with 150 mg/kg D-Luciferin and BLI was acquired in list mode for superior tem-
poral resolution. In accordance with previous reports using a subcutaneous tumor model, also the 
brain signal was dependent on the D-Luciferin biodistribution181,182. In case of the absorption-
independent iv injection, the photon emission reached 400% maximum in ¼ the time compared to 
the ip injection. In contrast, after ip injection the substrate bioavailability is delayed by the absorp-
tion process from the peritoneum into the blood system, which finally reduces PEmax while prolonging 
time-to-peak. In contrast to a study of Inoue et al.182 the sc injection resulted in the lowest photon 
emission accompanied by a small slope and long time-to-peak value. In conclusion, iv injection gen-
erates the highest photon flux, but has limitations for repetitive measurements. The very fast kinetics 
without a long plateau phase for imaging impede reproducible measurements at the PEmax and can 
induce additional error. Tail vein injections require more experimental skills than the simple ip injec-
tions and repetitive injections into the same tail can induce tissue necrosis. Therefore, at this experi-
mental stage, it was decided to use the ip injection, which is established and proven to work with a 
high success rate182 in a shorter time (more mice can be measured at the same time), repetitively 
without tissue irritation and permits experimental flexibility by a prolonged steady-state BLI signal.  
Anesthesia-dependent photon flux changes 
In vivo BLI of subcutaneously transplanted cells was reported to be strongly affected by the type of 
anesthesia37. In this work, the effect of different anesthetics (Isoflurane, Ketamine/Xylazine, Pento-
barbital) and the timing of Isoflurane anesthesia on brain-specific BLI was investigated. 
Compared to the standard protocol, PEmax decreased Ketamine/Xylazine and increased slightly for 
Pentobarbital anesthesia, without reaching statistical significance. In vitro, Keyearts et al.37 found no 
direct inhibitory effect of Ketamine, Pentobarbital or Medetomidine (belonging to the same family of 
α2 adrenoreceptor agonists like Xylazine). In conclusion, the signal modulation observed in experi-
ments reported here, might be the result of an altered hemodynamic situation. D-Luciferin biodistri-
bution197 and the BLI signal are affected.  
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However, anesthetics can have different effects on the blood system198. Isoflurane results in the 
slightest reduction of cardiac output, followed by Pentobarbital with medium reduction. The strong-
est impact on cardiac output is expected under Ketamine/Xylazine anesthesia, which induces hypo-
tension, bradycardia and hypothermia199,200. Although cerebral hemodynamics are autoregulated, the 
grading of the hemodynamic changes parallels our observation of delayed time-to-peak values for 
Pentobarbital and Ketamine/Xylazine anesthesia compared to Isoflurane.  
The slight difference in PEmax between Pentobarbital and Isoflurane anesthesia might be due to the 
direct inhibitory effect of Isoflurane on the luciferase enzyme, which we studied by comparing pre vs. 
post Isoflurane anesthesia. D-Luciferin injection before anesthesia consistently resulted in higher 
PEmax/AUC compared to the standard post injection. It was previously suggested, that D-Luciferin 
inhibition by Isoflurane is a mixed style inhibition with competitive binding at the substrate pocket 
site as well as a non-competitive binding, which will change the structure of the enzymatic pocket191. 
In line with previous reports37, inhibition is partially reversible by higher substrate concentrations, 
which is due to an increased KM value. Our data indicates that pre Isoflurane administration of 
D-Luciferin results in a better substrate distribution and an increased substrate availability in the 
brain compared to post Isoflurane injection. This results in an increased enzyme-substrate complex 
under pre Isoflurane condition, which is less affected by the inhibitory activity by Isoflurane. 
Imaging protocol-dependent in vivo detection limits 
We performed a quantitative comparison of the advanced vs. the standard imaging protocol applied 
to Luc2+ NSC transplanted into the mouse brain at different quantities. With this approach it was 
possible to study the detection limits of both protocols: 3,000 and 6,000 cells were not detectable 
with the standard protocol. Measuring these animals with the advanced protocol enables clear de-
tection of even 3,000 transplanted NSCs. To point out, such a small number of transplanted non-
immortalized NSC has not been imaged in vivo, yet.  
SNR values were calculated for each graft size and a SNR ≥ 3 determined as a quantitative measure to 
reliably distinguish BLI signal from the noise. Visual comparison of all BLI images (n=12) confirmed 
that signals outside the cell graft exhibited SNR < 3 and were identified as noise. Cell number approx-
imation, as it was shown under in vitro conditions201, seems to be possible in vivo providing that ex-
perimental conditions remain constant. Notably, the SNR values are not dependent on the 30 min 
acquisition time, they do not differ, if calculated for 1 min acquisition at the time-to-peak for each 
animal (300 mg/kg 3,000 cells: 30 min SNR=3.5±0.4, 1 min SNR=4.4±1.3). However, calculating SNR 
values for the 30 min acquisition is more convenient, as it requires no preprocessing (like determina-
tion of time-to-peak and image frame extraction) and can serve as a rapid estimation for a successful 
transplantation experiment.  
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High variability between animals receiving equal cell amounts was primarily induced by the trans-
plantation procedure. The number of cells is variable due to the error induced during cell counting, 
the injection and the transplantation depth. As it was pointed out before, the transplantation depth 
is one of the key determinants of photon flux as it controls the percentage of transmitted biolumi-
nescence light183. 
4.4 Conclusion and Outlook 
In this chapter, bioluminescence imaging was extensively revised for the optimal protocol conditions 
and type of luciferase suitable for highest sensitivity in optical cell tracking within the mouse brain. In 
contrast to the majority of previous studies, which applied BLI as a qualitative tool to assess the 
presence of the reporter gene according to e.g. tumor growth or cells infected by an in intracerebral 
injection of virus – the reported advancements can be used to fully exploit the potential of quantify-
ing the luciferase expression in vivo. The threshold determination adapted from MRI by determining 
SNR values represents a valuable tool to reliably distinguish background signal from cell grafts.  
The differences in photon flux between HEK-293 and NSCs emphasize the importance of further mo-
lecular and cellular biological optimization. A prerequisite to induce even higher levels of reporter 
gene expression could be realized potentially by adaption of an optimized high-level expression cas-
sette on retrovirus vectors202. Nevertheless, preservation of stem cell properties and retained re-
porter expression remains a requirement for using these novel reporter cells in a therapeutic applica-
tion, e.g. the treatment of neurodegenerative disease.   
Based on the improvements reported here, bioluminescence neuroimaging will be not limited on a 
single luciferase readout. By further improving the BLI sensitivity with luciferases bioengineered for 
far-red light emission, the combination with the green CBG99 luciferase to distinguish different cell 
types will become possible also for brain applications. An example of luciferase substrate-dependent 
cell discrimination is explained in the following chapter.     
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5. NONINVASIVE IMAGING OF NEURAL STEM CELL DIFFERENTIATION 
5.1 Project aim and experimental setup 
In vitro differentiation of embryonic and neural stem cells serves as a powerful tool to elucidate the 
complex gene regulations involved while cells shift from a pluri- and multipotent state to a definitive 
mature cell type, e.g. neuronal or glial cells. The conventional approach to follow the underlying cas-
cade of molecular events is the in vitro differentiation by definite culture conditions and the subse-
quent immunostaining at each time point for selected markers. This implies a great experimental 
complexity and the limitation of definite end time point images. For the in vivo condition – the track-
ing of stem cell fate after transplantation – histology is substantially limited by marker analysis for 
different animals in experimental subgroups for selected time points.  
The aim of this project was to develop a lentiviral-based assay for bimodal reporter gene detection of 
NSC differentiation into the glial lineage, which can be transferred into the in vivo application. 
The basic concept involves NSCs transduced to stably and constitutively express Renilla luciferase 
hRluc and the green fluorescent protein copGFP. These reporter genes are included for optical cell 
tracking independent of the differentiation state. To assess differentiation into the glial lineage, the 
GFAP promoter was selected to drive the expression of the firefly luciferase Luc2 and the red fluores-
cent protein mCherry. This set of reporter genes was inserted by two independent lentiviral vector-
mediated gene transfers into D3WT_N2Euro cells: 1) EF1-hRluc-T2A-copGFP and 2) GFAP-Luc2-T2A-
mCherry.  
The onset of GFAP expression could be monitored by the reporter genes under control of the GFAP 
promoter in vitro. This setup is intended to allow for the first time dual-luciferase and dual-color 
readout of the cell differentiation state by expression of the appropriate imaging reporters. The dif-
ferentiated GFAP-positive cells can be distinguished by hRluc bioluminescence and mCherry fluores-
cence.   
 
The experimental schedule included the following subprojects:  
1) Generation of lentiviral, bimodal reporter plasmids for constitutive and cell-specific imaging   
2) Validation of the human GFAP promoter for efficient reporter expression in a tumor cell line 
3) Transduction of bimodal reporter plasmids into D3WT_N2Euro cells 
4) Dual-reporter monitoring of glial differentiation in vitro 
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5.2 Results  
5.2.1 Validation of the GFAP promoter driven reporter gene expression 
In a first set of experiments, the human GFAP promoter was validated for efficient reporter gene 
expression in different mammalian cells (U373, GL261, HEK-293T). An appropriate model cell line was 
chosen based on the GFAP expression, triggered by stimulation with 0.5, 1.5 or 5.0 mM valproic acid 
(VPA). After 1 day of VPA treatment cells were fixed and stained for GFAP. These ICC stainings re-
vealed a strong increase in GFAP immunoreactivity only for the human gliobastoma cell line U373 
cells but not for GL261 cells. No increased ICC signal was detected for HEK-293T, which have no en-
dogenous GFAP expression and served as a control for the VPA effect on the ICC. The relative ICC 
signal normalized to the cell number for a representative fluorescence image increased by a factor of 
20 for U373 cells supplemented with 5 mM VPA for 24 h (Figure 42). 
 
Figure 42: Validation of GFAP promoter activity. A) GFAP expression was triggered by 0.5, 1.5 and 5.0 mM valproic acid 
(VPA) in U373, GL261 and HEK-293T cells shown by increased immunoreactivity for the GFAP antibody stained by Cy3-
coupled secondary antibody and counterstained with Hoechst (scale bar 25 µm). B) Quantitative evaluation of the fluo-
rescence in ICC stainings for GFAP normalized to the number of cells per ROI. U373 cells were most sensitive to the GFAP-
inducing VPA treatment.     
This paradigm was further tested by transfection of U373 with GFAP-T2A-copGFP, stimulation with 
5 mM VPA for 1 day and subsequently GFAP staining. The representative fluorescence microscopy 
images in Figure 43 illustrate, how the copGFP fluorescence signal (no additional ICC necessary) was 
significantly increased by a factor of 1.7±0.1 (p=0.0032). The increased expression of the GFAP-driven 
transgene was in accordance to the 1.8±0.3 (p=0.0300) fold ICC signal obtained for endogenous 
GFAP.  
Based on these experiments, the BLI performance of GFAP-driven Luc2 expression was studied. U373 
were transfected with different plasmids: 1) EF1-Luc2-T2A-mCherry (control), 2) GFAP-Luc2-T2A-
mCherry, 3) GFAP-Luc2-T2A-Puro and 4) GFAP-Luc2-P2A-mCherry-T2A-Puro. A longer VPA stimula-
tion for up to 72 h was necessary to reveal reliable results. Cells were measured in black 96-wells to 
avoid cross-well signals. Upon VPA stimulation BLI was acquired for 1 min directly after addition of 1 
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mM D-Luciferin. For each condition, a quantitative ROI analysis was evaluated on at least 5 inde-
pendent wells for each transfection. Figure 43 C summarizes the photon flux differences upon VPA 
stimulation normalized to the untreated samples set to 100%. The VPA stimulation had no effect on 
the conditionally expressed Luc2. In contrast, VPA stimulated GFAP-driven expression of Luc2 signifi-
cantly for GFAP-Luc2-T2A-Puro (p=0.0292) and GFAP-Luc2-P2A-mCherry-T2A-Puro (p=0.0325). For 
the GFAP-Luc2-T2A-mCherry transfected cells, the photon flux increase was not significant different 
from the untreated group. A substantial difference in photon flux was detectable for the constitutive 
EF1 promoter (27,956±8,065 ph/s/cm2/sr) in relation to e.g. GFAP-Luc2-T2A-Puro (14,883±4,329 
ph/s/cm2/sr).  
 
Figure 43: GFAP-induced expression of imaging reporters after stimulation of U373 with VPA. A) Representative fluores-
cence microscopy of GFAP ICC (red). U373 were transfected with GFAP-T2A-copGFP and stimulated for 24 h with VPA. In 
a subset of cells copGFP expression was initiated along with GFAP (arrow), whereas in other cells only GFAP was upregu-
lated (dotted arrow) (Hoechst nuclei staining, 40x magnification, 25 µm scale bar). B) Quantification of relative fluores-
cence signals for copGFP and ICC of GFAP pre and post VPA stimulation for 24 h. C) BLI of VPA-dependent GFAP promoter 
activation in U373 transfected with different GFAP vectors: 1) EF-Luc2-T2A-mCherry, 2) GFAP-Luc2-T2A-mCherry, 3) 
GFAP-Luc2-T2A-Puro, 4) GFAP-Luc2-P2A-mCherry-T2A-Puro. BLI data from wells without VPA-stimulation were used for 
normalization.    
5.2.2 Dual reporter neural stem cells 
In a first transduction experiment, D3WT_N2Euro cells were infected with a lentivirus carrying EF1-
hRluc-T2A-copGFP or EF1-T2A-copGFP as control. The cells from two independent experiments were 
sorted according to the copGFP expression by applying different FACS gatings: for very high express-
ing cells > 103 counts, for high expressing cells > 7x102 and middle expressing cells 5x102-1x103 counts 
(Figure 44). These cells were further passaged and subsequently compared against WT cells and cells 
transduced with the control vector EF1-T2A-copGFP based on photon flux and cell viability (Figure 44 
D). The cell viability was decreased only by the hRluc expressing cell lines with a significant stronger 
effect for the FACS High I cells (p=0.0075) compared to WT cells. As an exception, the High II cell line 
showed significantly higher cell viability compared to the WT cells (p=0.0025).  
In accordance with the FACS gating, High II cells exhibited 2.2-fold photon flux and the High I cells 
even a 3.4x-fold higher photons/cell value. In order to achieve highest BLI sensitivity, the 
D3WT_N2Euro EF1-hRluc-copGFP High I cell line was chosen for the second transduction. This time, 
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the plasmid with a cell specific promoter-driven Luc2 expression was transduced. In order to follow 
the GFAP promoter onset by histology, the red fluorescent protein mCherry was coupled via the T2A 
peptide to Luc2. However, the second transduction resulted in an additional cell stress, which im-
peded the efficient gene integration. Therefore, the GFAP-Luc2-T2A-mCherry plasmid was expanded 
by an additional SV40 promoter for driving the expression of zeocin resistance. Thus, additional GFAP 
promoter independent selection for successfully transduced cells was possible, by media supplemen-
tation with 200 µg/ml Zeocin. The resulting double transduced NSC line was used for the differentia-
tion experiments. 
 
Figure 44: Generation of D3WT_N2Euro cells with high expression of hRluc and copGFP. A) Representative fluorescence 
images for the cell lines transduced with EF1-T2A-copGFP or EF1-hRluc-copGFP with different levels of copGFP expres-
sion. Two cell lines with high copGFP expression (High I, II) and one with less copGFP (Middle) were generated (20x mag-
nification, scale bar 100 µm). B and C) Dot plots for the High I, High II and Middle cell line, named according to the FACS 
gate and copGFP fluorescence, respectively. D) These cell lines were tested by PrestoBlue assay for cell viability and by a 
BLI cell dilution series for the photon flux properties.   
5.2.3 Dual reporter monitoring of glial differentiation 
Double transduced D3WT_N2Euro cells were differentiated into the glial lineage according to the 
protocol described in section 4.2.1. The mCherry fluorescence onset was monitored after 7 days of 
differentiation. Figure 45 illustrates the differences between the undifferentiated, proliferative NSC 
state characterized by copGFP+/mCherry-/ICC-GFAP- and the glia cell culture after differentiation 
characterized by copGFP+/mCherry+/ICC-GFAP+. After differentiation, GFAP-negative cells (dotted 
arrow) can be clearly distinguished from cells expressing GFAP (arrow). These cells co-express the 
optical reporter mCherry, visible without any histological treatment (Figure 45 B). A potential down-
regulation of the constitutive copGFP reporter during differentiation was excluded by equal fluores-
cence measurements before and after differentiation (Figure 46 A).  
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The Luc2 expression under control of the GFAP promoter was monitored at 1, 4 and 7 days of glial 
differentiation in a 24-well plate (Figure 46 B). A significant increase was observed from day 1 to 4 
(p=0.048), in which the Luc2 expression increased and resulted in approx. 24-fold increase of photon 
flux. Until day 7, the photon flux tended to increase, although without reaching significance.  
 
Figure 45: Monitoring glial differentiation by fluorescence reporter. Fluorescence microscopy images for the endogenous 
expression of copGFP (EF1 promoter-driven), mCherry (GFAP promoter-driven) and the ICC for GFAP for A) proliferative 
and B) differentiation conditions (Hoechst used for staining nuclei, all images 40x magnification, 50 µm scale bar).  
 
 
  
 Figure 46: Fluorescence and bioluminescence reporter during 
glial differentiation. A) Differentiation induced changes in 
copGFP were not significant. B) The Luc2 photon flux 
increased during the glial differentiation specifically because 
of the GFAP promoter activity.  
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5.4 Discussion 
Noninvasive monitoring of neural stem cell differentiation has not been achieved until now. One way 
to highlight the glial fate of NSCs is presented here: the expression of bimodal optical reporters un-
der control of a differentiation sensitive promoter. The NSC line D3WT_N2Euro lacks GFAP expres-
sion in the proliferative state, but induces GFAP strongly upon glial differentiation. This endogenous 
off/on system was chosen for a molecular imaging approach. At first, the human GFAP promoter was 
tested in a tumor cell line for the efficient expression of optical imaging reporter. In a second step, 
D3WT_N2Euro cells were double transduced, which enabled 1) the constitutive, and 2) glia cell-
specific promoter driven expression of distinct bioluminescence and fluorescence reporters. This 
approach enabled for the first time the visualization of the glial fate in living neural stem cells by im-
aging reporter with a potential for in vivo applications. 
5.4.1 Validation of the GFAP promoter driven reporter gene expression 
The intermediate filament protein GFAP was discovered 40 years ago203 during an analysis of multiple 
sclerosis plaques and found to be almost exclusively expressed in astrocytes. The well described cell 
specificity in neural cells has recommended the human204 and mouse205 GFAP promoter for directing 
transgene activity in astrocytes206. Applications included GFAP-targeting in brain tumors207–209, astro-
cyte-specific production of bioactive molecules210,211 and creation of disease models212,213. Morpho-
logical studies on transgenic mice using the bacterial beta-galactosidase or jellyfish GFP under control 
of the GFAP promoter have been described204,205. More recently, Cho and colleagues214 generated a 
dual transgenic mouse expressing firefly luciferase under control of the human GFAP promoter and 
Renilla luciferase under control of constitutive human GAPDH promoter.  
In the experiments reporter here, imaging reporter plasmids were cloned, which include not only the 
luciferases Luc2 and hRluc, but also 2 different fluorescent reporters with clear advantages. Firefly 
and Renilla luciferases do not require post-translational modification, which allows fast maturation of 
the functional enzyme providing immediate reporter readout upon promoter activation215,216. Fur-
thermore, the BLI signal from both luciferases can be separated by the choice of substrate – 
D-Luciferin or Coelenterazine. The fluorescent proteins copGFP and mCherry belong to a group of 
advanced bright reporters and can be separated by the fluorescence emission (502 nm vs. 610 nm). 
For the initial validation of the GFAP promoter plasmids, the human astrocytoma cell line U373 was 
selected. GFAP expression could be efficiently modulated by the mood-stabilizer valproic acid, which 
inhibits cell growth and induces differentiation105. The short-term expression of GFAP-promoter driv-
en imaging reporters was achieved by transfection. These experiments showed clearly the imaging 
reporter activation upon stimulation of GFAP expression in U373 cells. The initial cloning approach 
included GFAP plasmids with puromycin resistance genes for selection of cells after differentiation. 
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Transfection with these plasmids resulted in the strongest luciferase response, which suggests no 
interference of the plasmid size for the expression of the transgene directly downstream of the pro-
moter. Nevertheless, in future studies mCherry fluorescence should be quantified dependent on the 
position in the reporter cassette.         
5.4.2 Dual reporter neural stem cells provide monitoring of glial differentiation 
As pointed out in the results section (5.2.2), double transduction of D3WT_N2Euro cells was not suf-
ficient for every plasmid tested with U373 cells. For this reason, only the additional antibiotic selec-
tion through an independent SV40-promoter driven zeo gene enabled the efficient 2nd transduction. 
The final NSC line was transduced with EF1-hRluc-T2A-copGFP and GFAP-Luc2-T2A-mCherry-SV40-
Zeo. As indicated by the viability measurements (Figure 44), not the transduction process, but the 
presence of a bimodal reporter can alter cell viability. These cells were used to target glial differentia-
tion by monitoring Luc2 and mCherry expression. The human GFAP promoter was sufficient to drive 
the expression of these reporter genes illustrated by the detectation of fluorescence and biolumines-
cence in vitro. This way, glial cells were distinguished after differentiation by the coexpression of 
copGFP and mCherry from mCherry and GFAP negative cells. During the differentiation process, the 
constitutive copGFP signal decreased without reaching a significant difference between undifferenti-
ated and differentiated cells. This stable reporter expression is one advantage of the lentiviral ap-
proach in relation to retroviral-mediated gene transfer and facilitates long-term observations164. The 
luciferase signal was 45-fold increased during the differentiation process. The measurements of 
hRLuc signals could not be combined and used for normalization as initially planned. The substrate 
CTZ-h is premixed in an organic solvent, which lead to the detachment of cells during 1-2 minutes. 
The measurements could be combined by including additional control wells only for the hRluc meas-
urements. Nevertheless, the dual luciferase approach was hampered also by the weak GFAP promot-
er and would need further improvement for in vivo studies. As proposed by Leeuw and colleagues217, 
the transcriptional activity of the GFAP promoter can be increased by inserting GFAP enhancer re-
gions. Transfection experiments revealed a 75-fold higher LacZ expression upon plasmid transfection. 
Preliminary results with this gfa2(ABD)3 promoter (data not shown), revealed a 5.6-fold higher Luc2 
BLI signal in the U373 experimental model and serves as a basis for further optimization.           
5.5 Conclusion and Outlook 
In this study, cell specific optical imaging was shown in vitro. Imaging reporter plasmids were cloned, 
which contain a luciferase and fluorescence reporter for both, the undifferentiated and differentiat-
ed state of neural stem cells. This approach enables the discrimination of glial cells from neural stem 
cells by the imaging reporters, which are detectable in the living cell. No histological staining is nec-
essary to assess the glial fate quantitatively, which overcomes conventional attempts to visualize the 
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fate of (transplanted) stem cells218. A remaining challenge is to enhance the transcriptional activity of 
cell-specific promoters. One possibility is the combination of additional enhancer elements, as shown 
for the GFAP219 and Synapsin220 promoter. Alternatively, a Cre/lox system could be used to drive ex-
pression of Cre under control of the GFAP promoter and subsequently cleavage of a stop cassette to 
facilitate imaging reporter expression221.  
Further sensitivity improvements for this dual reporter would allow the application to transplanted 
stem cells. This way, noninvasive imaging will be able to assess the fate of stem cells quantitatively 
and elucidate an additional key feature of stem cell therapy. 
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6. SYNOPSIS 
Noninvasive imaging is dedicated to visualize endogenous processes in the living cell, without affect-
ing the physiological state of the experimental animal. Stem cell therapy in neurodegenerative dis-
eases would substantially benefit from such methods visualizing processes like cell viability and dif-
ferentiation. During the last decade, magnetic resonance imaging (MRI) of contrast agent-labeled 
stem cells was established to locate the cells in the anatomical background and to observe migration 
processes noninvasively. The resulting images provide a high resolution projection of the labeled cells 
but provide no specific information about the cell status. Histological evaluation is still necessary 
after finishing the in vivo experiment to derive the fate of transplanted cells.   
This dissertation describes a novel MRI-based approach to overcome the limitations of conventional 
contrast agents. A molecular probe was designed to respond selectively to the most important en-
zyme in GABAergic neurons – the glutamic acid decarboxylase (GAD). For the first time, a responsive 
contrast agent has been found which is selectively activated by a neuron-specific enzyme, and pro-
vides the discrimination of GABAergic neurons based on T1 relaxation changes.  
An optical noninvasive method was analyzed in a second project aiming at optimal conditions for 
bioluminescence imaging (BLI). Neural stem cells (NSCs) were transduced with Luciferases, which can 
be used for noninvasive assessment of cell viability and quantity. Luciferases from different species 
were compared and validated for highest sensitivity. In conclusion, the codon-optimized firefly lucif-
erase Luc2 was superior for imaging NSC grafts in the mouse brain. Furthermore, a novel BLI protocol 
was developed for boosting BLI sensitivity by a factor of 2. Using this protocol the reliable detection 
of 3,000 transplanted NSCs has become possible for the first time. 
Based on these BLI optimizations, the third project invented a novel approach for cell-specific imag-
ing. Lentiviral plasmids were generated, which enable the constitutive and glia cell-specific expres-
sion of luciferases and fluorescence proteins. This system is based on the combination of 4 optical 
imaging reporters and allows the monitoring of glial differentiation in living cells.  
The results of these 3 projects promote additional noninvasive insights into stem cell biology of 
transplanted cells in the mouse brain. Cell-specific MRI and BLI as presented here improve the nonin-
vasive tools necessary for the understanding of cellular therapy. The use of transgene overexpression 
and non-approved contrast agents limits the direct transfer into a clinical therapy. However, this 
experimental setup can make unique predictions on stem cell fate and function, an indispensable 
knowledge for a safe clinical implementation.      
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7. LIST OF ABBREVIATIONS 
AOAA   Aminooxyacetic acid 
AP   Anteriorposterior 
ATP   Adenosine triphosphate 
AUC   Area under curve 
BBS   BES-buffered saline 
b-FGF   Basic fibroblast growth factor 
BLI   Bioluminescence imaging 
BLBP   Brain lipid-binding protein 
BrdU   Bromodeoxyuridine 
BSA   Bovine serum albumin 
CBG   Click beetle green 
CCD   Charge-coupled device 
CT   X-ray computed tomography 
DCX   Gene coding for doublecortin 
DIV   Days in vitro 
DMEM   Dulbecco’s modiﬁed Eagle's medium 
DNA   Deoxyribonucleic acid 
DV   Dorsoventral 
EC   Extinction coefficient 
ECL   Enhanced Chemoluminescence 
EF1   Elongation factor 1alpha   
EGF   Epidermal growth factor 
ES cell   Embryonic stem cell 
FACS   Fluorescence-activated cell sorting 
FCS   Fetal calf serum 
FID   Free induction decay 
FISP   Fast Imaging with Steady Precession 
FLASH   Fast Low-Angle Shot 
FLI   Fluorescence imaging 
FLT   Fluorescence tomography 
for   forward 
FOV   Field of view 
GABA   γ-Aminobutyric acid 
GAD   Glutamic acid decarboxylase 
Galc   Galactosylceramidase 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
Gata6   GATA binding protein 6 
Gd(III)   Gadolinium ion 
GE   Gradient echo 
GFAP   Glial fibrillary acidic protein 
GFP   Green fluorescent protein 
HBSS   Hank´s buffered salt solution 
HEK   Human embryonic kidney 
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hRluc   Humanized Renilla luciferase 
HRP   Horse radish peroxidase 
HS   Horse serum 
ICC   Immunocytochemistry 
IHC   Immunohistochemistry 
ip   Intraperitoneal 
ITS   Supplement containing insulin, human transferrin, and selenous acid 
iv   Intravenous 
LIF   Leukemia inhibitory factor 
Luc2   Codon-optimized firefly luciferase    
LTR   Long terminal repeat 
MAP2   Microtubule-associated protein 2 
MCAO   Middle cerebral artery occlusion 
MMLV   Moloney Murine Leukemia Virus  
MRI   Magnetic resonance imaging 
MSME   Multi-Slice Multi-Echo  
NEAA   Non-essential amino acids 
NF-H   Neurofilament heavy chain  
NMDA   N-Methyl-D-aspartic 
NMR   Nuclear magnetic resonance 
NPC   Neural precursor cell 
NSC   Neural stem cell 
Oct4   Octamer binding transcription factor 4 
Olig2   Oligodendrocyte transcription factor 2 
Pax6   Paired box protein 6 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PE   Photon emission 
PFA   Paraformaldehyde 
PET   Positron emission tomography 
PMSF   Phenylmethanesulfonylfluoride  
PLP   Pyridoxal phosphate 
POLA   Poly-L-ornithine/laminin 
PpyRE9   mutant red-shifted firefly luciferase  
P/S   Penicillin/streptomycin 
QY   quantum yield 
RARE   rapid acquisition  
RES   Reticuloendothelial system 
rev   reverse 
RNA   Ribonucleic acid 
ROI   Region of interest 
RT   room temperature (20°C) 
rtPA   Recombinant tissue plasminogen activator 
S100b   S100 calcium binding protein B 
sc   subcutaneous 
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SDS   Sodium dodecyl sulfate 
SE   Subependymal zone 
SGZ   Subgranular zone 
SNR   signal-to-noise ratio 
SPIO   Superparamagnetic iron oxide particle 
SV-40   Simian-Virus 40 
STAT3   Signal transducer and activator of transcription 3 
TA   acquisition time 
TE   Echo time 
TI   Inversion time 
TR   Repetition time 
TBS   Tris-buffered saline 
Tubb3   Gene encoding for tubulin beta-3 chain 
VPA   Valproic acid 
VSV-G   Glycoprotein of vesicular stomatitis virus 
WT   Wild type 
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